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The neuroendocrine hormone prolactin (PRL) and its cognate receptor (PRLr) have been 
implicated in the pathogenesis of breast cancer. PRL signaling relies on activating kinases such as 
the tyrosine kinase Jak2 and serine/threonine kinases ERK1/2, NEK3, PI3K, and AKT. In the 
canonical pathway of PRL signaling, JAK2 phosphorylates the transcription factor STAT5a at 
tyrosine residue 694 (pY694-STAT5a), preceding STAT5a nuclear translocation and 
transcriptional activity. However, STAT5a exists with functional duality as a transcription factor, 
having both pro-differentiative and pro-proliferative target genes. Other STAT family members 
(STATs 1, 3, and 6) have been shown to have transcriptional activity in the un-tyrosine-
phosphorylated (upY) state, distinct from that of pY-STAT activity. This distinction (upY vs. pY) 
may underlie the duality of STAT5a, coupled with additional regulatory non-canonical post-
translational modifications. Within this notion, STAT5a contains two serine residues, S726 and 
S780, whose phosphorylation are necessary for hematopoietic transformation. However, their 
functions in PRL-mediated breast cancer pathogenesis have not been examined. We hypothesize 
that STAT5a serine phosphorylation regulates STAT5a nuclear activity in a non-canonical fashion, 
contributing to its role in mammary oncogenesis, specifically in luminal breast cancer. As shown 
in a tissue microarray (TMA), human breast cancer tissues express both pS726- and pS780-
STAT5a. Nuclear Allred score for pS726-STAT5a increases two-fold with increasing tumor grade, 
with no difference in staining associated with estrogen or progesterone receptor (ER, PR) status, 
nor other clinical characteristics. Likewise, patient derived xenograft (PDX) tumors of various 
molecular subtypes express pS726- and pS780-STAT5a. Phosphorylation of S726-STAT5a is 
PRL-responsive in vitro. To examine the functional significance of STAT5a serine 





line MCF7. Following STAT5a KD, cells were rescued with phospho-site specific STAT5a mutant 
constructs targeting Y694, S726 and S780. Characteristics of breast cancer examined in these 
mutation-carrying cells, including anchorage-independent growth and proliferation, show distinct 
phenotypes compared to controls. Further, PRL-inducible gene expression changes on the global 
transcriptomic level showed differential effects of the STAT5a mutations compared to wild type 
STAT5a, specifically enrichment of different oncogenic signatures and transcription factor 
programs. Mechanistic studies examine the ability of these STAT5a mutant proteins to undergo 
nuclear translocation and their regulatory role on phosphorylation of STAT5a tyrosine residue 694. 
Collectively, these studies provide novel insights into the role of the non-canonical pathway of 
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1. Chapter 1: Introduction 
1.1 Breast Cancer 
In the United States, breast cancer is the most commonly diagnosed cancer in women and 
the second most common cause of death from cancer in women.1 In 2021, an estimated 281,550 
new cases of invasive carcinoma will be diagnosed in women, while around 43,600 women will 
die of the disease.2 Relative survival rates of women diagnosed with breast cancer are now 91% 
five years after diagnosis. Much progress has been made in understanding the disease and in our 
ability to diagnose breast cancer, and as such the incidence rate of invasive breast cancer rose 0.3% 
per year during the period from 2012-2016.3  
The clinical course of women with breast cancer is dependent upon the molecular subtype 
of breast cancer that is diagnosed, based on gene expression analysis and particularly the 
expression of hormone receptors (HR) estrogen receptor and progesterone receptor (ER and PR, 
respectively) and human epidermal growth factor 2 (HER2). There are five molecular subtypes of 
breast cancer, namely luminal A, luminal B, HER2-enriched, basal-like, and claudin-low.4  
Luminal A breast cancers are the most common subtype of breast cancer and are ER/PR 
positive (ER+/PR+) and HER2 negative (HER2-). These cancers are the least aggressive, with the 
most favorable prognosis, in part due to their responsiveness to hormonal therapies. Luminal B 
breast cancers are both ER+/PR+ and HER2+, are more proliferative than luminal A, and have 
slightly poorer outcomes. HER2-enriched breast cancers are HR- (ER-/PR-) and HER2+, and are 
currently treated with HER2-targeting therapies. Basal-like, or triple negative breast cancers 




subtype of TNBCs is the claudin-low subtype of breast cancer, which also expresses low amounts 
of genes involved in tight-junctions and epithelial cell-cell adhesions (proteins of the claudin 
family, E-cadherin). Claudin-low tumors are characterized by enrichment of genes involved in 
epithelial to mesenchymal transition (EMT), and have poor prognosis related to chemotherapy-
resistance.5 
The molecular subtypes of breast cancer illustrate the importance of understanding genetic 
alterations that drive mammary oncogenesis. The control of these genetic alterations in breast 
cancer is complex, with epigenetic changes to the DNA allowing for the activation of tumor-
promoting changes or repression of tumor-suppressing genes in response to a multitude of different 
signaling pathways. These signaling pathways are active in normal epithelial cells to modulate 
different stages of mammary gland development and mammary function but become dysregulated 
or hijacked in cancer cells. This leads to alterations in the transcription of genes that control cellular 
proliferation, apoptosis, differentiation, and motility, contributing to the onset of breast cancer and 
the heterogeneity of the disease. 
 
1.2.Prolactin 
 Prolactin (PRL) is a 23 kDa neuroendocrine polypeptide hormone produced mainly in the 
lactotroph cells of the anterior pituitary but is also produced in various other tissues such as the 
breast and uterus.6 PRL is a class I helical protein hormone and belongs to the PRL/growth 
hormone (GH)/placental lactogen (PL) family of protein hormones.7–9 PRL acts in an autocrine, 
paracrine, and endocrine manner at target tissues when it binds to the prolactin receptor (PRLr). 
PRL has multiple target tissues, and in fact it is now appreciated to have more than 300 separate 




importantly to this work, its most well-characterized role is for its actions in the mammary gland. 
PRL was first identified to have an autocrine/paracrine effect in breast epithelium by Clevenger et 
al, where it acts in a complex concert along with estrogen and progesterone signaling in normal 
mammary development.6 PRL is responsible for stimulating lobuloalveolar growth during 
pregnancy, as well as lactation postpartum. Specifically, PRL (PRL/PRLr signaling) is necessary 
for the differentiation of mammary epithelial cells into milk-producing cells during late 
pregnancy.11,12 
 
1.3.Prolactin receptor  
The prolactin receptor (PRLr) is a cell-surface receptor belonging in the hematopoietic type 
1 cytokine receptor superfamily, along with the growth hormone receptor (GHr), granulocyte-
macrophage colony-stimulating factor (GM-CSF) receptor, interleukin (IL) receptors, and the 
erythropoietin (EPO) receptor.13 The PRLr is a single-pass transmembrane receptor, existing as a 
dimer pair that lacks intrinsic kinase activity and relies on associated kinases for downstream 
signaling following ligand binding. Activation of receptor-associated kinases occurs as a 
consequence of conformational change of the dimer pair upon ligand binding. The conformational 
change of the PRLr is assisted by the peptidyl prolyl isomerase cyclophilin A (CypA).14,15 The 
PRLr itself has three main domains: the extracellular domain (ECD, where PRL binds), the 
transmembrane domain (TMD), and the intracellular domain (ICD). The ECD contains two type 
III fibronectin-like domains, the S1 and S2 domains. The N-terminal S1 domain contains the 
majority of ligand-binding sites, such that the receptor can bind the ligand in a 2:1 ratio.16,17 
Although the S2 domain has a smaller surface area for ligand contact, it does have a highly 




motif) that is both necessary for ligand-binding and receptor dimerization.18,19 The TMD, as it 
spans the cytoplasmic membrane, links the activity of the ECD binding to ligand to intracellular 
signaling, in an event that is not yet fully understood as the crystal structure of the PRLr has not 
been fully determined. Instead, we look to studies of the GHr, where ligand binding results in 
conformational change of the TMD dimers so that the ICD can then undergo conformational 
change to bring signaling kinases in close proximity to activate downstream signaling.20,21 The 
ICD is highly homologous to other cytokine receptors, containing common motifs (from 
membrane-proximal to C-tail) known as Box 1, Variable (V) Box, Box 2, X Box, and a unique, 
intrinsically-disordered, C-terminal tail. Briefly, Box 1 is highly proline-rich, and contains the site 
necessary for JAK2-PRLr association.22,23 The V Box links Box 1 and Box 2, and little is known 
about its function. Box 2 contains hydrophobic, acidic, amino acid residues. The X Box contains 
the site necessary for Cyp binding; as a peptidyl prolyl isomerase, CypA is critical for downstream 
signaling of PRL-PRLr binding and is discussed further below.14,15 
1.3.1. Isoforms:  
There are seven identified isoforms of the PRLr that have variable expression in both 
normal and malignant tissue (Figure 1.1A). Dimerized receptor pairs can thus be homo- or hetero-
dimers of these isoforms. Each form has altered downstream signaling from PRL-PRLr binding, 
although most of our understanding comes from the work done studying the long form.  
1. Long: this was the first human PRLr isoform identified, 598 amino acids long. Upon PRL 
binding, there is rapid phosphorylation of the ICD and subsequent downstream signaling.24 
2. ΔS1: this isoform is generated by alternative splicing with deletion of the S1 motif of the ECD. 
Therefore, the affinity for ligand-binding compared to the long form is about 94-fold less (with 




3. Intermediate: this isoform is also generated by an alternative splicing event which induces a 
frame shift after amino acid residue 316 with the addition of a novel, 13 amino acid tail due to 
a premature stop codon. Functionally, this causes deletion of a portion of the ICD including 
the site for STAT5a binding to the PRLr in the C-terminal tail.24 The function of the 
intermediate PRLr will be discussed further for its role in breast cancer in Section 1.5.3. 
4. Short 1a (S1a): short form of PRLr generated by alternative splicing in which part of exon 11 
replaces exon 10, contains both Box 1 and Box 2 motifs, does not have downstream signaling.25 
5. Short 1b (S1b): short form of PRLr generated by alternative splicing in which part of exon 11 
replaces exon 10, contains Box 1 motif only, does not have downstream signaling.25 
6. PRL-binding protein (PRLBP): generated by a proteolytic event, this is a freely circulating 
form of the ECD only, and thus can still engage ligand but does not signal. It therefore acts as 
a “ligand trap”, and in fact as much as 36% of circulating PRL is bound to PRLBP.26 
7. TM-ICD: this fragment lacks the ECD and is possibly generated by the same proteolytic 
cleavage event that generates the PRLBP, it can form heterodimers with other forms of the 
PRLr and therefore maintains signaling events through JAK2.27 
1.3.2. Downstream signaling 
As stated above, as ligand binds the pre-dimerized PRLr, the peptidyl prolyl isomerase 
CypA induces a conformational change of the ICD that allows associated kinases to come close in 
proximity to phosphorylate the receptor and themselves (termed autophosphorylation, Figure 
1.1B). This starts downstream signaling pathways that alter cellular growth, proliferation, survival, 






Figure 1.1 Schema of the PRLr and the conformational change PRLr dimers undergo 
upon PRL-binding. A) The PRLr isoforms shown with conserved proximal box motifs in 
each ICD and unique intracellular tails for the intermediate, S1a, and S1b receptors. B) The 
long form PRLr exists pre-dimerized. Upon PRL-PRLr binding, CypA facilitates cis-trans 
isomerization of the ICD, allowing auto-/trans-tyrosine phosphorylation of the kinase JAK2 to 
initiate downstream signaling events. 
 
1.3.2.1. JAK2 
The tyrosine kinase JAK2 is constitutively associated with the PRLr.29 Upon ligand binding 




phosphorylation levels between 10-15 min.24 JAK2 is responsible for phosphorylating the C-
terminal tyrosine residues in the PRLr for the subsequent association and tyrosine-phosphorylation 
of the transcription factor STAT5.24 The role of STAT5 will be discussed further below. 
1.3.2.2. RAS/RAF/MAPK 
Within 5 minutes of PRL stimulation in both normal mammary epithelial cells and breast 
cancer cells, the mitogen-activated protein kinase (MAPK) is activated.30,31 Specifically, RAF-1, 
MEK1, and the 42 and 44 kDa MAPKs known as extracellular regulated kinases 1 and 2 (ERK1/2) 
are induced 2-3 fold with PRL treatment, leading to PRL-regulated mitogenesis.30,31 ERK1/2 have 
some documented effects on STAT5 signaling in response to several cytokines, including PRL 
and GH.32–34 These interactions will be further detailed below, in the discussion of STAT5 
regulation. 
1.3.2.3. PI3K/AKT 
Upon activation of the PRLr, the p85 subunit of phosphatidylinositol-3 kinase (PI3K) 
associates with the PRLr, leading to its activation and the generation of metabolites known as 
phosphoinositides. These metabolites act as docking sites for AKT (also known as protein kinase 
B) and kinases upstream of AKT which activate it by serine/threonine phosphorylation.28,35,36 The 
AKT pathway initiates survival, inhibits pro-apoptotic signals (including transforming growth 
factor [TGF]-β-induced apoptosis), and modulates regulators of cell cycle progression including 
Cyclin D1.28,36,37   
 
1.3.2.4. NEK3/VAV2/RAC1 
The guanine nucleotide exchange factor (GEF) VAV was first found to be activated by 




(that is, activation of RAC), and nuclear translocation of VAV.38 It has since been shown that the 
NIMA (never in mitosis A)-related family kinase NEK3 is responsible for the phosphorylation and 
activation of VAV2 in breast cancer, leading to the exchange of GDP for GTP on RAC1, and its 
activation. This pathway is ultimately implicated in PRL-stimulated tumor progression and 
motility through cytoskeletal reorganization and formation of stress fibers and lamellipodia for 
cellular migration.21,22,23  
 
1.4. PRL/PRLr in mammary development and pregnancy 
Mammary gland development takes place in a series of distinct phases controlled by 
circulating hormones including GH, estrogen (E2), progesterone (P), and PRL.42,43 Although some 
development occurs in utero, most development occurs primarily after birth specifically at puberty 
(ductal development), and pregnancy (ductal/alveolar development in preparation for lactation).11 
Along with P, PRL works to stimulate mammary gland proliferation and differentiation of 
lobules prior to lactation.44,45 In fact, P induces the expression of PRLr and PRL induces the 
expression of PR in mammary cells, illustrating the complexity of the crosstalk needed between 
hormones for mammary development.46–48 During pregnancy, epithelial cells proliferate and 
generate alveolar buds that progressively cleave into distinct alveoli. By late pregnancy these 
alveoli involve most of the fat pad. By lactation, these alveoli have become milk-secreting 
lobules.42 At the end of lactation, that is, when the suckling stimulus is removed at weaning, 
involution remodels the epithelial milk-secreting lobules back to a simple ductal architecture.42  
The role for PRL in mammary development has been elegantly studied in Prl and Prlr 
knockout mice, which have made it clear that PRL is necessary for side-branching and alveolar 




In 1997, Ormandy et al showed that in mice carrying one mutated allele for Prlr, that is a 
heterozygous null mutation for the Prlr (Prlr+/-), mammary gland proliferation during the first 
pregnancy was so reduced as to lead to lactational defects, suggesting that epithelial cell 
proliferation depends on a threshold of Prlr expression that cannot occur even with one functional 
gene. Interestingly, after further estrous cycles, during a second pregnancy the mammary gland 
was more fully developed and capable of lactation.11 Targeting the Prl gene by homologous 
recombination resulted in homozygous female mice (Prl-/-) that were infertile, and although the 
mammary glands were able to develop a normal ductal tree, lobules failed to develop and the 
mammary gland resembled that of an adult virgin mouse. Heterozygous females (Prlm+/-) were 
able to produce Prl at normal bioactive levels, suggesting that loss of one Prl locus can be 
compensated for in such a way that PRL synthesis is not reduced.12 Rescue of Prl knockout mice 
with the human transgene, in a humanized PRL model, rescued all reproductive defects and 
mammary gland development.49 The requirement for PRL/PRLr signaling in alveologenesis was 
definitively demonstrated when, in 2003, Ormandy et al transplanted Prlr KO epithelium into the 
stroma of WT mice, which then developed alveolar buds during pregnancy but no lobuloalveolar 
development. 51 The recombination of WT epithelium and Prlr KO stroma showed normal 
development, which illustrated that a direct action of PRL on the epithelium is necessary for 
lobuloalveolar development.  
   
1.5. PRL/PRLr in breast cancer 
The function of PRL in human breast cancer has been the subject of debate since it was 
first recognized to contribute to rodent mammary cancer in the 1970s.52 However, in the 40+ 




epidemiologic levels strongly implicate autocrine/paracrine PRL/PRLr signaling in the 
pathogenesis of breast cancer. 
1.5.1. PRL and breast cancer risk  
Clinically, evidence for a positive association of plasma PRL levels and human breast 
cancer was established by examining the Nurses’ Health Study (NHS) and the NHS II. 53–56 The 
NHS and NHSII are two large cohorts of registered nurses that were established in 1976 and 1989, 
respectively. When first started, the NHS cohort of 121,700 US female nurses ranged in age from 
30 to 55 years old, and the NHSII cohort of 116,609 female nurses ranged in age from 25 to 42 
years old. Follow-up to the NHS was reported in 2000 as 99%.55 Together, the cohorts cover both 
pre- and post-menopausal women and therefore, risk of breast cancer associated with various life 
factors. Using these cohorts, prospective, nested case-control studies were performed studying the 
risk of breast cancer and PRL serum levels at different time points of follow up.53–56 
Examination of PRL levels and breast cancer risk in the NHS and NHSII resulted in 
multiple data sets to compare risk for women who are premenopausal and risk for women who are 
postmenopausal. A pooled analysis, along with these data sets, provided a summary of about 80% 
cases of published prospective studies.55 With the power of these studies, relative risk (RR) was 
calculated and could be associated with risk broken down by menopause status, tumor 
invasiveness, and lead-time to diagnosis.  
First, plasma PRL concentration was associated with breast cancer with a RR of 1.5 in both 
the NHS and NHSII women who were premenopausal. The risk of breast cancer increased to 60-
70% for premenopausal women older than 45 years old with high serum PRL.55 A positive 
association for PRL concentration and breast cancer risk for postmenopausal women was also 




In the pooled analysis (1,500 cases, in which both pre- and postmenopausal women were 
combined), the risk of breast cancer was 30% comparing the top versus bottom quartile of PRL 
concentrations, independent of estrogen and testosterone levels.55 In this combined analysis, there 
were no significant differences for tumor type or invasiveness, although a positive association for 
ER+ tumors was observed once more.55 One of the most interesting findings of these studies was 
a strong relationship between plasma PRL levels and breast cancer in women who were diagnosed 
less than 4 years after blood collection, suggesting that increased circulating levels of PRL may be 
due to subclinical breast tumors secreting PRL.55,57,58 Overall, these studies showed that PRL is 
associated with ER+, post-menopausal disease.53–56  
1.5.2. Preclinical studies of PRL in vitro and mouse models 
PRL promotes the growth, proliferation, and motility of breast cancer cells in vitro, acting 
as a mitogen and survival factor.44,52,53,59–63 These activities of PRL have been studied in a range 
of cultured mammary carcinoma cell lines that vary in their oncogenic mutations and steroid 
hormone (E2 and P) responsive-ness, illustrating PRLs role in a wide range of breast cancers.  
The study of the autocrine/paracrine effects of PRL in breast cancer cells in vitro began 
after clinical trials treating breast cancer patients using bromocriptine, a dopamine agonist that 
inhibits PRL secretion from the pituitary, failed.28 The pervading theory at the time was that PRL 
was secreted exclusively from the pituitary, but the failure of bromocriptine in these trials led 
researchers in the Clevenger and Vonderhaar laboratories to hypothesize separately that breast 
epithelium (and other nonendocrine tissues) locally produce PRL.6,28,44,57,64 These studies 
demonstrated that cultured breast cancer cells, namely MCF7 and MDA-MB-231, could synthesize 
and secrete PRL.6 Further evidence comes from using in situ hybridization of patient samples: 




The absolute expression levels (and relative expression levels of isoforms) of PRLr in 
established culture cell lines is also varied, and has been quantified on both the mRNA and protein 
levels.28,48 In 1997, Ormandy et al studied the mRNA expression of PRLr of 20 human breast 
cancer cell lines which model subtypes ranging from luminal A to triple negative, and stratified 
these lines from non-detected to high expression of PRLr mRNA (those lines which were 
quantified as to have measurable PRLr expression are listed in Table 1.1). They were further able 
to correlate the level of PRLr expression to PRLr-binding activity and showed that this was a 
positively correlated relationship. This suggests that any potential posttranslational modifications 
of the PRLr do not affect the maintenance of steady state PRLr levels.48 Finally, they showed that 
PRL induces the transcriptional upregulation of PRLr, thus potentiating further PRL/PRLr signal 
transduction.48 
 
Table 1.1 Selection of breast cancer cell lines with published PRLr expression. 
Breast cancer cell line Molecular subtype PRLr expression 
MDA-MB-134 Luminal A65,66 High PRLr48 
BT483 Luminal B65,66 High PRLr48 
T47D Luminal A/B65,66 High PRLr48 
BT474 Luminal B65,66 High PRLr48 
MDA-MB-361 Luminal B65,66 High PRLr48 
MCF7 Luminal A/B4,65,66 Moderate PRLr48 
ZR-75-1 Luminal A65,66 Moderate PRLr48 
MDA-MB-175 Luminal A65,66 Moderate PRLr48 
MDA-MB-453 HER2 enriched65,66 Moderate PRLr48 
BT549 Triple negative65,66 Low PRLr48 
SKBR3 HER2 enriched65,66 Low PRLr48 
MDA-MB-157 Triple negative65,66 Low PRLr48 





PRL also plays a role in regulating and enhancing ERα and PR expression in breast cancer 
cells. In fact, PRL increases ERα levels and E2 responsiveness in MCF7 breast cancer cells.67,68 
In one study, PRL induced ERα transcriptional activity in the absence of estrogen binding ERα.69 
The authors further went on to show that PRL activated both reporter plasmids containing estrogen 
response elements (EREs), as well as induced the ERα-target gene pS2, mimicking the effect of 
E2 by inducing recruitment of ERα to ERE-containing promoters and resulting in the recruitment 
of co-activators of transcription.69 Furthermore Ormandy et al found that PRL stimulation of 
MCF7 cells increases PR transcript levels and receptor binding activity in a dose-dependent 
manner.48 Finally, Fiorillo et al showed that the PRLr transactivation domain (TAD) was 
specifically necessary for regulation of ERα and PR levels in MCF7 breast cancer cells.70 Overall, 
these findings illustrate how there is complex interplay between these hormone pathways in breast 
cancer.  
Multiple transgenic mouse models have been developed to uncover the role of PRL in 
breast cancer. First, ubiquitous overexpression of PRL in transgenic mice was found to be 
sufficient to induce the formation of mammary tumors by activation of the PRLr within 11-15 
months.71 In contrast, in the mouse mammary tumor virus-polyoma middle tumor-antigen 
(MMTV-PyMT) model, for mice deficient in PRL, tumors appeared later in the mice and grew 
30% more slowly.72  
Possibly the most considerable in vivo experiments to date utilize rat PRL (rPRL) 
expression under control of the mammary-specific rat neu-related lipocalin (NRL) promoter, in a 
model named NRL-PRL.69 Mice with overexpression of PRL within the mammary gland 
epithelium readily develop mammary neoplasias by 6-9 months and invasive carcinomas within a 




(-), the majority are ERα+, and reflect diverse histological features.73 These characteristics of the 
NRL-PRL model make them useful models of aggressive ERα+ clinical disease. In fact, recent 
genomic analysis of tumors from this model showed that all tumors contained somatic alterations 
or amplifications of KRAS that were not seen in any of the pre-neoplastic mammary glands.75 In 
contrast, the pre-neoplastic mammary glands displayed constitutive expression of rPRL along with 
increased transcripts for inflammatory cytokines. Thus, constitutive PRL signaling in the 
mammary glands may induce a pro-tumor microenvironment to enable the oncogenic KRAS 
pathway and spontaneous tumorigenesis. Adding to this proposed role for PRL cooperating with 
other oncogenes, the NRL-PRL model has also been used to show that along with mutations in the 
tumor suppressor Adenomatous polyposis coli (APC) PRL facilitates higher cancer stem cell 
activity dependent on Notch signaling leading to rapidly-proliferating lesions that progress to 
adenocarcinomas.76 
In an effort to establish another in vivo ER+ breast cancer model, the researchers in Hallgeir 
Rui’s laboratory have generated a prolactin-humanized mouse. This mouse model was genetically 
engineered to express physiological levels of human PRL in place of mouse PRL and backcrossed 
into the immunodeficient NOD scid gamma (NSG) strain.77 Mouse PRL acts as an antagonist at 
the human PRLr, and so the researchers hypothesized that the lack of human PRL activity selected 
against the establishment of transplanted ER+ breast cancers.77 The resulting hPRL.NSG mouse 
model has thus far been validated for its usefulness and improvement over the NSG model in initial 
tumor establishment with subsequent increased growth rates of the breast cancer xenografts. 77 The 
mouse model has also shown increased responsiveness to the anti-estrogen tamoxifen, as well as 




most likely help in determining therapeutic targets of the PRL pathway along with other growth 
signaling pathways.  
1.5.3. In vitro studies of PRL/PRLr signaling mechanisms 
Given the role of PRL in breast cancer pathogenesis as enumerated above, the PRL 
signaling pathway deserves investigation to uncover mechanisms and possible clinical targets for 
future interventions. In vitro models of breast cancer focusing on PRL signaling have been 
significant in this effort. 
 It has been through these efforts that PRL has been shown to directly interact with the 
peptidyl-prolyl isomerase (PPI) CypA.14,15,78 CypA, acting as a molecular switch for potentiating 
PRL signaling, mediates a conformational change necessary for JAK2-PRLr binding.15,78 Further, 
while pharmacologic inhibition of CypA inhibits PRL signaling and decreases PRL-induced gene 
expression globally in T47D cells, it also inhibits MDA-MB-231 cell migration.78 Thus, PRL 
signaling relies on the activity of CypA, and CypA has been shown to be a potential therapeutic 
target in the PRL signaling cascade. 
 In vitro studies have also shown that PRL stimulates cytoskeletal re-organization and 
motility in breast cancer cells.40,41 PRL-mediated breast cancer motility relies on the 
serine/threonine kinase NEK3. When NEK3 was downregulated by small-interfering RNA 
(SiRNA), T47D cells exhibited decreased activation of the GTPase RAC1, by way of decreased 
VAV2 phosphorylation, as well as decreased cellular migration and invasion.39,40 Specifically, 
PRL activation of the ERK pathway regulates NEK3 phosphorylation and activation.41 When 
activated, NEK3 interacts with the focal adhesion adaptor protein paxillin, such that focal 




In studying PRL signaling in vitro, STAT5a has been examined for its role in enhancing 
proliferation of breast cancer cells by directly upregulating transcription of cytokine-inducible 
SH2-containing protein (CISH) and cyclin D1 (CCND1).79–82 STAT5a transcriptional activity in 
breast cancer cells was first studied using luciferase-reporter assays to monitor signal transduction 
and gene expression, which relied on exogenous expression of the promoter sequence of a known 
target gene, such as CISH.83 With PRL stimulation, these assays showed upregulation of CISH by 
increased bioluminescence, and experimental parameters could be manipulated to show how 
STAT5a regulation of CISH was affected. For example, VAV2, but not NEK3, has been shown to 
contribute to STAT5a signaling by use of luciferase assay; expression of VAV2 led to a PRL-
inducible increase in STAT5a-mediated gene transcription that was not affected by expression of 
NEK3.39 PRL stimulated STAT5a has also been shown to inhibit expression of the proto-
oncogene, BCL6, whereas STAT5a knockdown effectively abrogates this finding.84 The 
mechanism by which PRL regulates STAT5a transcriptional activity is an active area of research. 
 To this point, the histone deacetylase HDAC6 has been shown to deacetylate the 
chromatin-modifying high mobility group N2 protein (HMGN2) such that HMGN2 can be 
recruited by the PRLr TAD to enable STAT5a-mediated gene expression upon PRL 
stimulation.79,85 Further, the chromatin linker histone H1 antagonizes STAT5a binding at DNA, 
which is relieved by HMGN2 upon PRL stimulation.86 In a genomics study utilizing both 
chromatin immunoprecipitation (ChIP)-sequencing (seq) and RNA-seq methods in MCF7 cells, 
Craig et al identified PRL-inducible STAT5a binds at enhancers rather than promoters to convey 
specificity of PRL-regulated genes, and that these genes are also significantly enriched for cis-
regulatory elements bound by HDAC6 and HMGN2.87 Further, the selective HDAC6 inhibitor, 




significant proportion of PRL-stimulated gene expression.87 Lastly, this study also identified, 
through gene set enrichment analysis (GSEA), significant overlap of PRL-regulated genes with 
genes regulated by ERα, especially PRL-regulated genes with transcriptional regulatory elements 
co-occupied by both STAT5a and HDAC6.87 Overall, these findings illustrate that PRL-stimulated 
STAT5a target genes require cofactors HDAC6 and HMGN2 for transcription. 
The role the PRLr isoforms play in breast cancer has also been an area of active research. 
The recently published study by Grible et al found that when the intermediate PRLr isoform 
(PRLrI) is co-expressed with the wild-type long form (PRLrL) in a partially transformed breast 
epithelial cell line, MCF10AT, these cells underwent both in vitro and, when transplanted in mice, 
in vivo transformation.88 In contrast, knockdown of PRLrI in MCF7 cells decreased malignant 
potential in vitro.88 Interestingly, this study also uncovered an increase in KRAS signaling with 
increases in the PRLrI:PRLrL ratio, indicating that the potential oncogenic role of PRLrI:PRLrL 
heterodimers cooperate with KRAS signaling.88 This corroborates the findings in the NRL-PRL 
mouse model, discussed above.  
 
1.6.STAT5a 
1.6.1. STAT family 
Signal transducers and activators of transcription (STATs) are latent cytosolic transcription 
factors (TFs) which transduce extracellular stimuli to activation of target genes in the nucleus. 
Various cytokines activate STAT activity, including PRL, interferons (IFNα/β/γ), and interleukins 
4 and 6 (IL-4/6), among others.89 Canonically, STAT activity is controlled by tyrosine kinases 




translocate to the nucleus, where they interact with other various proteins of transcription to 
modulate gene expression.90,91 There are 7 known members of the STAT family: STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b, and STAT6, and they are involved in a range of regulatory 
events including hematopoiesis, immunomodulation, and development.92 STAT activity, and 
therefore biological function, is controlled by receptor-activation and crosstalk, interacting protein 
partners, and nuclear-cytoplasmic shuttling.  
STATs were first identified as mediators of IFN-stimulated gene transcription.93,94 
Through molecular and biochemical analysis of the promoter regions of IFN-stimulated genes, it 
was discovered that specific DNA consensus motifs, namely gamma interferon activation site 
(GAS) motifs, required binding with a TF that became known as STAT1.90,93 Identification of the 
rest of the STAT family subsequently followed using various techniques, one of which utilized 
purification of proteins bound to GAS motifs found at other gene promoter regions. For example, 
STAT5 was isolated from DNA-binding sequences from the β-casein gene.93,95 The GAS motif is 
a palindromic core motif recognized by all STATs: TT(C/A)YNR(G/T)AA. However, sequence 
specificity and binding affinity, as well as different STAT protein-protein interactions ensure that 
STATs each induce expression of exclusive genes in response to various cytokines.93,94 
Genetic mapping of human STATs which encode the TFs shows the family organized as 
closely linked clusters on three chromosomes: STAT1 and STAT4 on chromosome 2; STAT3, 
STAT5a, and STAT5b on chromosome 17; and STAT2 and STAT6 on chromosome 12. These 
clusters of STAT genes may be related to their functions, and in fact STAT5a and STAT5b have 
both convergent and divergent functions. The presiding theory is that a series of tandem gene 




chromosomes, gave rise to the seven STAT genes. Furthermore, the two STAT5 genes arose the 
most recently with a shared sequence identity of 93.6% at the cDNA level.89,92,96,97  
   
1.6.1.1. STAT structure and isoform homology 
The STAT family is highly conserved, with peptide sequence conservation scores between 
85-89% (Figure 1.2). Multiple sequence alignment produced by T-coffee and analyzed for 
conserved residues using the Jalview software illustrates the high conservation of amino acids for 
the STAT family members, with the greatest difference in amino acids in the C-terminus (Figure 
1.2).98–100 STAT5a and STAT5b have high sequence identity at the protein level across species: 
mouse Stat5a and Stat5b are approximately 95% identical, whereas T-coffee alignment of human 






Figure 1.2 Amino acid sequences of STAT family of proteins illustrate the homology of the 




sequence alignment produced using T-Coffee, and threshold for conservation (=2) set using 
Jalview software. 
 
The amino acid sequences of the STAT family result in a common set of six domains, each 
with features that contribute to the function of the TF, as well as, importantly, a conserved tyrosine 
residue (Tyr, Y) in the C-terminus. As illustrated in Figure 1.3, adapted from Nicholas C., and 
Lesinski G., 2011, from N-terminus to C-terminus, these domains are: 103 
1. N-terminal domain: together with the Src Homology 2 (SH2) domain, mediates homo-and 
hetero-dimerization of STAT monomers during activation, and mediates other protein-
protein interactions.89,104–106  
2. Coiled-coil domain: functions as a nuclear localization signal and interacting domain for 
other proteins, including IRF-9/p48 for STAT1; c-JUN, STLP1, and GRIM-19 for STAT3; 
and SMRT for STAT5a and STAT5b.106,107  
3. DNA binding domain: determines specificity of DNA association for each isoform, and is 
a highly conserved domain for the STAT family.89,94,105 
4. Linker domain: rich in proline (Pro), glycine (Gly), and hydrophilic residues to provide 
flexibility to permit the phosphotyrosine (pY) of one STAT to bind to the SH2 domain of 
the partner STAT for dimerization during activation.107 
5. SH2 domain: responsible for recruitment to, and binding to, receptors at specific tyrosine-
phosphorylated sequences in the receptors; mediates homo- and heterodimerization of the 
STATs by binding the pY domain of the partner STAT. STAT1, 3, 4, 5a, and 5b form 
homodimers. Depending on the activating ligand, STAT1 can partner with STAT2 or 





6. Conserved Y residue: key tyrosine residues on the STAT family are the targets of 
phosphorylation by the JAK tyrosine kinases, SRC family kinases, and other tyrosine 
kinases. These tyrosine residues are seen in Figure 1.3: Y701 for STAT1, Y690 for 
STAT2, Y705 for STAT3, Y693 for STAT4, Y694 for STAT5A, Y699 for STAT5B and 
Y641 for STAT6.110 Canonically, phosphorylation of tyrosine residues is understood to be 
the activation event necessary for STAT activity and dimerization, and that inactive STATs 
are found only in the cytoplasm.105–107 However recent evidence suggests in a non-
canonical model that non-phosphotyrosine-STATs (or unphosphorylated-Y/upY-STATs) 
have transcriptional activity which will be discussed further below.105  
7. Transactivation domain (TAD): the most carboxy-terminal region of the STATs, and it is 
the most diversified peptide sequence between the STATs.107,109 Except for STAT1 and 
STAT6, the TAD of all STAT contains at least one conserved phospho-serine (pS) residue, 
that, while less understood for its regulation of STAT activity, is appreciated for 
influencing STAT activity in some way, possibly by mediating protein-protein 
interactions.107 The regulation and activity of the two C-terminal phospho-serine sites in 
STAT5a are the focus of this thesis, and thus the regulation of pS-STAT will be discussed 






Figure 1.3. Structural homology of the STAT family and domain functions. Each isoform 
length is indicated by amino acids (aa), p=phosphorylation site, Y=conserved tyrosine residue, and 
S=conserved serine residues. Adapted from (Nicholas C., and Lesinski G., 2011).103 
 
1.6.2. Sites of involvement and homeostatic biological functions 
Each STAT family member is differentially activated by specific extracellular ligands, 
such as cytokines, hormones, or growth factors. This differential activation and downstream 
signaling lends each STAT its biological role.111 These roles were originally defined by tissue 
distribution, in vitro studies, and the phenotypes that arose in mouse models lacking their 
expression. 
As stated above, STATs were identified as mediators of IFN-stimulated gene transcription, 




hematologic and immunologic development and response, STAT3, STAT5a, and STAT5b have 
roles in other sites of the body.108 STAT1 and STAT2 chiefly mediate the effects of IFNs; mice 
that lack STAT1 or STAT2 are prone to microbial infections as well as viral infections.112,113 
Targeted loss of STAT1 in natural killer cells (NK cells), impairs NK cytolytic activity, and mice 
harboring these NK cells more easily grow tumors.114 Gene-targeted mice that are null for STAT3 
expression are embryonic lethal, however specific tissue targeting for STAT3 knockout has shown 
that STAT3 has roles in skin, the thymus, liver, and neurons, as well as in immunological 
development.108 As discussed below, STAT3 also antagonizes STAT5 action in mammary 
development.115,116 Loss of STAT5a in mice leads to failure of breast tissue development, which 
is covered in depth in Section 1.6.4.1. STAT5a and STAT5b have roles in red blood cell 
production: embryos that are Stat5a-/-5b-/- are severely anemic, due to a decrease in erythroid 
progenitors ultimately due to a loss of responsiveness to erythropoietin.117,118 STAT5a has also 
been shown to have a role in immune regulation, from the stimulation of peripheral T cells in 
response to IL-2 to repopulation of hematopoietic stem cells in bone marrow.119,120 Loss of STAT4 
or STAT6 in mice leads to impaired TH1 differentiation, owing to loss of response to IL-12 
(STAT4) or IL-4 (STAT6), ultimately leading to impaired immunologic response.108 
 
1.6.3. Regulation of STAT5a signaling 
STATs are activated by cytokines, hormones, and growth factors interacting with their 
respective cell surface receptors. Phosphorylation of tyrosine residues, subsequent dimerization, 
and translocation to the nucleus all precede canonical STAT transcriptional activity. STAT activity 
is influenced by modifying protein-protein interactions, expression levels of STATs, and 




1.6.3.1. Cytokine and hormone receptors upstream of STAT5a 
In normal mammary epithelial cells, STAT5a activation is mediated predominantly by 
PRL/PRLr and JAK2.28 However, activation of STAT5a through JAK2-tyorsine phosphorylation 
has also been shown downstream of the GH receptor, IL-3 receptor, and EPO receptor.121 Further, 
binding of the insulin-like growth factor (IGF) to the IGF receptor, E2 to the ERα, or epidermal 
growth factor (EGF) or TGFα to the EGF receptor (EGFR), activates cellular-Src (c-Src) tyrosine 
phosphorylation of STAT5a.122 Additionally, ErbB4 has been shown to be required for STAT5 
activation during lactation.122,123 
1.6.3.2. Proteins that modulate STAT5a phosphorylation and dephosphorylation 
The protein tyrosine phosphatase (PTP) SH2 domain containing protein tyrosine 
phosphatase (SHP-2), has been shown to dephosphorylate STAT5a on Y694 in IL-2 stimulated 
cells.121 In MCF7 and T47D breast cancer cells, knockout of PTP1B sustains pY694-STAT5a, as 
well as STAT5a transcriptional activity, indicating PTP1B may be responsible for 
dephosphorylation of STAT5a in malignant breast epithelial tissue.124 
In addition to tyrosine phosphorylation, STAT5a is serine phosphorylated on residues S726 
and S780, however the kinase responsible is still unclear. The mitogen activated protein 
kinase/extracellular signal regulated kinase (MAPK/ERK) cascade is often activated concurrently 
to JAK/STAT signaling by cytokines and hormones, including PRL/PRLr signaling.125 These 
kinases, which are serine/threonine kinases, have been implicated in phosphorylation of STAT5a 
S780.32 However, study findings on ERK1/2-STAT5a interactions, as well as the requirement for 
active ERK1/2 for pS-STAT5a are inconsistent.32,34,126,127 GH stimulated ERK1/2 is capable of 
phosphorylating S780-STAT5a in an in vitro kinase assay.32 However, this may not be the case in 




immunoprecipitation, the kinetics of this interaction in response to cytokine stimulation varies. In 
one study of CHO cells (PRLr/GHr-null) stably expressing GHr, preformed complexes of ERK1/2-
STAT5a dissociated with GH stimulation.32 In a similar study, upon GH stimulation, the 
association of ERK1/2 and pY- and pS-STAT5a was increased in CHO cells.34 Additionally, 
studies using pharmacologic inhibitors of the MAPK pathway in cell culture are inconsistent. For 
example, in Nb2 lymphocytes, the inhibitor PD98059 had no effect on IL-2 induced pS-STAT5a 
nor its ability to bind DNA.126 In another study of Nb2 lymphocytes, PD98059 had no effect on 
PRL-inducible phosphorylation of S726, but decreased PRL-independent, constitutive serine 
phosphorylation of STAT5a.127 Finally, in an oncogene RhoA-driven model of Madin-Darby 
Canine Kidney (MDCK) cells, PD98059 treatment decreased phosphorylation of S726 with no 
decrease in phosphorylation of S780.128 These findings indicate that ERK1/2 phosphorylation of 
STAT5a may be cell-type and cytokine dependent. 
1.6.3.3. Transcriptional modulators and epigenetic modifiers 
Coactivators of STAT5a transcriptional activity include general transcription factory 
machinery such as CREB-binding protein (CBP) and p300.121 Our laboratory and others have 
shown that the PRLr itself translocates to the nucleus upon PRL stimulation and acts as a 
coactivator of STAT5a.70,85 Further work in our laboratory determined that HMGN2, a chromatin 
modifying protein, facilitates STAT5a recruitment to the promoter region of the CISH gene, 
promoting STAT5a-mediated transcription.79,85 In response to PRL, HMGN2 facilitates the 
displacement of the linker histone H1 at STAT5a GAS consensus sequences in the CISH 
promoter.86 H1 loss is necessary to allow STAT5a binding and transcriptional activation, and is 
therefore a critical negative regulator of STAT5a-mediated transcription.86 Thus, chromatin 




Epigenetic modifications include DNA methylation and acetylation which play important 
roles in regulating transcription. The histone-lysine N-methytransferase enzyme enhancer of zeste 
homolog 2 (EZH2) is responsible for the trimethylation of lysine 27 of histone H3 (H3K27me3).129 
Loss of EZH2 in mammary stem cells was shown to result in precocious differentiation of alveolar 
epithelium.129 This also resulted in increased STAT5 occupancy of mammary-specific STAT5 
target genes and their subsequent activation.129 These findings led the authors to propose that the 
presence of EZH2 enables controlled recruitment of STAT5 and transcriptional co-activators to 
genes.129 
STAT5a transcriptionally upregulates the expression of suppressors of cytokine signaling 
(SOCs) proteins and CISH. These proteins act as negative feedback on STAT5a activity.82,121 
These proteins can bind directly to tyrosine kinases to deactivate them, or block docking sites on 
cytokine receptors to inhibit STAT5 activation.121 
1.6.3.4. STAT5a and the nuclear receptor family 
As shown in models of both normal and malignant breast epithelium, STAT5 physically 
interacts with PR, glucocorticoid receptor (GR), and ERα, with subsequent effects on 
transcriptional activity.121,130–132 In cells stimulated with both PRL and the glucocorticoid 
dexamethasone, STAT5a physically interacts with GR, and STAT5a transcriptional activity is 
enhanced.121,133,134 This indicates that GR acts as a coactivator for STAT5a gene transcription. 
STAT5a also acts as a coactivator in the regulation of some PR genes.135 Conversely, direct 
physical interaction of ERα and STAT5 has been shown to repress STAT5 activity at some 
promoters, but enhance STAT5 activity at others, indicating promoter-dependent cross-talk 




a PRL-dependent manner to increase expression of PRLr.136 Finally, PRL-induced transcription of 
ERα relies on STAT5a binding to GAS elements in the ERα promoter.137 
PRL-activated pY-STAT5 has also been shown to cooperatively act with androgen receptor 
(AR) in breast cancer cells at the promoter for the carboxypeptidase-D gene.138 While AR is 
expressed in 70-90% of invasive breast cancers, its role in breast cancer progression is unknown.138 
Cross-talk between PRL-STAT5 and AR is much better studied and understood in prostate cancer, 
where STAT5 has been shown to promote AR signaling and physically interact with AR.139 
 
1.6.4. Canonical pathway of JAK/STAT 
1.6.4.1. In normal mammary development 
The JAK2/STAT5 pathway downstream of PRL/PRLr binding plays an essential role in 
establishing alveologenesis during pregnancy. Both Jak2-/- and Stat5-/- (targeting both Stat5a and 
Stat5b) mice were shown to phenocopy Prlr-/- mammary gland defects.96,97 Jak2 deletion impaired 
alveologenesis and pregnancy-induced branching that could not be rescued with multiple 
pregnancies.140 When Stat5 was conditionally deleted prior to pregnancy, epithelial proliferation 
and differentiation were inhibited. When Stat5 was deleted during pregnancy, premature cell death 
occurred, indicating that cell proliferation, differentiation, and survival require STAT5.141  
When Stat5 is introduced as a transgene under control of β-lactoglobulin gene (BLG) 
regulatory sequences to direct it to the mammary epithelium in mice, these BLG/STAT5 mice 
exhibit larger alveoli in mid-pregnancy and delayed onset of involution, along with elevated levels 
of β-casein secretion into milk.142 This study, by Iavnilovitch et al, extended the functional 




Not only does STAT5 act on normal mammary cell proliferation, but it also acts on milk protein 
gene expression (i.e. β-casein), and post-lactational involution. 
The mechanism by which the STAT family regulate the developmental switch from 
lactation to involution is mostly by regulating survival signaling through the PI3-kinase/AKT 
pathway.42,115,143 In response to PRL, STAT5 binds to the consensus motifs within the Akt1 locus, 
initiating Akt transcription, and generating a strong cell survival signal.143  Indeed, overexpression 
of Stat5a does not promote aberrant proliferation of epithelial cells, but, in fact, delays mammary 
gland involution in transgenic mice.143 In contrast STAT3 antagonizes pro-survival STAT5 signals 
and promotes pro-apoptotic pathways.115 
1.6.4.2. STAT5a in breast cancer 
The mechanisms through which STATs promote breast cancer are actively being 
investigated, and while this investigation has included the roles of STAT3 and STAT5b, the focus 
of this thesis will be on STAT5a. Prior to the early 2000s, most of the pro-tumorigenic gene targets 
of STATs were identified not necessarily in models of breast cancer, but rather in other cancers 
such as prostate, or normal mammary epithelium, and extrapolated to breast cancer. The first 
indications of STAT5a activity in breast cancer came about through the observation that STAT5a 
is a survival factor in normal mammary epithelium, as discussed above. Evidence for functioning 
STAT5a in breast cancer includes its expression in breast cancer tissues and cell lines, mouse 
models, and target-gene activation. Increasingly, however is evidence that pY-STAT5a is a 
positive prognostic indicator. This duality in STAT5a in breast cancer warrants thorough 
investigation. 
In order to first explore the in vivo role of STAT5a in establishing mammary hyperplasia 




is driven by TGFα, which is under the control of whey acidic protein (WAP) promoter for targeting 
expression to the mammary gland. The authors then took this model and generated WAP-TGFα 
mice with homozygous loss of Stat5a (Stat5aKOTGFα).144 In the WAP-TGF-α model, mammary 
targeted TGFα binds EGFR, delaying mammary involution and transforming mammary 
epithelium in mice bred ad lib after three pregnancies. In this model, during involution, STAT5a 
was persistently phosphorylated on Y694, stimulated by TGFα-EGFR binding. However, loss of 
STAT5a increased the rate of involution in the mammary glands after pregnancy, and increased 
the levels of apoptotic cells, demonstrating that STAT5a is mandatory to avoid programmed cell 
death in mammary epithelial cells. Further, loss of STAT5a in the mammary gland delayed any 
appearance of EGFR-mediated hyperplasia and hypertrophy by 1.5 months and resulted in single 
gland involvement rather than multiple gland involvement in the TGFα transgenic mice. In this 
study, persistent STAT5a phosphorylation by TGFα stimulation linked STAT5a to the 
transformation of the mammary gland, which the authors concluded occurred with loss of cell 
survival regulation.144  
In a similar model of mammary cancer progression initiated by expression of the Simian 
Virus 40 T antigen (TAg), i.e. the WAP-TAg transgenic mouse model, 86% of the 
adenocarcinomas demonstrate activated STAT5a (pY-STAT5a). Ren et al set out to determine if 
pY-STAT5a was a driver of these cancers or if it was a bystander effect. In this model, hemizygous 
loss of Stat5a (Stat5a+/- WAP-TAg) significantly reduced the number of mice with palpable 
tumors after 7 months, reduced the size of tumors overall, and delayed tumor onset from 188 days 
to 208 days.145 Concordant with delayed mammary cancer progression, Stat5a+/- WAP-TAg 




proportion of mitotic cells, nor histologic grade, indicating that proliferation and differentiation of 
the tumors was not affected by loss of STAT5a. 
Rather than STAT5a knockout, Iavnilovitch et al generated a transgenic mouse model in 
which several variants of STAT5a were expressed in the mammary gland using regulatory 
sequences of the BLG.146 This study set out to investigate the deregulation of STAT5 in mammary 
cell transformation. Mammary-directed expression of either WT-STAT5, a constitutively active 
form of STAT5a (Stat5ca), or a dominant negative form of STAT5a in which the TAD was mostly 
deleted (Stat5Δ750) in FVB/N mice resulted in mammary tumors of four main phenotypes as 
analyzed by histology within 8-12 months: undifferentiated carcinoma, adenocarcinoma, papillary 
adenocarcinoma, and micropapillary adenocarcinoma. Interestingly, of the three transgenic 
variants of STAT5, BLG/Stat5Δ750 mice more often developed undifferentiated carcinomas, 
while BLG/Stat5 or BLG/Stat5ca mice developed papillary or micropapillary adenocarcinomas 
most frequently. Tumors from all three variants expressed high levels of cyclin D1, however 
tumors from mice bearing the Stat5ca variant expressed three-fold cyclin D1 compared to the other 
two STAT5 variants. This study concluded that mammary cell transformation and tumor 
development may by independent from the transactivation of STAT5, however this conclusion 
relies heavily on the presumption that the Stat5Δ750 transgene functions as a dominant negative 
transcriptional regulator. The Stat5Δ750 transgene is assumed to be a dominant negative form of 
STAT5 because it has been shown to bind canonical STAT5-DNA response elements and block 
transcription, however, it should be noted that this conclusion came from studies limited by the 
use of luciferase reporter assays with GAS motif sequences or immunoblot for milk proteins such 
as β-casein, so global transcriptomic effects are still unknown.142,147 With the truncation of the 




this thesis, S780, is contained in the deleted sequence, and residue S726 is still present and 
presumptively phosphorylated. These serine residues will be discussed at length. 
While these experiments in mouse models demonstrated STAT5a as an important survival 
factor and possible promoter of mammary cancer progression, it is important to correlate this data 
to human mammary cancer. One of the first studies to examine the expression of tyrosine-
phosphorylated STAT5a in human breast cancer tissue samples, by Cotarla et al in 2003, utilized 
immunohistochemistry of 78 patient primary breast adenocarcinomas samples compared to normal 
non-pregnant breast tissue samples obtained from reduction mammoplasties.148 
Immunohistochemistry (IHC) of these samples examined extent of nuclear localization, 
disregarding staining intensity. IHC determined nuclear localized STAT5a in 59 of 78 (76%) of 
the breast adenocarcinomas, and 38 of 78 (49%) of these tissues exhibited relatively high levels 
(per the methodology: ≥51%) of nuclear staining for STAT5a.148 The phosphorylation status of 
STAT5a was also examined in these samples, and all samples with nuclear STAT5a exhibited pY-
STAT5a. When the authors correlated STAT5a nuclear localization with patient clinical 
characteristics, a significant positive association was found between nuclear localized STAT5a 
and increased levels of histologic differentiation; poorly differentiated cancers were mainly 
STAT5a negative.148 No relationship was found with any other clinical outcomes data, i.e., 
menopausal status, ER status, HER2 status, or lymph node metastases. This study concluded that 
STAT5a may be an independent prognostic indicator for breast cancer patients, however limited 
by a small cohort, a larger study with patient outcomes data would be needed to verify this data.  
Yamashita et al and Peck et al would examine this question independently with larger 
cohorts.149,150 Although Yamashita et al examined a cohort of 517 patients, the authors failed to 




of STAT5 for statistical correlations with clinical data (this may be due to their antibody choice, 
as they found only 18 out of 517 tumors were positive for nuclear STAT5).149 In this study, they 
found 33.8% of the tumors to be positive for STAT5 by IHC, and this staining was correlated to 
lower histologic grade, reproducing the findings of Cotarla et al.148,149 STAT5 was also found to 
be positively associated with ER and PR expression, and increased overall survival in ER+ disease 
(but not disease-free survival).149 Further, this study attempted to determine if STAT5 could be a 
predictive response to endocrine therapy for metastatic breast cancer. However, as has been seen 
before, the cohort of this study was a limitation: overall 70 patients received endocrine therapy for 
metastatic breast cancer, 32 of which responded to the therapies they were given in clinic.149 Of 
the total cohort, 19 out of 70 (27.1%) patient’s primary tumors were STAT5 positive. Of the 19 
STAT5 positive primary tumors, 13 of these patients responded to the endocrine therapies they 
were given, and thus 13 out 32 responders had STAT5 expressed in the primary tumor (or 
40.6%).149  
Peck et al attempted to overcome the shortcomings of the previous studies by 
distinguishing expression of STAT5a and STAT5b in clinical patient samples, in a study with five 
independent cohorts totaling clinical outcomes data for 686 patients.150 Citing the discrepant 
evidence for a role for STAT5a in promoting tumor initiation but also maintaining tumor 
differentiation and suppression of disease progression in established human breast cancer, these 
authors undertook a systematic effort to quantify STAT5a and STAT5b expression during human 
breast cancer progression relative to normal breast tissue.150 In these cohorts, frequent and selective 
loss of nuclear and total STAT5a protein was observed in invasive breast cancer and lymph node 
metastases, whereas expression of STAT5b remained unchanged.150 Nuclear-localized STAT5a 




This study was powerful in that this finding was validated in multiple patient cohorts of therapy-
naïve, lymph node negative disease, as well as in patients who had been treated with antiestrogen 
therapy. This study also examined two independent cohorts of patients treated with antiestrogen 
therapy alone and found that low levels of nuclear-STAT5a associated with elevated risk of failure 
of antiestrogen treatment.150 A limitation of the study was the use of archival cohorts, and that the 
high and low levels of STAT5a differed between these cohorts for prognostic outcomes and 
antiestrogen therapy-response. Unfortunately, to date, no follow up studies with randomized 
prospective trial material have been reported.  
 
1.6.5. Non-canonical activity of STATs without tyrosine phosphorylation 
Unphosphorylated STATs (upY-STATs) have long been considered the dormant, non-
functioning form of STATs residing in the cytoplasm. Recently, the canonical dogma of STAT 
activation exclusively through tyrosine-phosphorylation has been challenged as reports have 
demonstrated STAT actions in non-tyrosine phosphorylated (or “latent”) states. In fact, upY-
STATs are present in the nucleus regardless of cytokine stimulation.151–153 Further, at this time, 
upY-STAT 1, 3, and 5a have all been reported to have some transcriptional activity distinct from 
their pY-states.111,154–159 
STAT1 is a principal target of type I and type II IFNs implicated in malignancy as a tumor 
suppressor, and is tyrosine-phosphorylated at residue 701.111 Evidence supporting STAT1 
functioning as a transcription factor in the absence of tyrosine phosphorylation comes from 
several lines of research. First, in a rescue of STAT1-null cells with STAT1 or the tyrosine-to-
phenylalanine mutant Y701F, both rescues were sensitive to tumor necrosis factor (TNF)-induced 




that STAT1 is required for TNF-mediated apoptosis, and appears to act in the absence of 
phosphorylation of Y701.154 In another study, upY-STAT1 and interferon regulatory factor 1 
(IRF-1) were found to bind to partially overlapping interferon consensus sequence 2 (ICS-2) and 
GAS sites in the LMP2 promoter to activate transcription.155 This study used DNA microarrays 
and revealed that basal expression of many genes was regulated similarly by wild-type 
unphosphorylated STAT1 (that is, in untreated cells) and mutant Y701F STAT1.155     
Activation of STAT3 has been defined by the phosphorylation of tyrosine residue Y705. 
However, unphosphorylated STAT3 has been shown to activate gene expression important to 
oncogenesis, as well as mediate the antiviral and antiproliferative actions of cytokines.111,158,160 
In fact, STAT3 serves two distinct roles in cytokine-dependent transcription: during the acute 
response through the actions of phosphorylated STAT3 dimers, and secondarily as part of the 
complete response through actions of increased amounts of upY-STAT3.160 Unphosphorylated 
STAT3 has been shown to directly interact with other transcriptional co-activators, and has been 
said to form a “novel transcription factor” that might recognize half of a GAS element plus a 
DNA element which the non-STAT partner can bind.111,160 There is also evidence that 
unphosphorylated STAT3 suppresses tumor formation by influencing heterochromatin dynamics 
through its association with heterochromatin protein 1 (HP1).159 These data all indicate that upY-
STAT3 has noncanonical functions influencing transcription through a variety of mechanisms. 
Although there have only been two studies to date on upY-STAT5a activity, the genome-
wide approach taken by Park et al in 2016 supports the idea that upY-STAT5 may act as a partial 
antagonist of the biological activity of pY-STAT5.157,161,162 Park et al studied STAT5 in a 
hematopoietic stem cell line that undergoes megakaryocytic differentiation in the presence of 




nuclear accumulation of phospho-tyrosine STAT5 after TPO treatment. ChIP-seq revealed 
STAT5 redistribution within the cell genome with TPO treatment and three distinct binding site 
clusters were identified that represented exclusive upY-STAT5 binding, exclusive pY-STAT5 
binding, or binding sites for STAT5 in both unstimulated and TPO-treated cells.161 Further, the 
authors identified binding cites for CCCTC-binding factor (CTCF) close in proximity to two-
thirds of the sites bound by upY-STAT5, and the vast majority of upY-STAT5 binding close to 
CTCF was lost with TPO treatment. These regions for upY-STAT5 and CTCF binding were 
highly enriched for genes involved in megakaryocyte differentiation and platelet development, 
which were repressed in the presence of upY-STAT5.161 Overall, this data was found to support 
the concept that upY-STAT5 suppresses transcriptional programming required for 
megakaryocytic differentiation, while TPO/pY-STAT5 redistribution to promoters with GAS 
sequences allows for transcription of genes involved in survival of differentiating cells. 
 The study by Hu et al (2013), found that, in a similar manner to upY-STAT3, upY-STAT5a 
contributes to heterochromatin formation and maintenance suppressing tumorigenesis by 
interacting with HP1 in colon cancer cells.157,159 However, these authors concluded that upY-
STAT5a has an exclusive role in heterochromatin formation and therefore transcriptional 
repression.157 The concept that HP1 interaction with STAT5a is either an alternative mode or 
related to the biological activity of upY-STAT5a in other cell types was not addressed and remains 
an open question. 
 
1.6.6. Serine phosphorylation of STATs 
The phosphorylation of STAT proteins on serine residues may occur in a manner that is 




Ser‐Pro (PMSP) serine phosphorylation motif, whereas STAT5a and STAT5b contain a Pro-Ser-
Pro (PSP) sequence.163 
STAT1 is phosphorylated on serine residue 727 (S727) and has been described as playing 
an important role in some constitutive functions of STAT1.111 STAT1 serine phosphorylation has 
been found to be independent of tyrosine phosphorylation, and is phosphorylated in response to 
ultraviolet light (UV), IL-1, or TNF.111,164 Notably, transcriptional activation of Fas and FasL in 
cardiac myocytes has been found to be dependent on STAT1 S727 phosphorylation but not 
Y701.165 In another example, when S727 was mutated to alanine (A, S727A), basal transcription 
of caspase, GBP1, TAP1, and IFP53 genes we       re all effected.111,154 Thus, S727 has been 
determined to be essential for effective STAT1 transcriptional activity for certain genes. 
Like STAT1, STAT3 is phosphorylated on residue S727, and phosphorylation of S727 is 
independent of phosphorylation of Y705.111 It has been shown to be phosphorylated in response 
to growth factors, and as necessary for maximal transcriptional activity.111,163 However, this 
requirement for phosphorylation of S727 on STAT3 may be promoter and cell-type dependent. In 
one study, activation of the IRF-1 promoter was found dependent on S727.166 Conversely, 
mutation of S727 to the phospho-deficient alanine (S727A) was not found to have any effect on 
activation of the haptoglobin acute phase promoter compared to WT-STAT3.167 STAT3 nuclear 
import has been found to be both serine and tyrosine phosphorylation independent.163,168 There is 
some evidence that S727 phosphorylation inhibits tyrosine phosphorylation or increases tyrosine 
dephosphorylation, however the relationship is still unclear.163   
Human STAT5a and STAT5b contain serine residues in the highly divergent TAD located 
in conserved PSP motif at positions 726 (STAT5a) and 730 (STAT5b), as seen in Figure 1.2 and 




motif found across species including mouse, rat, and pig.169,170 It should be noted that previous 
publications regarding human STAT5a used the amino acid sequence numbering for mouse Stat5a, 
whereas this work used the amino acid sequence for human STAT5a obtained from the current 
National Center for Biotechnology Information (NCBI) genome assembly and protein 
database.107,171,172 The current human STAT5a peptide sequence gives the serine residues of 
interest the positions 726 and 780, while the mouse Stat5a peptide sequence gives the serine 
residues positions 725 and 779. Thus, some labelling from the literature uses S725 or S779 for 
S726 and S780, respectively. Further, studies showing the phenotypic effects of either S726 or 
S780 use models in which the residues are mutated to the phospho-deficient amino acid alanine 
(A). 
Expression of STAT5a phosphorylated at residues S726 and S780 has been shown in 
human immune cells and mouse tissues. Phosphorylation of S726 in response to IL-2 was first 
shown in human T lymphocytes by Kirken et al in 2000, and Nagy et al (2002) replicated this 
finding.173,174 Phosphorylation of both S725 and S779 in response to IL-3 was shown in the mouse 
hematopoietic pro-B cell, Ba/F3 cell line.169 Constitutive phosphorylation of S726 was shown in 
both human chronic myeloid leukemia (CML) and human acute myeloid leukemia (AML) cell 
lines, whereas constitutive phosphorylation of S780 was restricted to CML cell lines.169 In two 
separate studies, phosphorylation of S779 and S725 were examined throughout mouse mammary 
gland development and found to increase throughout pregnancy and lactation, with no expression 
at involution. 170,175 Evidence for expression of pS779 in the mouse spleen and heart has also been 
shown.170 
PRL-induced serine phosphorylation of STAT5a is less well established. Whereas Kirken 




lymphocytes, Yamashita et al reported in two different studies that pS725 in transfected COS-7 
cells was constitutive.127,175,176 Further, Yamashita et al also showed pS779 was constitutive using 
the same cell line.175 On the other hand, Beuvink et al found that pS779 was induced by PRL in 
transfected COS-7 cells.170 Each of these reports utilized either audioradiographic phospho-amino 
analysis, western blotting, or a combination of the two methods. These discrepancies in PRL-
inducible phosphorylation highlight the need for understanding cell type-specific signaling events.  
1.6.6.1. Hematopoietic models 
While there have been studies on the STAT5a serine residues in mammary cells regarding 
STAT5a transcriptional activity, the phenotypic effects of mutations of the STAT5a serine 
residues, either alone or together, have mainly been shown in hematopoietic models. 
The study of STAT5a serine residues in hematopoietic systems came about because 
constitutive activation of STAT5a has been shown to be directly involved with oncogenic 
transformation, however activating mutations of STAT5a have not been reported. Thus, in 
studying the function of STAT5a serine residues in leukemogenic transformation, Friedbichler et 
al first determined that STAT5a was still biochemically functional with serine-to-alanine S725A 
or S779A mutations; in these STAT5a mutants tyrosine phosphorylation was stimulated with EPO 
treatment, and these STAT5a mutants exhibited no significant differences in DNA binding 
properties measured by electrophoretic mobility shift assay (EMSA) using the β-casein response 
element.169 Further, although STAT5a serine phosphorylation is not essential for mast cell and T-
cell proliferation, constitutively active STAT5a confers factor-independent survival of IL-3 
dependent pro-B cells (Ba/F3 cells) only in the presence of S725 or S779, showing that the serine 
residues are necessary for oncogenic transformation.169 Lastly, this study showed that loss of serine 




mutants of constitutively active STAT5a. Whereas mice transplanted with cells expressing 
constitutively active STAT5a succumbed to leukemia within 10 weeks, mice with single serine 
STAT5a mutants developed signs of disease after 4 months, and throughout the period of analysis 
(40 weeks), the double point mutants (S725A + S779A) remained disease-free.169 
In CML and AML, STAT5 signaling is often activated downstream of oncogenic tyrosine 
kinases such as the BCR-ABL oncogene, a constitutively active form of the Abelson (ABL) 
tyrosine kinase capable of transforming hematopoietic cells.177 Berger et al therefore studied the 
expression of STAT5a serine mutants S725A-, S779A-, and a double point mutant (termed SASA), 
in leukemic cell lines expressing BCR-ABL. They found that expression of the STAT5a mutant 
lacking both the serine residues S725 and S779 did not support transformation and induced 
apoptosis in the oncogenic cell lines.178 Further, expression of STAT5a lacking either S725 or 
S779 alone, or both (the SASA mutant) suppressed the leukemic potential of BCR-ABL cells in 
vivo. Interestingly, single mutation of S779A prolonged disease latency in mice transplanted with 
leukemic BCR-ABL cell lines compared to S725A- or WT-STAT5a. Additionally, survival was 
further enhanced in mice transplanted with the double point mutant.178 Finally, S779A-STAT5a 
failed to accumulate in the nucleus with BCR-ABL activation, indicating a role for this residue in 




Figure 1.4 Described roles for pY694-, pS726-, and pS780-STAT5a in regulating STAT5a 
activity. In breast tissue, phosphorylation of residue Y694 has been ascribed the major canonical 
role for regulating STAT5a activity, while phosphorylation of the serine residues has been 
described to have modulatory effects on pY694-STAT5a activity. However, phosphorylation of 
S726 and S780 is implicated in BCR-ABL leukemogenesis. 
 
1.6.6.2. Normal breast development 
Like tyrosine phosphorylation, STAT5a serine phosphorylation increases throughout 
pregnancy and lactation, however there is a sharp decline of pS- but a slower decline of pY-
STAT5a at involution as examined in mouse mammary gland tissue. 170,175 During pregnancy, 
levels of circulating PRL also increase, however milk production remains suppressed until late 
pregnancy. Only at parturition, when circulating progesterone decreases and glucocorticoid levels 
begin to rise does lactation occur. In fact, GR enhances STAT5 activation, prolonging STAT5a 
DNA binding, and phosphorylation of Y694.133 Accordingly, glucocorticoid acts synergistically 
with PRL-stimulated STAT5a at the promoter for β-casein, a highly abundant protein in milk.134 
PRL-inducible reporter gene constructs for β-casein have been heavily relied on to understand the 
potential functions of STAT5a serine phosphorylation with PRL treatment in normal and 
malignant breast tissue.127,170,175 
Use of similar methodology across laboratories, in which COS-7 cells were transfected 




STAT5a mutants have yielded different results. First, in 1998, the laboratory of Hallgeir Rui 
showed that the S725A- mutant had no significant change in PRL-inducible β-casein gene 
expression compared to WT-STAT5a.127 Beuvink et al expanded this nonsignificant (yet 
significant) finding to include the S725A-, S779-, or S725+S779-STAT5a mutants in 2000.170 
Then, in 2001, Rui’s laboratory published another paper in which the S725A- mutant had increased 
PRL-induced β-casein gene transcription, and the S725A+S779A mutant had further increased 
PRL-induced β-casein gene transcription compared to WT-STAT5a in both COS-7 and MCF-7 
cells.175 This finding lent itself to their hypothesis that the combined mutation led to a gain of 
function for STAT5a transcriptional activity at the β-casein gene. That is, although they could not 
replicate their earlier findings or the findings of other laboratories, the new observations indicated 
that functional cooperativity exists between the two serine phosphorylation sites which negatively 
affect the transcriptional activity of STAT5a.127,169,170,175  
Beuvink et al and the work published out of Hallgeir Rui’s laboratory did agree that 
STAT5a mutated at both S725 and S779 had longer DNA binding times measured by EMSA up 
to 30 hours and 24 hours of PRL stimulation, respectively.170,175 Beuvink et al also found that the 
S725A mutant decreased Y694 dephosphorylation, which they concluded allowed STAT5a to bind 
to DNA longer. Together, the findings from Beuvink and Rui suggested serine phosphorylation 
suppresses STAT5a binding to the GAS element of the β-casein promoter. Finally, Rui’s 
laboratory showed that costimulation of the GR reversed the inhibitory effect of STAT5a serine 
phosphorylation.175 Thus, glucocorticoid could act like a time release for STAT5a activity at the 
beginning of lactation.   
 Utilization of the β-casein reporter assays, while useful, are limited in scope when 




in transcriptional activity of single-point STAT5a phospho-mutants compared to WT-STAT5a, 
expression of the double mutant, S725A+S779A-STAT5a, decreased expression of one reporter 
construct (ntcp) but increased expression of another (β-casein) in the presence of PRL in COS-1 
cells.179 Additionally, in GH stimulated HepG2 cells or COS-1 cells expressing the 
S725A+S779A-STAT5a and the ntcp reporter gene construct, transcription of the ntcp reporter 
gene was decreased in the HepG2 cells, but unaffected in the COS-1 cells compared to WT-
STAT5a.179 Thus, serine phosphorylation affects STAT5a transcriptional activity in both an 
enhancer/promoter context as well as a cell-type context, a concept that was not revealed when 
only the β-casein promoter was examined previously. 
1.6.6.3. Mammary cancer 
Other than occasionally using MCF7 or T47D luminal breast cancer cell lines with 
exogenous over-expression of STAT5a serine mutants and examining transcription of a reporter 
gene construct, no phenotypic studies have been performed to this date to understand how the 
serine residues affect STAT5a function. 
However, two naturally occurring dominant-negative, C-terminally truncated forms of 
STAT5a, STAT5aΔ740 and STAT5aΔ713 have been studied in T47D and MCF7 cells.130 Mutant 
STAT5aΔ740 lacks residue S779, but retains S725, while STAT5aΔ713 lacks both serine 
phospho-sites S725 and S779. Both dominant-negative forms of STAT5a retain the phospho-
tyrosine 694. Yamashita et al (2003) set out to determine the impact these dominant-negative 
forms of STAT5a have on ER activity, and found that overexpression of STAT5aΔ740 completely 
blocked transcriptional activity of endogenous ER in T47D and MCF7 cells, and reduced 
endogenous PR expression, an ER transcriptional target, in T47D cells.130 Further, dominant-




did not inhibit the growth of MCF7 cells, which are deficient in caspase 3.130,180 The authors 
concluded that apoptosis of T47D cells may have occurred as an effect of combined inhibition of 
the STAT5a and ER signaling pathways. These findings indicate that loss of the C-terminal TAD 
containing both phospho-serine sites of STAT5a may have regulatory functions in ER 
transcriptional activity and apoptosis in ER+ breast cancer cells.  
 
1.7. Goal of this work and hypothesis 
The overall goal of this thesis is to investigate the functional role of non-tyrosine 
phosphorylated STAT5a as well as serine phosphorylation of STAT5a in luminal breast cancer. 
Luminal breast cancer cell lines are used with the aim to model the functional significance of 
phosphorylation of residues S726 and S780 on upY-STAT5a, individually and together. The 
central hypothesis is that non-canonical activation of STAT5a by serine phosphorylation in 
response to PRL regulates STAT5a nuclear activity and modulates transcriptional 
programming to contribute to mammary oncogenesis. This hypothesis will be tested by the 
studies in the specific aims that follow: 
Aim 1: Characterize the functional significance of STAT5a serine phosphorylation in PRL 
signaling in breast cancer in vitro. Knockdown/rescue mutagenesis targeting STAT5a in luminal 
breast cancer cell line (MCF7), is studied and related to PRL signaling, phenotypic hallmarks 





Aim 2: Determine the global transcriptomic effects of loss of each phospho-site (p-site) of 
STAT5a in luminal breast cancer and relate this to patient datasets. Differential gene expression 
in MCF7 cells expressing the STAT5a mutants generated in Aim 1 will be determined using RNA-
sequencing. We hypothesize that loss of each p-site will differentially affect PRL-induced gene 
programs. We will compare this data to publish datasets for patient gene expression, as well as 
patient derived xenografts (PDX), to determine if expression of these STAT5a mutants signals 
intrinsic subtype-switching. 
 
Aim 3: Determine the mechanism by which PRL regulates serine phosphorylation of STAT5a 
activity in vitro. We hypothesize that ERK1/2 mediates phosphorylation of S726- and S780-
STAT5a and investigate this by co-immunoprecipitating STAT5a with ERK1/2 and using 
pharmacologic inhibition of ERK1/2. These methods will be validated in our cell models if 
phospho-deficient STAT5a is able to interact with ERK1/2 and related to the assays in Aim 1, with 




2. Chapter 2: Materials and Methods 
2.1 Materials 
2.1.2 Chemicals 
Table 2.1. Chemicals used in the pursuit of this dissertation. 
Chemical Supplier 
Agar Thermo Fisher Scientific (Waltham, MA) 
Agarose EMD-Millipore (Burlington, MA) 
Ammonium persulfate Sigma-Aldrich (St. Louis, MO) 
Ampicillin/carbenicillin Gemini Bio-Products (West Sacramento, CA) 
β-mercaptoethanol Bio-rad (Hercules, CA) 
Bovine serum albumin, Fraction V Sigma-Aldrich (St. Louis, MO) 
DMSO sterile-filtered, hybridoma 
tested (for drug studies) 
Sigma-Aldrich (St. Louis, MO) 
DNase I Promega (Madison, WI) 
EDTA Quality Biological (Gaithersburg, MD) 
EGTA Quality Biological (Gaithersburg, MD) 
Ethanol, 200 proof VWR (Radnor, PA) 
HEPES Thermo Fisher Scientific (Waltham, MA) 
Isoproponal WorldWide Medical (Bristol, PA) 
LB broth, ready pack Thermo Fisher Scientific (Waltham, MA) 
Methanol WorldWide Medical (Bristol, PA) 
Phosphatase Inhibitor Cocktail Set II Sigma-Aldrich (St. Louis, MO) 
Polybrene Sigma-Aldrich (St. Louis, MO) 
Protease Inhibitor Cocktail 
(cOmplete) 
Sigma-Aldrich (St. Louis, MO) 
Puromycin Gemini Bio-Products (West Sacramento, CA) 
SDS, 10% (w/v) Bio-Rad (Hercules, CA) 
Sodium chloride Sigma-Aldrich (St. Louis, MO) 
Sodium hydroxide Thermo Fisher Scientific (Waltham, MA) 
TEMED Bio-rad (Hercules, CA) 
Tris base Thermo Fisher Scientific (Waltham, MA) 
Triton-X Sigma-Aldrich (St. Louis, MO) 
Tween-20 Sigma-Aldrich (St. Louis, MO) 




2.1.3 Buffers, Media, Stock solutions 
Table 2.2. Buffer Recipes and Suppliers. 
Buffer Recipe Supplier 




20 mM HEPES (pH 7.4) 
10 mM KCl 
2 mM MgCl2 
1 mM EDTA 
1 mM EGTA 
Fresh before each use: 1:1000 1 mM DTT 
1% (v/v) Phosphatase Inhibitor 




Tris-HCl pH 7.4 
150 mM NaCl  
1 mM EDTA 
0.1% (v/v) Triton X-100 
5% (v/v) glycerol 
1% (v/v) Phosphatase Inhibitor Cocktail 2 












Western Blot Resolving 
Gel buffer 
1.5 M Tris-HCl, pH 6.8 
Western Blot Stacking 
Gel buffer 
0.5 M Tris-HCl, pH 8.8 
10% (w/v) SDS solution  
TEMED  
Western Blot Running 
Buffer 
1X Tris/Glycine/SDS 
Western Blot Transfer 
Buffer 
1X Turbo-blot Transfer buffer 
20% (v/v) 200 proof Ethanol 
Western Blot Stripping 
Buffer 
1.5% glycine (w/v) 
0.1% SDS (w/v) 




4x Laemmli Sample 
Buffer 
 Bio-rad (Hercules, 
CA) 





1x TBE   
LB Medium   
LB agar   
 
2.1.4 Kits, Reagents, and Enzymes 
 
Table 2.3 Kits and Reagents. 
Reagent Supplier 
QIAprep Spin Miniprep kit Qiagen (Hilden, Germany) 
Endofree Plasmid Maxi kit Qiagen (Hilden, Germany) 
Purelink RNA Mini kit (cat# 12183020); 
Purelink DNase set (cat# 12185010) 
Thermo Fisher Scientific (Waltham, MA) 
iScript cDNA synthesis kit Bio-rad (Hercules, CA) 
SYBR Green PCR master mix Thermo Fisher Scientific (Waltham, MA) 
Phusion Site-directed mutagenesis kit Thermo Fisher Scientific (Waltham, MA) 
Q5 Site-directed mutagenesis kit NEB (Ipswich, MA) 
Kaleidoscope protein ladder Bio-rad (Hercules, CA) 
Mini-protean TGX gels Bio-rad (Hercules, CA) 
Immobilon Forte Western HRP substrate Sigma-Aldrich (St. Louis, MO) 
DNA ladder, 1 kb NEB (Ipswich, MA) 
DNA ladder, 100 bp NEB (Ipswich, MA) 
E. cloni competent cells Lucigen (Middleton, WI) 
2.1.5 Prolactin 
Human recombinant prolactin (PRL) was a gift from Dr. Anthony Kossiakoff (University of 
Chicago, Chicago, IL). Aliquots of PRL were stored at -80°C.  
2.1.6 Mammalian Cell Lines and tissue culture 
Table 2.4 Human cell lines used for in vitro work. 
Cell line Description Source 
MCF-7 Low-invasive human breast cancer cell line; 
ER+/PR+/Her2- (Luminal A/B) 
American Type Culture 





T-47D Low-invasive human breast cancer cell line; 
ER+/PR+/Her2- (Luminal A) 
American Type Culture 
Collection (ATCC; Manassas, 
VA) 
HEK293T Human embryonic kidney cell line containing 
temperature-sensitive SV40 T-antigen for virus 
production 
American Type Culture 
Collection (ATCC; Manassas, 
VA) 
2.1.7 Tissue culture reagents and media 
Table 2.5 Tissue Culture Reagents. 
Reagent Supplier 
Bovine serum albumin Thermo Fisher Scientific (Waltham, MA) 
Gibco DMEM Thermo Fisher Scientific (Waltham, MA) 
Gibco DMEM, phenol free Thermo Fisher Scientific (Waltham, MA) 
Corning DMSO (for general tissue 
culture, ie cryopreservation) 
Thermo Fisher Scientific (Waltham, MA) 
DPBS Thermo Fisher Scientific (Waltham, MA) 
Fetal bovine serum (FBS), heat 
inactivated 
Thermo Fisher Scientific (Waltham, MA) 
Lipofectamine 3000 Thermo Fisher Scientific (Waltham, MA) 
Mycoalert Mycoplasma detection kit Lonza (Morristown, NJ) 
Opti-MEM Thermo Fisher Scientific (Waltham, MA) 
Penicillin/streptomycin Thermo Fisher Scientific (Waltham, MA) 
Versene Thermo Fisher Scientific (Waltham, MA) 
 
Complete growth media for MCF-7, T-47D, and HEK239T cells: DMEM, 10% (v/v) FBS, 1% 
P/S. 






STAT5a rescue plasmids 
STAT5a cDNA was cloned into the pTracer-EF/V5-His mammalian expression vector (v. 
C, Invitrogen #V88720, Thermo Fisher Scientific, Waltham, MA) such that it was in nucleotide 
sequence with the C-terminal V5 tag. This plasmid allows high level constitutive expression of the 
inserted gene under the control of the EF-1α promoter. The pTracer plasmid also has a 
constitutively expressed Cycle 3 GFP-Zeocin fusion gene for selection in mammalian cells. For 
this work, Zeocin was added to complete media for 1 to 2 weeks after viral transduction into MCF-
7 cells. 
Plasmid Transfection and Viral Transduction 
For transient transfections, the Lipofectamine 3000 transfection reagent protocol was used 
and scaled according to manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA). 
Prior to transfection, adherent cells were washed with PBS at 37oC, and media was replaced with 
Opti-MEM reduced-serum media (Thermo Fisher Scientific, Waltham, MA). 
For stable viral transductions, viral particles were generated using HEK293T cells (ATCC).  
For lentiviral production, HEK293T cells in Opti-mem media were transfected with 4.5 μg of Lenti 
construct DNA, 1.5 μg pMDG plasmid (containing VSV-G envelope) and 6 μg pCMVΔR8.91 
(packaging construct) using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA) 
following manufacturer’s protocol. After transfection complexes were added, the cells were 
returned to the incubator O/N. The following morning, Opti-mem media was replaced with 
complete growth media (DMEM supplemented with 10% (v/v) FBS and 1% (v/v) P/S), and plates 




from the HEK293T cells and centrifuged at 1000 g for 5 min and filtered through a 0.45 μm filter. 
This supernatant contains the viral particles for stable transduction of mammalian cell lines, and 
aliquots were stored at -80oC until use.  
Breast cancer cell lines, namely T47D and MCF-7, were “spinfected” in 6-well plates at a 
cell density of 25-50% confluency. To each well of a 6-well plate, 2 ml of viral particles were 
mixed with 1 ml complete media, and then 8 μg/ml polybrene was added. Plates were then 
spinfected at 500 g for 2 h at 32oC, and plates were placed back in the tissue culture incubator O/N. 
Viral media was replaced with complete growth media the next morning, and selective drugs were 
added 24 h after that.  
Antibiotic selection 
Antibiotics were used to selective for cells that were stably transduced with viral particles. 
For vectors containing a puromycin resistance gene, puromycin (Gemini Bio-Products, West 
Sacramento, CA) was used to select cells at 2 μg/ml for 1 week. After 1 week, puromycin was 
delivered to a concentration of 1 μg/ml for maintenance. Zeocin (Thermo Fisher, Waltham, MA) 
was used to select for cells transduced with pTracer viral particles. For MCF-7 cells, 400 μg/ml 
zeocin was added to media for 2 weeks, and after 2 weeks cells were maintained in 200 μg/ml 
zeocin. For T47D cells, 200 μg/ml zeocin was added to media for 2 weeks, and subsequently 
maintained in 100 μg/ml zeocin. 
 
2.1.9 Primers 
Primers for sequencing, PCR, and cloning were designed using Integrated DNA 




validated from literature sources. Primers for site-directed mutagenesis were designed using the 
Phusion Site-Directed Mutagenesis Kit (Thermo Fisher Scientific, Waltham, MA) guidelines for 
primer design or the NEBase Changer v1.2.9 (NEB, Ipswich, MA) online tool for Q5 site-directed 
mutagenesis. All primers were synthesized by Eurofins Genomics (Louisville, KY), and 
lyophilized powder was resuspended in dH2O for a stock of 100 μM. Primer stocks were diluted 
1:10 for working concentration of 10 μM. All primers were stored at -20°C.  
 
Table 2.6 Primers used in this dissertation work. 
Site-directed mutagenesis primers 
Targeted amino acid change For and Rev primers (5’-3’) 
Y694F* For GCTGTTGATGGATTTGTGAAACCACAG 
 Rev TTTAGCCAGCACAGGAGTGTAGTACTTGG 
S726A* For CAGGCCCCCGCCCCAGCT 
 Rev GTCCATGTACGTGGCGCTGCTGCC 
S780A For CTCCCGCCTCGCGCCCCCTGC 
 Rev TCAAGACTGTCCATTGGTCGGCGTAAGAGTTC 
Cloning primers  
pTracer Multiple Cloning 
Site (MCS) 
For and Rev primers (5’-3’) 
T7 promoter  For TAATACGACTCACTATAGGG 
BGH Rev TAGAAGGCACAGTCGAGG 
STAT5a KpnI For AAAAGGTACCATGGCGGGCTGGATC 
STAT5a NotI Rev AAAAGCGGCCGCTGAGAGGGAGCCTCTGGCAGA 
Sequencing primers 
STAT5a sequencing primer 1 For CCGAGAAGCACCAGAAGACCC 
 Rev GGGTCTTCTGGTGCTTCTCGG 
STAT5a sequencing primer 2 For GCCTGACCAAGGAGAACC 
 Rev GGTTCTCCTTGGTCAGGC 
STAT5a sequencing primer 3 For CCATCATCAGTGAGCAGCAGGC 
 Rev GCCTGCTGCTCACTGATGATGG 
qRT-PCR primers 
Gene Target For and Rev primers (5’-3’) 
BCL6 For CTGCAGATGGAGCATGTTGT 




CCND1 For CCGTCCATGCGGAAGATC 
 Rev GAAGACCTCCTCCTCGCACTT 
CEBPβ For AGAACGAGCGGCTGCAGAAGA 
 Rev CAAGTTCCGCAGGGTGCTGA 
CISH For AGAGGAGGATCTGCTGTGCAT 
 Rev GGAACCCCAATACCAGCCAG 
ERα For GGAAGCTACTGTTTGCTCCTAACTTG 
 Rev AGATCTCCACCATGCCCTCTAC 
GAPDH For CATGAGAAGTATGACAACAGCCT 
 Rev AGTCCTTCCACGATACCAAAGT 
ID1 For CTGGACGAGCAGCAGGTAA 
 Rev CTCCAACTGAAGGTCCCTGA 
PR For TCAGTGGGCAGATGCTGTATTT 
 Rev GCCACATGGTAAGGCATAATGA 
STAT5a For GTTCAGTGTTGGCAGCAATGAGC 
 Rev AGCACAGTAGCCGTGGCATTGT 
ZYX For AGGACATGGAGCATCCTCAGA 
 Rev GCATCGGCCGCAGAGTT 
*: 5’ phosphorylated 
2.1.10 Stat5a shRNA 
Table 2.7 shRNA constructs. 
Target Type Name Supplier Clone ID Sequence (5’-3’) 































Table 2.8 Primary antibodies. 
Antibody Host Application Dilution Supplier (product number) 
α-pY694-
STAT5a 
rabbit IB, IP, IHC 1:1000 Cell Signaling Technology 
(9359S) 
α-pS726-STAT5a rabbit IB, IHC 1:1000 Abcam (ab128896) 
α-pS780-STAT5a rabbit IB, IHC 1:1000 Abcam (ab30649) 
α-STAT5a mouse IB, IF 1:1000, 1:50 Santa Cruz (sc-271542) 
α-STAT5a rabbit IB, IHC 1:1000 Bioss Antibodies (bs-1142R) 
α-STAT5 rabbit IB 1:1000 Cell Signaling Technology 
(94205) 
α-pERK1/2 rabbit IB 1:1000 Cell Signaling Technology 
(9101S) 








rabbit IB 1:1000 Cell Signaling Technology 
(9491) 
α-tubulin mouse IB 1:1000 Invitrogen/Thermo Fisher 
Scientific (32-2500) 




α-vinculin mouse IB 1:2000 Bio-rad (MCA465GA) 
 
2.1.12 Secondary Antibodies 
Table 2.9 Secondary antibodies. 
Antibody Application Dilution  Supplier (product number) 
Goat anti-rabbit IgG 
HRP 





Cell Signaling Technology (7076) 
Alexa Fluor 568 Goat 
anti-mouse IgG  






2.1.13 Software & Online Tools 
Table 2.10 Software and online tools. 
Software/Online Tool Source Website 




BLAST NCBI, NIH https://blast.ncbi.nlm.nih.gov/Bl
ast.cgi 
CorelDraw CorelDraw https://www.coreldraw.com/en/ 
DeepVenn 2020 Tim Hulsen https://www.deepvenn.com/  
Enrichr Ma'ayan Lab, Icahn School of 
Medicine, Mount Sinai  
https://maayanlab.cloud/Enrichr
/  
Galaxy  Part of the Center for 
Comparative Genomics and 
Bioinformatics at Penn State, the 
Department of Biology at Johns 
Hopkins University and the 
Computational Biology Program at 
Oregon Health & Science 
University 
https://usegalaxy.org/  
Geneious Geneious https://www.geneious.com/ 
GraphPad Prism 7 and 
8 and 9 
GraphPad https://www.graphpad.com/ 
GSEA Broad Institute, Inc., 
Massachusetts Institute of 
Technology, and Regents of the 




ImageJ NIH https://imagej.nih.gov/ij/ 












Jalview Geoff Barton's Group at the 










NEBCloner (v1.4.0) NEB http://nebcloner.neb.com/#!/ 
OligoAnalyzer Integrated DNA Technologies https://www.idtdna.com/pages 
T-Coffee Comparative Bioinformatics 
Group 
Bioinformatics and Genomics 
Programme 
Center for Genomic Regulation 
(CRG) 
University of Barcelona 
http://tcoffee.crg.cat/ 




2.2.2 Molecular Biology methods 
Cloning and subcloning 
DNA gel electrophoresis 
DNA was analyzed on 0.8-1% agarose gels, with gel percentage chosen in order to 
optimize DNA fragment resolution based on size. Agarose was mixed with 1X TBE buffer and 
heated in a microwave to dissolve. Once the mixture cooled to ~60oC, the gel was poured into a 
horizontal gel tray and set for ~1 h at RT. The gel was then placed in the ENDURO Gel XL 
Electrophoresis System (Labnet International Inc, Edison, NJ), and covered with 1X TBE buffer. 
Samples were diluted with 6x DNA Gel Loading Buffer (NEB, Ipswich, MA), and 5-10 μl were 
loaded into each well. Gels were run at constant voltage (120 mV) for 45 m-1 h. DNA fragments 




Electrophoresis Documentation and Analysis System (EDAS) 290 system (Kodak, Rochester, 
NY). 
Gel purification 
While visualizing DNA fragments under UV-light using a Kodak EDAS 290 system, DNA 
fragments were excised from the gel using a clean razor blade. The E.Z.N.A.® Poly-Gel DNA 
Extraction Kit (Omega Bio-Tek, Norcross, Georgia) was used following manufacturer’s protocol 
to extract and purify DNA fragments and PCR products. Final purified DNA was eluted in 25 μl 
dH2O. 
 
Restriction enzyme digestion 
Restriction digests were set up as 50 μl reactions following the NEBCloner (v1.4.0; 
http://nebcloner.neb.com/#!/) protocol for double digests. 1 μg of DNA was incubated with 20 U 
of each restriction enzyme in NEB CutSmart Buffer for 15 min at 37oC.  
 
Ligation 
After digestion of vector and intended gene insert, ligation was accomplished using T4 
DNA Ligase in a 5 min reaction at RT following manufacturer’s protocol (Thermo Fisher 





Transformation of competent cells 
E. cloni 10G Chemically Competent Cells (Lucigen, Middleton, WI) were thawed on ice 
briefly. To each vial of competent cells, 5 μl of ligation reaction was added. Reactions were tapped 
briefly to mix, and incubated on ice for 30 min. Then, the cells were heat-shocked in a 42oC water 
bath for 45 s, followed by 2 min on ice. 960 μl of RT Recovery media (antibiotic-free) was added 
to the cells, and tubes of cells were incubated at 37oC with shaking at 250 rpm for 1 h. 100-200 μl 
of these cells were added to LB plates containing appropriate antibiotic for selection, and incubated 
upside down O/N at 37oC.  
 
Glycerol stocks 
Individual plasmid clones were stored in glycerol stocks prepared with a 1:1 ratio of LB 
media containing the clone and a 50% (v/v) sterile glycerol and dH2O mixture. Glycerol stocks 
were stored at -80oC. For recovery of the glycerol stock, a sterile loop was inoculated by scraping 
the top of the glycerol stock and streaking a LB agar plate for O/N growth at 37oC. 
 
Plasmid DNA purification (mini- and maxi-prep) 
Individual clones of plasmid DNA was cultured O/N in 4 ml of LB media with appropriate 
antibiotic at 250 rpm at 37oC. About 2-4 ml of the O/N culture was purified using QIAprep Spin 
Miniprep Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol, and final DNA 
was eluted in ~45 μl dH2O. For larger yields of plasmid DNA, individual clones were cultured in 




was purified using the Endofree Plasmid Maxi Kit (Qiagen, Hilden, Germany) following 
manufacturer’s protocol. Final DNA was eluted in ~250 μl dH2O. 
  
DNA purity and concentration 
To determine DNA purity and concentration, the NanoDrop 2000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA) was utilized. DNA purity and concentration were 
determined at an absorbance at 260 nm. A 260/280 ratio of ~1.8, and a 260/230 ratio of ~2.0 are 
generally accepted as indications of DNA purity. 
 
DNA sequencing 
Once DNA was purified after mini- or maxi-preparation, aliquots were taken for 
sequencing using the Eurofins Genomics sequencing services. Pre-designed sequencing primers 
were sent with the samples, or standard sequencing primers were used to cover up to 1000 bases. 
Sequencing results were analyzed against the known sequence of the gene or vector using the 
Geneious Bioinformatics Software for Sequence Data Analysis (https://www.geneious.com/).  
 
Ethanol precipitation of DNA 
To recover DNA in aqueous solutions to better concentrate it for downstream applications, 
DNA was ethanol precipitated. First, 3M sodium acetate (pH 5), was added to DNA to a final 
volume ratio of 1:10. Glycogen was then added as a carrier to a final concentration of 1 µg/µl. 
100% ethanol was added to a final concentration >80% (v/v), and the DNA-ethanol solution was 




at 13000 g for 30 min at 4°C. Supernatant was then removed, and the pellet was washed with ice-
cold 75% ethanol (v/v), and centrifuged again at 13000 g for 30 min at 4°C. The supernatant was 
removed, and the pellet was pulse-centrifuged for 5-10 s, and residual ethanol was evaporated off 
by allowing the pellet to air dry for 10 min. The pellet was then resuspended in nuclease-free dH2O, 
and the concentration and purity were measured by NanoDrop 2000 (Thermo Fisher Scientific, 
Waltham, MA). 
RNA extraction 
To avoid RNase contamination, all benchtop surfaces and pipettes for RNA extraction were 
cleaned with RNaseZap RNase Decontamination Solution (Thermo Fisher Scientific, Waltham, 
MA). Cells were washed once with 37oC PBS, and then harvested in 500 μl ice-cold TRI Reagent 
Solution (Thermo Fisher Scientific, Waltham, MA). Samples were pipetted up and down ~2 dozen 
times to lyse the cells and transferred to a 1.5 ml DNase/RNase/pyrogen-free microcentrifuge tube. 
An additional 500 μl of 4oC TRI Reagent was added to the 1.5 ml tube, and samples were incubated 
at RT for 5 min.200 μl chloroform (Sigma-Aldrich, St. Louis, MO), was then added to each sample, 
and inverted several times before shaking each tube vigorously for 15 s. Samples were then 
centrifuged at 10,000 rpm for 20 m at 4oC. The aqueous layer was then removed (~550 μl) and 
transferred to a new 1.5 ml microcentrifuge tube. 550 μl of 100% isopropanol (WorldWide 
Medical, Bristol, PA) per 1 ml TRI Reagent originally used was added to this tube, mixed gently, 
and incubated at RT for 5 min. These samples were then centrifuged at 14,000 rpm for 20 min at 
4oC. The isopropanol supernatant was then discarded, and pellets were gently washed with 1 ml 
75% ethanol in DEPC-treated H2O, before being centrifuged at 9,500 rpm for 10 min at 4oC. 
Supernatant was then discarded, and pellets were allowed to air dry for 10 min, making care not 




in 15-20μl nuclease free (DEPC-treated) H2O. The samples of RNA were then measured for 
concentration and purity using the Nanodrop, and for downstream processing the 260/280 ratio 
was greater than 1.8. RNA was kept at -80oC until further processing. 
 
cDNA synthesis 
cDNA was synthesized using the iScript cDNA synthesis kit (Bio-rad, Hercules, CA) 
following manufacturer’s protocol and 1 μg of purified RNA as the template for the reaction. 
Reactions were incubated in a thermal cycler using the following conditions: 5 min at 25oC, 20 
min at 46oC, 1 min at 95oC, and final hold at 4oC. For qRT-PCR, 100 ng of the first strand synthesis 
reaction was used as a template.  
 
Polymerase chain reaction (PCR) 
Cloning PCR 
For cloning PCR, NEBNext® High-Fidelity 2X PCR Master Mix (NEB, M0541) or 
OneTaq® 2X Master Mix with Standard Buffer (NEB, M0482S) were used according to 
manufacturer’s protocol (NEB, Ipswitch, MA). In general, 1-10 ng of template DNA was added 
to each reaction. 
 
Table 2.11 Reaction using NEBNext® High-Fidelity 2X PCR Master Mix (NEB, M0541): 
STAT5a in plasmid, ie pTracer 
Step Temperature Time Cycles 
Initial denaturation 98oC 30 s 1 




Annealing 72oC 30 s 25 
Extension 72oC 5 m 
Final extension 72oC 2 m 1 
 4oC hold 
 
Table 2.12 Reaction using OneTaq® 2X Master Mix with Standard Buffer (NEB, M0482S): 
STAT5a in plasmid, ie pTracer 
Step Temperature Time Cycles 
Initial denaturation 94oC 30 s 1 
Denaturation 94oC 10 s  
30 Annealing 70oC 60 s 
Extension 68oC 5 m 
Final extension 68oC 5 m  
1 4oC hold 
 
Site-directed mutagenesis 
Phusion Site-Directed Mutagenesis (Thermo Fisher Scientific, Waltham, MA) 
The Phusion Site-Directed Mutagenesis kit and protocol were utilized for single-point 
mutations in non-GC rich areas of the STAT5a sequence (ie, for Y694F and S726A point 
mutations). Primers for these reactions are listed in section 2.1.8. 1 ng of plasmid template was 
used in each reaction, along with 0.5 μM of forward and reverse primers. Reactions were subjected 
to the following conditions: 
 
Table 2.13 Reaction for Phusion Site-Directed Mutagenesis: 
Y694F 
Step Temperature Time Cycles 
Initial denaturation 98oC 30 s 1 
Denaturation 98oC 10 s  




Extension 72oC 5 m 25 
Final extension 72oC 10 m  
1 4oC hold 
S726A 
Step Temperature Time Cycles 
Initial denaturation 98oC 30 s 1 
Denaturation 98oC 10 s  
25 Annealing 72oC 30 s 
Extension 72oC 5 m 
Final extension 72oC 10 m  
1 4oC hold 
 
After performing the Phusion Site-Directed mutagenesis PCR reaction, 1 μl of FastDigest 
DpnI enzyme was added directly to the reaction mixture to digest Dam-methylated parental 
plasmid DNA and allowed to react for 15 m at 37oC. 5 μl of this reaction product were ligated 
following the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA) using T4 DNA 
Ligase in a 5 min reaction at RT. Following this reaction, 5 μl of ligated product were transformed 
in competent cells. 
 
Q5 Site-Directed Mutagenesis (NEB, Ipswitch, MA) 
The Q5 Site-Directed Mutagenesis kit and protocol were utilized for single-point mutations 
in GC rich areas of the STAT5a sequence (ie, for the S780A point mutation). Primers for these 
reactions are listed in section 2.1.8. 1 ng of plasmid template was used in each reaction, along with 






Table 2.14 Reaction for Q5 Site-Directed Mutagenesis. 
S780A 
Step Temperature Time Cycles 
Initial denaturation 98oC 30 s 1 
Denaturation 98oC 10 s  
25 Annealing 72oC 30 s 
Extension 72oC 6 m 
Final extension 72oC 2 m  
1 4oC hold 
 
Following the Q5 Site-Directed mutagenesis PCR reaction, 1 μl of PCR product was 
subjected to kinase, ligase and DpnI (KLD) treatment following the Q5 NEB protocol. The 
reaction was incubated at RT for 5 min prior to transformation of competent cells. 
 
Quantitative real time PCR (qRT-PCR) 
For quantitative real time PCR (qRT-PCR), Power SYBR Green PCR Master Mix (Thermo 
Fisher Scientific, Waltham, MA) was used. For each desired PCR amplicon, forward and reverse 
primers were brought to a final concentration of 900 nM, along with a total of 100 ng cDNA 
template in 1X Power SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA). Each 
reaction was run in triplicate in a MicroAmp Optical 96-well reaction plate (Applied Biosystems, 
Foster, CA) in a CFX96 thermal cycler (Bio-rad, Hercules, CA) using the following settings: 
 
Table 2.15 qRT-PCR Reaction settings. 
Step Temperature Time Cycles 
Initial denaturation 95oC 10 m 1 
Denaturation 95oC 15 s  








2.2.3 Protein methods 
Protein lysis 
For detection of endogenous or rescued proteins, adherent cells were first rinsed in ice-cold 
PBS and scraped in ice-cold RIPA buffer containing 1x protease inhibitor cocktail and 1% (v/v) 
phosphatase inhibitor cocktail. Samples were sonicated in two cycles of 10 1s pulses, with 1 min 
rest between each cycle. Lysates were then incubated on ice for 10 min, and subsequently 
centrifuged at 12,000 g for 10 min at 4°C. Samples were then diluted in 4x Laemmli buffer and 
run on SDS-PAGE gel followed by WB analysis. 
 
Nuclear-cytoplasmic fractionation 
Separation of nuclear and cytoplasmic fractions of cell cultures was performed following 
the Abcam protocol for subcellular fractionation (Abcam, Cambridge, UK). Briefly, after PRL 
stimulation, cells were washed with ice-cold PBS, and harvested in 500 μL fractionation buffer by 
scraping. After incubating for 15 min on ice, the cell suspension was passed through a 27-gauge 
needle 10 times. After another 20 min incubation on ice, the samples were centrifuged at 720 g for 
5 min at 4oC. At this point, the pellet contained the nuclei, and the supernatant (containing the 
cytoplasm, membrane, and mitochondria) was transferred to a fresh tube and kept on ice. The 
nuclear pellet was then washed with 500 μL fractionation buffer, and the pellet was passed through 




4oC. The supernatant was discarded, and the pellet was then resuspended in TBS with 0.1% (v/v) 
SDS. The nuclei were then sonicated briefly to shear genomic DNA and homogenize the lysate (3 
s on ice at a power setting of 2-continuous). The cytoplasmic/membrane/mitochondrial supernatant 
was then centrifuged at 10,000 g for 5 min at 4o, and the resulting supernatant containing the 
cytoplasm and membrane fractions was transferred to a new tube on ice. Both the cytoplasmic and 
nuclear fractions were then placed in 4x Laemmli buffer and run on a SDS-PAGE gel followed by 
WB analysis. 
 
Transient transfection and harvest for apoptosis assay 
MCF7 or T47D cells with endogenous STAT5a KD were assessed for signs of apoptosis after 
transient transfection with the STAT5a rescue constructs. After cells adhered in 6- or 12- well-
plates, the media was changed to Opti-mem, and cells were transfected using Lipofectamine 3000 
(Thermo Fisher Scientific, Waltham, MA). 24 hours after transfection, cells were scraped in media 
and all media was collected and centrifuged for 5 min at 1000 g. Cells were resuspended in ice-
cold PBS to wash off any remaining media, and centrifuged. The PBS supernatant was discarded, 
and cells were then resuspended in RIPA buffer containing 1x protease inhibitor cocktail and 1% 
(v/v) phosphatase inhibitor cocktail. Samples were sonicated in two cycles of 10 1s pulses, with 1 
min rest between each cycle. Lysates were then incubated on ice for 10 min, and subsequently 
centrifuged at 12,000 g for 10 min at 4°C. Samples were then diluted in 4x Laemmli buffer and 
run on SDS-PAGE gel followed by WB analysis. Cleaved caspase 3 (CC3) antibody or cleaved 
caspase 7 antibody (CC7; Cell Signaling Technology, #9661, #9491) were used to probe samples 






For immunoprecipitation experiments, adherent cells were first rinsed in ice-cold PBS, and 
scraped in ice-cold co-immunoprecipitation buffer (Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
0.1% Triton X-100, 5% glycerol, 1% Phosphatase Inhibitor Cocktail 2, and 1x Protease Inhibitor). 
Cells were lysed and pelleted at 12,000 g for 10 min at 4°C. Supernatants were transferred to a 
new tube. In all cases, 5% input was saved for WB analysis before 4 μg of α-V5 antibody (or α-
IgG2a antibody control) was added and incubated overnight. 50 µl of Dynabead protein G magnetic 
beads (Thermo Fisher Scientific, Waltham, MA) were added for 1 h at 4°C and samples were 
collected on a magnetic particle concentrator (DynaMag™-2 Magnet, Themo Fisher Scientific) 
and washed three times in fresh IP buffer. Bound proteins were recovered in 2x Laemmli buffer 
and run on a 7% SDS-PAGE gel followed by WB analysis. 
 
SDS-PAGE electrophoresis for protein analysis 
Handcasting SDS-PAGE gels 
In the case that protein detection required an SDS-PAGE gel of a single percent, gels were 
prepared by handcasting following the Bio-rad “Handcasting Polyacrylamide gels” protocol 
online. In brief, resolving gels were prepared using 30% acrylamide/bis (29:1) solution, 10% (w/v) 
SDS, dH2O, and Resolving Gel buffer (1.5 M Tris-HCl, pH 8.8; Bio-rad, #1610798), de-gassed 
for 15 min, and 10% (w/v) APS and TEMED were added. Gels were poured into casting modules, 
and topped with water-saturated n-butanol, and allowed to set for 1h. The stacking layer was 
prepared using 30% acrylamide/bis (29:1) solution, 10% (w/v) SDS, dH2O, and Stacking Gel 




addition of 10% (w/v) APS and TEMED. Before adding the stacking layer, the n-butanol was 
discarded, and the top of the resolving layer was rinsed with dH2O. After adding the stacking layer, 
a comb was placed into the casting module and the gel was set to polymerize for 1 h.  
 
SDS-PAGE electrophoresis 
Protein separation was achieved under reducing and denaturing conditions using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Protein samples were mixed 
with 4x Laemmli sample buffer (Bio-rad, Hercules, CA) containing 20% (v/v) β-mercaptoethanol, 
and boiled at 100oC for 10 min. Equal amounts of protein were run along with 10 μl Precision Plus 
Protein™ Kaleidoscope™ Prestained Protein Standards on 7%, 10%, or 4-20% Mini-PROTEAN 
TGX acrylamide gels to optimize size separation utilizing the Mini-PROTEAN 3 System (Bio-
rad, Hercules, CA). 1x Tris/Glycine/SDS running buffer was used for electrophoresis. Gels were 
run under constant voltage (105 mV) until the dye front was run off the gel. 
 
Western blot 
Following protein separation as described above, proteins were transferred to PVDF 
membranes using Trans-blot Turbo system (Bio-rad, Hercules, CA) following the manufacturer's 
instructions. After transfer, membranes were blocked in 5% milk (w/v) in TBST, or, for phospho-
specific antibodies, 5% BSA in TBST (w/v). After 1h, membranes were incubated overnight (O/N) 
in the appropriate antibody diluted in blocking buffer at 4oC. The following day, primary antibody 
was removed and membranes were washed in TBST 3 times for 5 mins/wash. Secondary antibody 




followed by 3 washes of 5 min/wash. Membranes were developed with Immobilon Forte ECL 
substrate (Sigma-Aldrich, St. Louis, MO) for 5 min. Membranes were imaged using the GE 
ImageQuant LAS 4000 (Chicago, IL). Images were analyzed by densitometric analysis in the 
ImageQuant TL software. 
 
Western blot stripping 
To remove primary and secondary antibodies from the membranes for re-probing, blots 
were washed for 15 min in Western blot stripping buffer, then washed twice in TBS for 10 
min/wash, followed by two 5 min washes with TBST. Membranes were then blocked in blocking 
buffer for 1h at RT, followed by primary antibody diluted in blocking buffer O/N at 4oC for 
continuation of the Western blot protocol. 
 
Western blot analysis and quantification 
Preliminary densitometric analysis of western blots was performed using ImageQuant TL 
Toolbox software. Normalization to loading controls was performed in Excel. 
 
2.2.4 Cell culture methods 
Maintenance of human cell lines 





Serum starvation and prolactin stimulation 
For experiments requiring serum starvation and prolactin (PRL) stimulation, cells were 
washed with 37oC DPBS, and the media was replaced with serum free media [phenol-free DMEM, 
0.1% (v/v) BSA] for 20-24h. PRL was added at 250 ng/ml at the indicated time point.  
 
Soft agar colony growth 
A base agar layer [0.6% noble agar, 10% serum (v/v)] was established in a 6-well plate. 
The bottom layer was overlaid with 0.5 mL of top agar solution [0.3% noble agar, 10% serum 
(v/v)] containing 1.0x106 cells in a single-cell suspension. Cells were incubated at 37°C for 2 
weeks and stained using MTT. 10 images/well were obtained for subsequent quantification. 
Quantification was performed using CellProfiler (cellprofiler.org). 2.5x103 µm2 was the defined 
cut-off for colony calling. 
 
Proliferation assay utilizing the xCELLigence apparatus 
Real-time monitoring of the effects of prolactin on proliferation of breast cancer cell lines 
in vitro was measured using the xCELLigence Real-Time Cell Analyzer (RTCA; Acea 
Biosciences, San Diego, CA). 50 μl of complete media was first added to the E-Plate 16 and a 
baseline reading was obtained on the RTCA software. Breast cancer cells were seeded at a density 
of 5,000 cells/50 μl per well in the E-Plate 16, such that 100 μl of media total was added. The plate 
was set at RT for 30 min before being placed back in the xCELLigence for 20-24 h in a humidified 
incubator at 37oC with 5% CO2, until a Cell Index (CI) between 1-2 was reached. At that point, 




twice with PBS, and 100 μl serum free media (phenol-free DMEM containing 0.1% BSA) was 
added to the cells and the E-Plate was placed back in the xCELLigence for 24 h as the CI leveled 
off. After 24 h, the experiment was again paused, and 50 μl of media was replaced with either 50 
μl of serum-free media as described above, or with serum-media containing 2x prolactin for a final 
concentration of 250 ng/ml in each well. The plate was placed back on the apparatus and the 
experiment was resumed for at least 72 hours. 
  
Scratch wound assay utilizing the Incucyte WoundMaker 
To assess cellular migration, the Incucyte WoundMaker (Sartorius, Essen Bioscience, Ann 
Arbor, MI) was used to monitor real-time scratch wound migration in a 96 well plate containing 
the cells of interest. Following the manufacturer protocol, cells were seeded onto the 96 well plate 
at a density of 40,000 cells per well in 100 μl. Cells were allowed to adhere at 37oC for about 20-
24 h until 100% confluency was reached. A scratch was made in all wells simultaneously using a 
WoundMaker (Essen Bioscience) according to the manufacturer’s instructions. The cells were 
washed with culture media twice, and complete media was added to the wells before placing the 
plate in the Incucyte and programming image acquisition at 10x every 3 hours for 72 hours (1 
image/well). Image data were analyzed using the Incucyte software and quantification of relative 
wound width closure over time was performed in Excel.  
 
Immunofluorescence (IF) slide preparation 
Single cell suspensions were seeded onto sterile glass microscope slides at a density of 




and replaced with serum free media. After 24 h of serum starvation, slides were stimulated with 
250 ng/ml PRL for indicated time points. Cells were then fixed with 4% paraformaldehyde in PBS, 
and permeabilized in PBS containing 0.1% (v/v) Triton X-100. Cells were labeled with α-Stat5a  
antibody (Santa Cruz, Dallas, TX) at a concentration of 1:50 in PBS containing 0.1%(v/v) Triton 
X-100 and visualized with Alexa Fluor 594 nm donkey anti-mouse fluorescein (FITC) conjugated 
secondary antibody at 1:2000 in PBS containing 0.1%(v/v) Triton X-100. Nuclear staining was 
done with 1 μg/ml Hoechst (Thermo Fisher Scientific, Waltham, MA) in PBS before mounting in 
ProLong Gold antifade reagent without DAPI (Thermo Fisher Scientific, Waltham, MA) and 
curing for 24 h. 
 
2.2.5 Tissue methods 
Tissue microarray (TMA) 
Human breast cancer tissues were obtained from VCU Anatomic Pathology in the form of 
a TMA. All tissues were stripped of all patient identifiers before use and were therefore anonymous 
to investigators. The TMA consisted of 47 human unmatched breast cancer samples including 
invasive ductal and lobular carcinoma, and ductal carcinoma in situ (DCIS). Each sample has 
triplicate cores to mitigate against possible tumor heterogeneity. The presence and integrity of 
tumor in each sample was confirmed by hematoxylin and eosin (H & E) staining. Samples of the 
TMA were stained for pY694-, pS726-, pS780-, and total STAT5a following standard IHC 
protocol. The TMA was scored independently by a clinical pathologist in the VCU Department of 
Pathology and scored for both Proportion Score and Intensity Score for Allred score calculations 




2.2.6 RNA-sequencing methods 
RNA isolation for RNA sequencing (RNA-seq) 
Cells were plated on 15 cm tissue culture dishes to about 70% confluency in complete 
media before incubation in serum starvation media for 20-24 hours in phenol-free DMEM (Life 
Technologies) with 0.1% FBS, and subsequently treated with PRL (250 ng/ml in PBS) or PBS 
control for two hours. After treatment, cells were washed with 37oC PBS and mRNA was isolated 
with PureLink™ RNA Mini Kit (cat #12183018A) with on-column DNase treatment (PureLink™ 
DNase Set, cat#12-185-010, Thermo Fisher Scientific) according to manufacturer’s instructions. 
Each rescue (EV, WT-, Y694F-, S726A-, or S780A-STAT5a) treated with or without PRL 
(NO/PRL) was assessed in three independent biological replicates, for a total of 30 RNA samples. 
RNA purity was determined by spectrophotometry at 260, 270, and 280 nm. RNA integrity number 
(RIN) was assessed on the Agilent 2200 TapeStation Bioanalyzer (Agilent Technologies), all 
samples possessed RIN ≥9. mRNA library preparation and sequencing were performed the 
Genomics and Microarray Core at the University of Colorado Anschutz Medical Campus (CU 
Anschutz). mRNA library was prepared by polyA selection on ≥500 ng RNA using the Universal 
Plus mRNA-Seq Library Preparation Kit (NuGEN) following manufacturer’s protocol. 
Sequencing was performed on the S4 flow cell platform of the Illumina NovaSEQ6000 System 
(Illumina, Inc), generating ≥50 million 150 bp paired-end (PE) reads per sample. All libraries were 






FastQ files were analyzed with FastQC, and read trimming was done with CutAdapt to 
trim adapter contamination.182,183 Reads were then aligned to the latest version of the human 
genome, GRCh38 distributed by Gencode. The primary genome fasta file was downloaded from 
ftp://ftp.ebi.ac.uk/pub/databases/gencode/Gencode_human/release_29/GRCh38.primary_assembl
y.genome.fa.gz. The matching gene annotation GTF file was downloaded from 
ftp://ftp.ebi.ac.uk/pub/databases/gencode/Gencode_human/release_29/gencode.v29.primary_asse
mbly.annotation.gtf.gz. STAR v2.7.3a was used to align the fastq files to the human reference 
genome.184 STAR log statistics were compiled with the MultiQC tool, and report that over 90% of 
reads in each sample were uniquely mapped, with less than 5% reads in each sample being left 
unmapped. Prior to transcript quantification, the GFFRead utility was used to create a 
transcriptome fasta file from the main reference genome fasta file.185  Salmon v0.12.0 utilized the 
transcript fasta file to quantify each transcript from the STAR-aligned data using “quant” mode 
and library type set to “ISF”.186  Salmon output included the raw count estimate, TPM value, and 
estimated transcript length for each gene.  The tximport R package was used to import the Salmon 
quantifications from each sample into R v3.6.0, identify the official gene symbol, and merge raw 
count and TPM values into a single matrix file.187,188 Trimmed BAM files of  Chr17:42,287,547-
42,311,943 for GRCh38 human genome were generated to confirm point-mutations of the STAT5a 
mutants in Integrated Genome Browser (IGB, BioViz).189  
Differential expression  analyses were performed in EdgeR using the Galaxy web platform, 
specifically, raw estimated read counts from Salmon were analyzed using the public server at 
usegalaxy.org.190–192 Genes with zero expression in all samples included in the contrasts were 




expressed genes (DEGs) were determined using a cutoff of absolute log fold change >0.58 (fold 
change >1.5). DEGs were determined for the following contrasts: each rescue line PRL vs NO 
(untreated, ie WT_PRL-WT_NO). Heatmaps for DEG expression were generated using heatmap2 
in the Galaxy web platform. Lists of DEGs, with gene identifiers and corresponding expression 
values (in log fold change) and p values, were uploaded into Ingenuity Pathway Analysis software 
(IPA 2020, Qiagen) for pathway predictions. DeepVenn (Tim Hulsen, 2020) was used for 
generating all proportional venn diagrams.193 Enrichr analysis (https://maayanlab.cloud/Enrichr/) 
of the ENCODE gene sets library was performed on significant DEGs for the PRL vs untreated 
contrast of each STAT5a mutant.194 Gene set enrichment analysis (GSEA) of annotated gene sets 
from the Molecular Signatures Database (MSigDB) was used on expression values of all DEGs 
from the PRL versus untreated contrast of each STAT5a mutant as well as each STAT5a mutant 
+ PRL versus WT-STAT5a + PRL.195,196  
TCGA and PDX datasets were integrated with the MCF7 STAT5a phospho-deficient 
mutant dataset by Amy L. Olex, Senior Bioinformatics Specialist affiliated with C. Kenneth and 
Dianne Wright Center for Clinical and Translational Research as defined previously.197 
All data generated and analyzed in this study are included in this published article. RNA-
seq datasets have been submitted to the National Center for Biotechnology Information Gene 
Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE165678 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE165678). 
2.2.7 Statistical analysis 
Statistical analysis was performed using one-way or two-way analysis in GraphPad Prism 




was considered statistically significant. All experiments were done three times unless otherwise 




3. Chapter 3: Serine residues 726 and 780 have nonredundant roles 
regulating STAT5a activity in luminal breast cancer 
3.1. Introduction 
In mammary epithelium, the polypeptide prolactin (PRL) acts through its cognate receptor 
(PRLr), and is responsible for terminal maturation and differentiation of lactating glands during 
pregnancy. 6,11,12,44,45,49,51 As a potent mitogenic factor, PRL/PRLr signaling is also associated with 
mammary tumorigenesis. 6,73,85,86,198,199 Canonical PRL/PRLr signaling involves the tyrosine janus 
kinase 2 (JAK2), which phosphorylates the transcription factor (TF) signal transducer and activator 
of transcription 5a (STAT5a) on tyrosine 694 (Y694).  The resulting phosphorylated STAT5a 
(pY694-STAT5a) dimerizes and translocates to the nucleus. 
 STAT5a is one of seven members of the STAT family of transcription factors. The STAT 
family is highly conserved, each having a tyrosine residue near residue position 700 that is 
phosphorylated by JAK in the cytoplasm. This phosphorylation event has historically been 
considered as the activation switch for STAT (pY-STAT), whereas dormant, unphosphorylated 
STAT (upY-STAT), has long been considered to have no significant functions. However, 
accumulating evidence shows that upY-STATs are present in the nucleus regardless of cytokine 
stimulation. 157,200 Studies have illustrated that upY-STATs actively bind chromatin to drive gene 
expression distinct from that of the pY-STAT forms. 111,152,155,158,168,200,201 Notably, other functions 
described of upY-STATs include promotion of heterochromatin and global downregulation of 
transcription. 157,159 These differing reports highlight the possibility of stimulus- and tissue-specific 




Compounding this growing understanding of the regulation of STAT activity, STATs (with 
the exception of STATs 2 and 6) also have serine residues in the Transactivation Domain (TAD) 
that are capable of being phosphorylated, with known function in regulating STAT activity. 
163,166,202–205 To this point, STAT5a has two serine residues, S726 and S780, which regulate 
STAT5a-dependent malignant hematopoietic transformation. 169,178 The function of 
phosphorylation of either S726 or S780 in PRL-responsive normal or malignant breast tissue, 
however, is less well understood. 
Several studies regarding STAT5a serine phosphorylation have focused on PRL-induced 
β-casein expression using luciferase gene reporter assays. 127,170,175 However, the results of these 
studies are inconsistent regarding the loss of the serine residues on PRL-stimulated β-casein gene 
induction. Beuvink et al (2000) reported that loss of S726 or S780 had no effect on PRL-stimulated 
β-casein promoter activity. 170 While Yamashita et al (2001) also observed that loss of S780 had 
no effect on PRL-stimulated β-casein promoter activity, in contrast they found that expression of 
phospho-deficient S726A-STAT5a in COS-7 and MCF7 cells increased the PRL-stimulated β-
casein promoter activity compared to WT-STAT5a. 127,175 These studies did not examine the 
physiologic effect of phospho-deficient STAT5a expression.  
In this study, we examine the expression of serine-phosphorylated (pS-)STAT5a in human 
breast cancer, describe the effects of tyrosine and serine phospho-deficient STAT5a mutants on 
breast cancer characteristics in vitro, and show for the first time how these residues differentially 





We hypothesize that loss of the STAT5a phospho-sites will differentially affect STAT5a activity 
that do not indicate regulation of pY694-STAT5a but indicate non-redundant, discrete roles as 
evidenced by changes in the transcriptome and phenotypic characteristics of breast cancer. 
3.3. Results 
Stat5a serine residues 726 and 780 are phosphorylated in human breast cancer cell lines and 
patient tumor samples 
Serine phosphorylation of STAT5a has been observed in mouse mammary epithelial cells 
throughout mammary development, however this has yet to be clinically characterized in human 
breast cancer. 170,175 We performed immunohistochemical (IHC) staining of a breast cancer tissue 
microarray (TMA) using phospho-specific antibodies for pY694-, pS726-, and pS780-STAT5a, as 
well as total STAT5a. The TMA consisted of 47 clinically staged cancers I-III, with diagnoses 
ranging from ductal carcinoma in situ (DCIS) to invasive ductal or lobular carcinoma 
(Supplemental Table S1, Appendix). Visual scoring of STAT5a S726 phosphorylation revealed 
a significant increase in nuclear intensity in tumor samples grade III compared to grade I (nuclear 
Allred scores of 6 and 2, respectively; Figure 3.1A). Notably, STAT5a S780 phosphorylation was 
also observed in the nucleus of tissue samples, however there was no significant association of 
expression with either tumor grade or proliferative status (Ki67 staining; Figure 3.1A). While total 
nuclear STAT5a expression remained high throughout malignant progression in these breast tissue 
samples, a weak signal for nuclear pY694-STAT5a was observed in the tissue samples 
independent of tumor grade, hormone receptor status, or Ki67 staining, consistent with previous 




Patient derived xenograft (PDX) whole cell extract (WCE) samples (Figure 3.1B) and 
established breast cancer cell lines (Figure 3.1C) spanning the intrinsic molecular subtypes were 
probed for STAT5a S726 and S780 phosphorylation. 206 HCI-011 (luminal B, ER+/PR+/HER2-) 
showed expression of both pS726- and pS780-STAT5a (Figure 3.1B), in concordance with the 
luminal A/B breast cancer cell lines MCF7 and T47D (Figure 3.1C). 4,197 Interestingly, the 
claudin-low breast cancer cell line MDA-MB-231  exclusively exhibited pS780-STAT5a as well 
(Figure 3.1C). 4 Ex vivo analysis of HCI-011 lysates demonstrated pY694- and pS726-STAT5a 
expression following PRL stimulation (Figure 3.1D). Likewise, PRL stimulation of both T47D 
cells and MCF7 cells results in robust S726-STAT5a phosphorylation (Figure 3.1E, F). However, 
phosphorylation of STAT5a at S780 was observed to be constitutive and independent of PRL 









Representative anti-pS726- and anti-pS780-STAT5a IHC images from unmatched Grade III, ER-
/PR-/Her2 amplified primary tumors included in the TMA (scale bars, 100 μm). Note the nuclear 
accumulation of pS726- and pS780-STAT5a. Graphs show quantification of nuclear Allred scores 
according to the tumor grade, Ki67 status, and molecular subtypes. Panels of PDX samples (B) 
and established breast cancer cell lines (C) immunoblotted for pY694-, pS726- and pS780-
STAT5a. Note the presence of pS726/S780-STAT5a in the luminal B subtype (ER+/PR+/Her2-) 
sample HCI-011, and in the luminal B cell lines T47D and MCF7, along with pY694-STAT5a. 
Lysates for C) were run in triplicate and representative blots for STAT5a and tubulin are shown. 
D) HCI-011 lysates were subjected to PRL stimulation and analysis for pS726-STAT5a and 
pY694-STAT5a induction. PRL stimulation of the human breast cancer cell lines T47D (E), and 
MCF7 (F), show induction of pS726-STAT5a but constitutive pS780-STAT5a, quantified by 
densitometric analysis. n=3, *p≤0.03, **p=0.001, ***p≤0.0004 compared to untreated, time 0.  
 
STAT5a serine residues have nonredundant transcriptional roles in luminal breast cancer 
cells  
Previous studies have shown that STAT5a serine phosphorylation affects PRL-induced 
STAT5a DNA binding kinetics (as measured by electrophoretic mobility shift assay, or EMSA) 
and phosphorylation kinetics of residue Y694, however the role of these phospho-sites in PRL-
regulated gene expression has not been investigated on a global scale.170 We hypothesized that 
expression of serine phospho-deficient STAT5a mutants would affect breast cancer transcriptomic 
programs and these alterations in gene expression patterns would lead to changes on a phenotypic 
scale. To test this hypothesis, we utilized MCF7 cells stably transduced with either STAT5a 
shRNA (STAT5a KD) or nontargeting (NT) control shRNA (Figure 3.2A, B). The STAT5a 
shRNA targeted the 3’untranslated region (UTR) of Stat5a on chromosome 17 such that rescue of 
STAT5a by cDNA was possible. Pools of MCF7 cells with stable STAT5a KD were rescued with 
lentiviral transduction of WT STAT5a, phospho-deficient single-point mutants (containing a C-
terminal V5-tag), or empty vector (EV), such that stable novel MCF7 cell lines were established. 
Hereafter, these transfectants are referred to as WT-STAT5a, Y694F-STAT5a, S726A-STAT5a, 
S780A-STAT5a, or EV (Figure 3.2A, C). Relative STAT5a KD and rescue protein expression 
was confirmed by Western blot (WB; Figure 3.2B, C, D). Endogenous STAT5a KD was 




250-400-fold higher than that of the nontargeting control (Supplemental Figure S2). However, 
on the protein level, STAT5a was equally expressed by the rescues (Figure 3.2D). Therefore, 
quantification of all subsequent studies using these MCF7 pooled rescue cell lines is reported 
normalized to V5-STAT5a expression. 
Figure 3.2. The human breast cancer cell line MCF7 as a model for STAT5a serine 
phosphorylation. A) Schema for generating of stable knockdown and rescue cell lines. B) 
STAT5a knockdown in MCF7 cells after antibiotic selection confirmed by WB. C) 
Representations of WT-, Y694F-, S726A-, and S780A-STAT5a constructs with C-terminal V5 
tags used to generate MCF7 rescue cell lines. Confirmation of STAT5a rescue expression in MCF7 
cells by D) protein analysis with appropriate antibodies targeting each phospho-site of STAT5a. 
 
These generated stable MCF7 cells were then stimulated with PRL (250ng/mL) and 




STAT5a mutagenesis. These analyses revealed that following PRL treatment, MCF7-WT-
STAT5a cells had 510 differentially expressed genes (DEGs), and each STAT5a phospho-
deficient mutant had fewer DEGs than the WT-STAT5a (ranging from 171 [Y694F-STAT5a] to 
285 DEGs [S726A-STAT5a]; Supplemental Table S2). Next, the top 50 DEGs from the four 
STAT5a rescues when treated with PRL vs untreated (for a total of ~200 DEGs) were hierarchical 
clustered (Figure 3.3A). Results from Y694F-STAT5a MCF7 cells treated with PRL were most 
similar to untreated WT-STAT5a MCF7 cells, indicating that loss of Y694-STAT5a is sufficient 
to inhibit most PRL-induced transcript expression. When treated with PRL, S726A- and S780A-
STAT5a MCF7 cells had similar expression of the top 50 DEGs from each contrast, visualized by 
the clustering of the S726A + PRL and S780A + PRL samples. Interestingly, when untreated, the 
three STAT5a point mutants top 50 DEGs cluster away from the untreated WT-STAT5a MCF7 
cells. This indicates that in these cells STAT5a may drive expression of a subset of genes in the 
absence of tyrosine or serine phosphorylation. This would be a distinct function for STAT5a that 
is independent from its role of inducible, phosphorylation-dependent gene expression, similar to 
descriptions of STAT3. 158,160 
WT-STAT5a PRL-induced or inhibited genes were compared to previous PRL-
transcriptomic data released by our laboratory, such that after matching the criteria that the DEG 
be present in at least two datasets, 105 putative PRL-regulated genes were identified 
(Supplemental Table S2). 70,78 A subset of these genes was used to identify functionally-enriched 
pathways with PRL treatment that may be changed by expression of the STAT5a mutants through 
Ingenuity Pathway Analysis (IPA, Qiagen, Figure 3.3B). The PRL treatment of WT-STAT5a 
MCF7 cells significantly activated pathways responsible for cellular proliferation and survival, 




had an opposite effect on 10 of the 13 (76.9%) queried functional predicted pathways compared 
to WT-STAT5a, including cell survival and colony formation pathways (Figure 3.3C). Expression 
of the S726A-STAT5a mutant similarly affected 7 of the same pathways that Y694F-STAT5a 
expression did (7/13, 53.8%), and S780A-STAT5a affected the senescence pathway only (1/13, 

















gene expression in MCF7 cells. A) Hierarchical clustering of each STAT5a species’ top 50 DEGs 
(≥1.5-fold change) from RNA-seq analysis of PRL treated versus untreated MCF7 cells expressing 
STAT5a rescues. B) IPA functional pathway enrichment analysis shows upstream regulators and 
predicted pathway activation or inhibition with PRL treatment of WT-STAT5a-expressing MCF7 
cells. C-E) IPA functional pathway analysis of indicated STAT5a phospho-mutants overlaid with 
the regulatory network shown in panel B to predict activation or inhibition.  p value calculated by 
Fisher’s exact test. 
 
 Confirmation of the gene expression changes observed in the RNA-seq data was done with 
MCF7 cells similarly stimulated with PRL. qRT-PCR was performed on a panel of genes, 
including the gene encoding cytokine inducible SH2 containing protein (CISH), a known STAT5a-
target gene induced by PRL in breast epithelial cells and in mammary carcinoma. 83,207 As seen in 
Supplemental Figure S3, loss of pY694 completely ablated PRL-induced CISH expression 
compared to WT-STAT5a. S726 and S780 point mutagenesis similarly were sufficient to 
significantly reduce CISH expression following PRL stimulation, compared to that of WT-
STAT5a, albeit to a lesser extent than was observed for the tyrosine mutant.  These results indicate 
some role for serine phosphorylation in modulating STAT5a transcriptional activation. Further, 
Estrogen Receptor α (ESR1) expression was shown to rely on phosphorylation of the phospho-
serine residues differentially. Loss of pS726 increased PRL-induced ESR1 expression relative to 
WT-STAT5a (an increase that is more pronounced when the expression of total STAT5a is 
considered; Supplemental Figure S3), whereas loss of pS780 did not significantly affect ESR1 
expression.  
Function of the STAT5a phospho-serine residues in vitro are independent of pY694 
To confirm these functional predicted effects observed with expression of these STAT5a 
mutants, we next assessed the loss of the STAT5a phospho-sites on cancer characteristics in vitro. 
The ability of transformed cells to grow independently and survive without extracellular matrix 




Therefore, we performed a quantitative evaluation of soft agar assay with various growth 
conditions. In quantifying three independent experiments compared to WT-STAT5a rescue 
colonies, MCF7 cells rescued with either Y694F- or S780A-STAT5a had fewer colonies (Figure 
3.4A, Supplemental Figure S4). This indicates that not only phosphorylation of Y694, but also 
phosphorylation of S780 on STAT5a is involved in the clonogenicity of breast cancer, in that fewer 
MCF7 colonies were established with loss of the phospho-sites. When analyzed for the size of 
colonies established, total STAT5a knockdown had increased colony size compared to WT-
STAT5a rescue (p=0.02, Figure 3.4A). Together, these results illustrate that STAT5a expression 
restricts the extent of breast cancer outgrowth and clonogenicity, and that loss of any individual 
phospho-regulatory site on STAT5a does not mimic total loss of STAT5a. 210  
To further study the roles of each phospho-site of STAT5a, proliferation in 2D culture of 
the MCF7 rescues was measured on an xCELLigence apparatus (Agilent Technologies). In the 
presence of PRL, the S726A-STAT5a rescues showed decreased proliferation compared to WT-
STAT5a rescues from 12 to 21 hours (Figure 3.4B, Supplemental Figure S4). This change from 








Figure 3.4. Effect of single-point phospho-deficient STAT5a mutants on characteristics of 
MCF7 cells. A) Representative images and quantification of number and size of the colonies 
formed in soft agar by indicated MCF7 cells with knockdown (KD) of STAT5a rescued by 
phospho-deficient mutants. n=3, *p<0.02 compared to WT-STAT5a. B) Proliferation in serum 
free media (SFM) supplemented with PRL was assessed using XCELLigence, cell index indicates 
proliferation. n=3, p<0.02 compared to WT-STAT5a. C) Immunoblots of T47D cells (top) and 
MCF7 (bottom) cells carrying transient rescues of STAT5a point mutants assessed for apoptosis 
by expression of cleaved caspase 3 or 7. 
 
 The migratory ability of MCF7 cells in 2D culture was analyzed by real time imaging using 




containing STAT5a rescues were 100% confluent once more (Supplemental Figure S5). 
Unremarkably, the knockdown of STAT5a, or the rescue with various phospho-deficient point 
mutations, had no effect on the ability of MCF7 cells to migrate on the 2D plastic layer, indicating 
single-phospho-point mutants are not sufficient to elicit a phenotypic effect on migration. 
 STAT5a and PRL are both implicated in dysregulating apoptotic machinery in breast 
cancer cells, which was confirmed in our pathway analysis of the MCF7 STAT5a mutants RNA-
seq data (Figure 3.3B-E). 24,62–64 Further, it was observed that the T47D breast cancer cell line, 
when either transiently transfected or stably transduced with the STAT5a rescue constructs, had 
variable success in establishing 2D colonies; ultimately only transient expression was viable for 
performing quantitative assays. MCF7 cells do not express caspase 3, therefore to investigate this 
phenomenon, we analyzed protein expression of cleaved caspases 3 (CC3) and 7 (CC7) in T47D 
and MCF7 cells, respectively, with endogenous STAT5a knockdown and transient re-expression 
of the STAT5a rescues (Figure 3.4C).180,212 T47D cells rescued with S726A-STAT5a were highly 
positive for CC3, indicating that this serine residue contributes to the survival of the T47D cell 
line. On the other hand, MCF7 cells exhibited no CC7, indicating that these cells do not rely on 
STAT5a for survival. This difference in STAT5a regulation of apoptosis may be due to the 
difference in apoptotic pathways used in T47D and MCF7 cells, or by the reported reliance of 
T47D cells on STAT5a for survival, and now, specifically pS726-STAT5a.130  Overall, these 
studies illustrate that phosphorylation of S726 may be responsible for STAT5a involvement in 
evasion of apoptosis, while phosphorylation of S780 is responsible for STAT5a involvement in 
tumor clonogenicity and establishment of anchorage-independent colonies.  




 To determine the role of pS726 and pS780 in regulation of the canonical pathway of 
STAT5a signaling, the kinetics of phosphorylation of Y694-STAT5a was analyzed in the 
corresponding rescue cell lines. Previously it was reported that loss of S726 stabilized PRL-
induction of pY694, while WT-STAT5a loses pY694 by 5 h of PRL stimulation. 170 However, 
MCF7 cells re-expressing either WT-STAT5a or S726A-STAT5a have comparable induction of 
pY694 up to 6 h (Figure 3.5A). Similarly, we found that after 2 h and 6 h of PRL stimulation, the 
S780A-STAT5a mutant MCF7 cells had no effect on PRL-induced phosphorylation of the JAK2-
target Y694 (Figure 3.5B), indicating that neither phospho-serine contributes to maintenance of 
pY694. 
Figure 3.5.  Induction of phosphorylation on residue Y694 is independent of either S726 or 
S780. MCF7 cells with stable re-expression of either WT-STAT5a, S726A-STAT5a (A), or 
S780A-STAT5a (B) were treated with PRL up to 6 h. Representative blots of 3 independent 
experiments for pY694-STAT5a induction shown, with quantification by densitometric analysis.  
 
Unphosphorylated STAT5a undergoes nuclear translocation 
To determine if differences in transcriptional activity between WT-STAT5a and the 




both immunofluorescence (IF) imaging and WB analysis of nuclear-cytoplasmic fractionation with 
PRL stimulation (Figure 3.6, Supplemental Figure S6). Nuclear-localized WT-STAT5a began 
to increase by 30 minutes and was significantly increased by 60 minutes of PRL stimulation. While 
there was an upward trend for Y694F-STAT5a translocating to the nucleus, there was a no net 
change in translocation into or out of the nucleus with PRL stimulation (Figure 3.6A). The loss of 
S726 phosphorylation increased STAT5a nuclear translocation compared to WT over time with 
PRL stimulation (Figure 3.6A) and retained STAT5a in the nucleus up to 60 minutes following 
PRL stimulation. The loss of S780 phosphorylation shifted the kinetics of STAT5a nuclear 
translocation such that the amount of STAT5a peaked in the nucleus with 15 minutes of PRL 
treatment, and then decreased to close to baseline after 30 minutes (Figure 3.6A). WB analysis of 
nuclear and cytoplasmic fractions after 15 minutes of PRL treatment illustrates a snapshot of these 
trends (Figure 3.6B). In agreement with previous data, Y694F-STAT5a was present in the nucleus 
independent of PRL stimulation, confirming reports that have also found upY694-STAT5a is 
continuously shuttled  into and out of the nucleus (Figure 3.6B). 157,200 These results indicate that 
each phospho-serine could play an independent role in STAT5a nuclear translocation, degradation, 




Figure 3.6. Nuclear translocation of STAT5a occurs in absence of pS726 and/or pS780. MCF7 
cells with stable re-expression of STAT5a carrying specific phospho-deficient point mutations 
were imaged with immunofluorescence with up to 60 min PRL stimulation, representative merged 
Hoechst and STAT5a images shown, and quantified for nuclear translocation (A) or analyzed by 
WB nuclear cytoplasmic fractionation after 15 min PRL stimulation (B). *p<0.04 compared to 





 In order to examine how STAT5a phospho-mutants regulate the functional phenotypes 
uncovered in this study, we used our RNA-seq data in combination with the open-source Enrichr 
web-based platform.194 Enrichr transcriptional gene set analysis (using ENCODE project 
chromatin immunoprecipitation [ChIP]-seq data) confirmed STAT5a is one of the top 
transcriptional regulators in the WT-STAT5a MCF7 cells when treated with PRL (OR 2.05, 
p=0.03; Figure 3.7A), along with HDAC2, a class IIb histone deacetylase similar to HDAC6 (a 
known STAT5a cofactor).79 Further, amongst the top 10 enriched TF terms, the AP-1 subunits 
(JUN and FOS), as well as the FOX TF family (FOXA1), were also present, confirming our 
laboratory’s recent findings that STAT5a shares chromatin binding sites with these TF families as 
well as the ETS, AP-2, SP/KLF, CREB, and Nuclear Receptor (NR, e.g. ESR1) TF families.87 
Conversely, Enrichr analysis of Y694F-STAT5a or S780A-STAT5a data did not identify STAT5a 
as one of the top significant transcriptional regulators with PRL treatment (Figure 3.7B). 
Furthermore, the STAT5a transcriptional signature with PRL treatment was significantly enriched 
in the case of S726A-STAT5a Enrichr analysis (OR 1.21, p=0.007). Intriguingly, expression of 
Y694F- or S726A-STAT5a increased the involvement of the SREBF (Sterol regulatory element-
binding factor, or protein [SREBP]) TF family (Figure 3.7B, C), that was not seen with the 
expression of S780A-STAT5a (Figure 3.7D). Expression of S780A-STAT5a with PRL treatment, 
however, showed involvement of STAT3, SP1, and two of the FOX TF family members (Figure 




compensate for the loss of pY694- and pS-STAT5a differentially to uphold oncogenic signals in 
MCF7 cells. 
Figure 3.7. Transcription factor gene set analysis identifies complex transcriptional networks 
contributing to STAT5a mutant-driven phenotypes. TF analysis of the DEGs from MCF7 cells 
treated with PRL for A) WT-STAT5a, B) Y694F-STAT5a, C) S726A-STAT5a, and D) S780A-
STAT5a. The ENCODE project ChIP-seq data set library was used to find the top-ranking 
transcription factors by odds ratio (OR), p<0.05. 
3.4. Discussion  
The phospho-regulation of STAT5a by PRL in breast tissues has long been thought to only 
encompass the phosphorylation of the residue Y694. However, it is becoming clearer that 
regulation of this transcription factor is more nuanced. Here, we demonstrate for the first time, 




phosphorylated in tumor grades I-III, pS726 increases with tumor grade, and is PRL-responsive. 
Further, pS726 expression is restricted to luminal breast cancer cell lines and PDXs. Conversely, 
pS780 is PRL-independent, confirming earlier reports that it is constitutively phosphorylated, and 
occurs in both luminal breast cancer cell lines and PDX lines, but also in the basal-like breast 
cancer cell line MDA-MB-436. 170 The constitutive, wide-ranging expression of pS780 suggests 
that it could result from a non-specific phosphorylation event in breast cancer pathogenesis, 
however studies performed herein determined that it has a non-redundant role for STAT5a in 
MCF7 breast cancer characteristics. 
It has been assumed that pY694-STAT5a is necessary for most, if not all, PRL-induced 
gene expression changes. This assumption prior to this study had not been directly assessed by 
qRT-PCR, or, more globally, RNA-sequencing, chromatin immunoprecipitation (ChIP), or ChIP-
sequencing. 85,86,136,213–216 Rather, pharmacologic inhibition or total knockdown of STAT5a had 
been the focus of previous work to understand STAT5a transcriptional functions, ignoring the 
gradation of STAT5a transcriptional function that may be in play in breast cancer and other 
pathologies. 86,213,214 In this study we performed RNA-sequencing of MCF7 cells expressing 
single-point phospho-deficient STAT5a mutants treated with PRL in attempts to identify 
differentially expressed genes and functional pathways for cancer outgrowth. Examination of 
PRL-regulated DEGs from the WT-STAT5a expressing cells compared to previous studies 
allowed us to first identify core genes responsive to PRL in this study. Then we were able to 
examine the activation or inhibition of upstream regulators and downstream functional pathways. 
While loss of pY694-STAT5a had the largest effect on these functional pathways, loss of either of 





For the first time, we have analyzed STAT5a serine phosphorylation on breast cancer 
phenotypic characteristics that fall within the hallmarks of cancer.217,218 As presented here, the 
roles for the serine residues of STAT5a are nonredundant, exhibiting different effects on cancer 
characteristics, and different regulatory roles on the canonical pathway of PRL/STAT5a signaling.  
Our results indicate a role for STAT5a in establishing and maintaining anchorage-independent 
growth that may rely on phosphorylation of S780. Expression of Y694F-STAT5a led to a decrease 
in colony number compared to MCF cells expressing WT-STAT5a. However, the expression of 
S780A-STA5a in MCF7 rescue cells led to a further decrease in colony number. Therefore, 
phosphorylation of S780 may contribute to the potential for breast cancer cells to establish viable 
colonies, indicating a delicate balance for STAT5a regulation. On the other hand, loss of pS726-
STAT5a had no effect on colony number or size at the end point for the soft agar assay, which 
indicates that S726 does not singularly contribute to the overall regulatory effect of STAT5a on 
anchorage-independent growth. Therefore, it is possible that targeting pS780 on STAT5a would 
decrease tumorigenicity, leading to better prognostic outcomes for patients. 
The biologic affects from loss of either phospho-serine residue regarding proliferation and 
viability were likewise nonredundant. Loss of pS726 decreased PRL-stimulated proliferation in 
MCF7 cells, and increased the expression of cleaved caspase 3, an effector of apoptosis, in T47D 
cells. Interestingly, the expression of cleaved caspase 7, another effector molecule of apoptosis, 
was not increased in MCF7 cells. With the loss of caspase 3, MCF7 cells may be at an advantage 
when faced with yet another hit to cell viability, i.e. the loss of pS726-STAT5a, compared to T47D 
cells. 219 Increased apoptosis in T47D cells, on the other hand, illustrates the reliance on intact 




mutant. Loss of pS780-STAT5a was unremarkable on these characteristics, indicating roles for 
each phospho-serine residue independent of each other. 
We sought to determine the mechanism by which loss of STAT5a phospho-residues 
affected breast cancer characteristics differentially by examining canonical STAT5a activity, and 
found 1) the canonical phosphorylation of pY694 is independent of either pS residue, and 2) there 
is nuclear localized STAT5a with loss of pY694, pS726, or pS780, with altered kinetics for 
translocation. These results determined that the phospho-serine residues of STAT5a perform roles 
independent from pY694. Taken together with the RNA-seq data, the STAT5a serine residues 
appear to regulate functional phenotypes at the transcriptional level.   
Accordingly, in silico analysis using TF gene set enrichment analysis was used to establish 
how these residues alter STAT5a function at the transcriptional level. Our data from this analysis 
indicates that an array of TF families may be involved as compensation with loss of pY- or pS-
STAT5a function. In this study, the SREBP TF family had indicated involvement in both Y694F- 
and S726A-STAT5a PRL-regulated gene expression changes. As a TF, SREBP has been found to 
play a critical role in breast cancer migration and invasion, and its involvement in conjunction with 
the loss of pY694 or pS726 may indicate a role in oncogenic signal switches that confound the 
loss of STAT5a. 220 Activation of SREBPs are required for growth factor-independent growth and 
proliferation, which could explain our phenotypic findings with our functional studies. Further, 
SREBP acts downstream of oncogenic PI3K or K-Ras, and our laboratory recently found that 
expression of K-Ras is a necessary co-factor for PRLr-mediated oncogenic transformation (Grible 
et al, in press). This illustrates the complexity of transcription factor activity in breast cancer, and 




Future studies of the loss of these phospho-sites on STAT5a are warranted. With loss of 
one phospho-site, compensatory mechanisms for recovering STAT5a activity may still be in effect. 
However, if two or more of these phospho-residues are targeted, we may be able to study how only 
one remaining phospho-site regulates STAT5a activity. Further studies of how loss of these 
residues affects STAT5a binding to transcriptional cofactors, or to binding sites on chromatin, will 




4. Chapter 4: Studies of double-point STAT5a mutants illustrate 
requirements for cooperative activation of serine and tyrosine 
residues 
4.1. Introduction 
The results for STAT5a single point phospho-deficient mutants indicate non-redundant 
roles for the serine residues S726 and S780 in luminal breast cancer. However, these residues may 
also act together to affect STAT5a activity and phenotypic characteristics of breast cancer.  
Studies showing phenotypic effects of mutations of both serine residues have mainly been 
performed in hematopoietic models. In the mouse interleukin (IL)-3 dependent, pro-B cell, cell 
line Ba/F3, it was shown that phosphorylation of either serine residue is required to abolish IL-3 
dependence of Ba/F3 cells.169 Further, this finding was exacerbated in cells expressing a double 
phospho-serine STAT5a mutant. Importantly, this contrasts to constitutively active STAT5, which 
provides survival and proliferation stimuli resulting in cytokine-independent cell expansion.169 In 
another study, the loss of both serine residues of STAT5a hampered both v-ABLp160+ and BCR-
ABLp185+  leukemic cell viability in vitro. Further, in both of these studies, transplantation of 
leukemic cells expressing double-serine STAT5a phospho-mutants into lethally irradiated or nod 
scid gamma (NSG) mice significantly increased disease latency.169,178  
 Like the literature examining single-point STAT5a phospho-mutants and cytokine 
stimulation, the literature for the double-point STAT5a phospho-mutants (i.e., S726A + S780A-
STAT5a) has focused mainly on reporter assays for known STAT5a target genes or STAT5a 
promoter sequences. Beuvink et al (2000) found that loss of both serine residues did not decrease 
PRL-stimulated β-casein promoter transcription via luciferase activity compared to WT-STAT5a 
in COS-7 cells.170 Conversely, Yamashita et al (2001) found that loss of both serine residues 




in both COS-7 and MCF7 cells. Further, the double mutant STAT5a led to elevated luciferase 
activity above either single point phospho-mutant, which the authors concluded suggested 
functional cooperativity between the two serine sites.175 Interestingly, both studies used the same 
concentration and timing for PRL treatment, so it may be possible that the difference in these 
findings lies with the β-casein reporter construct.170,175  
Park et al (2001) found that expression of the double mutant of STAT5a decreased 
expression of one reporter construct but increased expression of another compared to WT-
STAT5a in the presence of PRL in COS-1 cells.179 Adding to this complex finding, when the 
authors stimulated HepG2 cells or COS-1 cells with growth hormone (GH) and examined the 
luciferase activity (i.e. gene expression) of the same reporter construct, they found the double 
point mutant in HepG2 cells decreased luciferase activity, whereas luciferase activity was not 
affected in the COS-1 cells compared to WT-STAT5a.179 These findings lend to the argument 
that serine phosphorylation affects STAT5a transcriptional action that is dependent upon both the 
enhancer/promoter as well as the cell-type.  
Overall, the evidence regarding loss of both serine residues on STAT5a transcriptional 
activity is confounding, and there remains a lack of evidence for any phenotypic effects this 
phospho-mutant has on breast cancer cells. Therefore, in this Aim, we sought to determine if loss 
of these serine residues of STAT5a, together or in conjunction with loss of tyrosine residue 694 
(Y694) affected phenotypic characteristics of breast cancer in a way similar to the hematopoietic 
studies.    
4.2. Hypothesis 
We hypothesize that STAT5a serine residues S726 and S780 cooperatively act with Y694 to 





Immunohistochemical (IHC) staining and scoring for pS726-, and pS780-STAT5a of the 
breast cancer tissue microarray (TMA) we reported on in Aim 1 was used to determine how 
concordant phosphorylation of both S726- and S780- STAT5a were in the samples. As shown in 
Table 4.1, 77% of the 47 cancer tissues were highly concordant between pS726- and pS780-
STAT5a nuclear staining (with a difference of ≤1 modified nuclear Allred score). Specifically, 22 
cases, or 47%, had equal modified nuclear Allred scores for both phospho-antibodies. Conversely, 
only 5 cases, or 11%, were met the criteria of having a modified nuclear Allred score of ≥5, 
indicating either specifically staining for pS726- or pS780-STAT5a and excluding staining for the 
other phospho-antibody. These results indicate that phosphorylation of both serine residues occurs 
clinically in breast cancer.   
 
Table 4.1 Cases with Nuclear Allred Scores for both pS726 and pS780 as scored in the breast 
cancer TMA. pS726 and pS780 occurred together in 77% of the tissues. 
Criteria Number of cases 
Percentage (of 47 total 
cases) 
With ≥5 Nuclear Allred 
Score difference 
5 11% 
Between 2 and 5 Nuclear 
Allred Score difference 
6 13% 
With ≤1 Nuclear Allred 
Score difference 
36 77% 
With Equal Allred Scores 22 47% 
 
In a manner similar to Aim 1, we sought to utilize mutant constructs of STAT5a to 
determine the effects of loss of the phospho-sites. Figure 4.1A shows a schematic of the structure 
of STAT5a with double point mutants. MCF7 cells were stably transduced with either STAT5a 
shRNA (STAT5a KD) or nontargeting (NT) control shRNA (Figure 4.1B). Pools of MCF7 cells 




deficient double-point mutants (containing a C-terminal V5-tag), or empty vector (EV), such that 
stable novel MCF7 cell lines were established. Hereafter, these transfectants, which were 
confirmed by WB, are referred to as WT-STAT5a, Y694F+S726A-STAT5a, Y694F+S780A-
STAT5a, S726A+S780A-STAT5a, or EV (Figure 4.1B, C). 
Figure 4.1 Concept and schematic of MCF7 rescues with STAT5a double point phospho-
deficient mutants. A) Structure of STAT5a protein with indicated point mutations, in which the 
peptide tyrosine (Y) is mutated to phenylalanine (F) and serine (S) is mutated to alanine (A). B) 
Schema for stable knockdown and rescue using antibiotic selection. C) Confirmation of double 
point phospho-deficient mutants by WB. 
 
To study the effects of the expression of the STAT5a double point mutants on cancer 




apparatus (Agilent Technologies). As seen in Figure 4.2A, the proliferative ability of MCF7 cells 
expressing Y694F+S780A-STAT5a or S726A+S780A-STAT5a without PRL treatment was 
significantly decreased from WT-STAT5a. This decrease in proliferation was not rescued with 
PRL treatment. Conversely, MCF7 cells expressing Y694F+S726A-STAT5a had no difference in 
proliferation compared to WT-STAT5a with or without PRL treatment. Altogether, MCF7 
expressing Y694F+S780A-STAT5a or S726A+S780A-STAT5a had decreased proliferation 













Figure 4.2 MCF7 cells expressing STAT5a lacking both Y694 and S780 or both S726 and 
S780 are unable to proliferate, and prolactin does not rescue this phenotype. Proliferation was 
assessed using XCELLigence, cell index (CI) indicates proliferation. A) Individual graphs of CI 
for cells grown in serum free media (SFM) or with PRL treatment (SFM+PRL), significance 
compared to cells expressing WT-STAT5a without PRL or with PRL treatment, respectively. B) 
Combined graph of MCF7 cells grown in SFM and with PRL treatment shows significance 





To further study the effects of the STAT5a phospho-sites together, we performed 
quantitative evaluation of the MCF7 rescues grown in soft agar. The ability of cancer cells to grow 
independently and survive without attachment to extracellular matrix is a hallmark of 
carcinogenesis.209 Compared to WT-STAT5a, loss of either pS726 or pS780 in combination with 
loss of pY694 (Y694F+S726A-, or Y694F+S780A-STAT5a) or together (S726A+S780A-
STAT5a) significantly decreased MCF7 colony growth in soft agar measure by both colony 
number and size (Figure 4.3). Further, the double point phospho-mutants significantly differed 
from each other in colony number. MCF7 cells expressing the phospho-serine double mutant, 
S726A+S780A-STAT5a, formed the least number of colonies in soft agar compared to MCF7 cells 
expressing the other two phospho-mutants. Alternatively, MCF7 cells expressing Y694F+S780A-
STAT5a formed the most colonies compared to the MCF7 cells expressing the other phospho-





Figure 4.3 Loss of either STAT5a serine residue in combination with loss of Y694 or loss of 
both serine residues decreases MCF7 ability to grow in soft agar as measured by both colony 
number and colony size. Representative images and quantification of number and size of the 
colonies formed in soft agar by indicated MCF7 cells with knockdown (KD) of STAT5a rescued 
by double phospho-deficient mutants. n=3, *p≤0.04, ***p=0.0002, ****p<0.0001 compared to 
WT-STAT5a. 
 
Metastatic cancer is responsible for 90% of human cancer deaths.217 Invasion and 
metastasis rely on cancer cells ability to migrate from the primary tumor. Cell migration is easily 
studied in vitro using a scratch wound assay with real-time imaging.221,222 12 hours after 
establishing a scratch wound, MCF7 cells expressing the phospho-serine double point mutant, 




cells continued to migrate further than WT-STAT5a, or any other cell type, up to 30 hours after 
the scratch wound was established. 
Figure 4.4 Loss of both STAT5a serine residues in combination expedites MCF7 migration. 
MCF7 cells expressing indicated STAT5a phospho-deficient mutants were subjected to scratch 
wound assay and imaged at indicated time points for fraction of wound closure. n=3, *p=0.02, 
**p≤0.002, ***p=0.0004 compared to WT-STAT5a. 
 
4.4. Discussion 
The data presented in this chapter indicate cooperative actions for the STAT5a phospho-
sites that result in distinct phenotypic breast cancer characteristics. Whereas loss of Y694 and S726 
decreased anchorage-independent growth, this combination of loss did not affect proliferation or 
migration of MCF7 cells. Loss of Y694 and S780 affected anchorage-independent growth, as well 
as proliferation. However, loss of these phospho-sites did not affect MCF7 cell migration. Loss of 
both phospho-serine sites, S726 and S780, decreased anchorage-independent growth and 




phospho-serine residues led to the greatest decrease in MCF7 cells establishing colony number in 
an anchorage-independent manner.  
Overall, this data indicates that loss of both phospho-serine residues modulates STAT5a 
activity leading to decreased tumorigenesis, and that intact phosphorylation of S726 and S780 
increases tumorigenesis. However, the migration data indicate that intact phosphorylation of S726 
and S780 on STAT5a decreases breast cancer cells migratory programs. These data suggest that 
these residues cooperatively modulate STAT5a activity at different gene loci responsible for 
different tumorigenic pathways. Moreover, these results are similar to the results in the 
hematopoietic studies which showed decreased leukemic potential both in vitro and in vivo.169,178 
It would be of interest to perform IHC on a TMA panel that includes matched primary and 
metastatic tissue examining the concordance of pS726/pS780 expression to determine if migration 
and therefore metastatic potential is indeed decreased with these STAT5a phospho-sites intact. 
Previous literature has shown when STAT5a lacks both S726 and S780, it is still capable 
of being phosphorylated at residue Y694.130,169,170,175 Therefore, because the canonical pathway of 
STAT5a tyrosine phosphorylation is not affected, future mechanistic studies can focus elsewhere. 
Complex formation of STAT5a and other transcriptional activators and repressors will give insight 
into how serine phosphorylation regulates STAT5a interactions in the nucleus. Additionally, RNA-
sequencing, and confirmatory qRT-PCR, coupled with ChIP-sequencing, will better determine 
how STAT5a actions are modulated by phospho-serine and phospho-tyrosine at the transcriptional 
level in an enhancer/promoter dependent context. 
Integration of the single-point and double-point STAT5a phospho-deficient mutant data 
was not performed due to technical limitations. The rescue of STAT5a in MCF7 cells as WT-




leading to two WT-STAT5a MCF7 cell lines. Thus, analyses comparing the STAT5a mutants to 
WT-STAT5a was performed separately for the single-point STAT5a mutants and double-point 
STAT5a mutants. 
 This study was limited to in vitro characterization of the double point phospho-mutants of 
STAT5a. Therefore, it is limited in the conclusions we can draw about how these phospho-serine 
residues affect STAT5a in a physiologic setting. Thus, future studies in vivo are warranted, with 
implantation of the MCF7 cells expressing the STAT5a double point phospho-mutants in the 
mammary gland. An interesting, and warranted study, for the development of spontaneous 
metastasis with IHC examination of tissue from the primary and, if applicable, metastatic tumors. 
As a corollary to the TMA proposed above, this would allow for the study of whether the double 




5. Chapter 5: Global transcriptomic changes with expression of STAT5a 
single-point mutants by RNA-sequencing 
5.1. Introduction 
PRL-induced gene expression changes have largely been assumed to necessitate only the 
pY694 residue of STAT5a, but not the pS726 or pS780 residues. This assumption has been upheld 
by studies of phospho-point mutant STAT5a transcriptional activity limited to utilizing readouts 
relying solely on the STAT5a GAS consensus sequence or the canonical β-casein gene reporter 
assays (i.e. transfection-based luciferase activity assays or EMSAs).127,170,175,179 In fact, this 
assumption has not been directly assessed by qRT-PCR, or, more globally, RNA-sequencing 
(RNA-seq), chromatin immunoprecipitation (ChIP), or ChIP-sequencing.85,86,136,213–216 When 
studies of global transcriptomics have been undertaken, the approach often employed relies either 
on pharmacologic inhibition or total knockdown of STAT5a, therefore focusing on the role of 
pY694-STAT5a and ignoring the gradation of STAT5a activity that may occur in breast cancer 
and other pathologies.86,213,214 This has led to a general lack of understanding for the biology of 
endogenous upY694-, upS726-, or upS780-STAT5a. 
The phenotypic characteristic changes observed in MCF7 cells harboring STAT5a serine 
phospho-mutants in outlined in Aim 1 led us to hypothesize that the phospho-serine residues on 
STAT5a may regulate PRL-induced gene changes throughout the transcriptome. Therefore, in this 
study we performed RNA-seq of MCF7 cells expressing single-point phospho-deficient STAT5a 
mutants treated with PRL in attempts to identify differentially expressed genes, functional 
pathways for cancer outgrowth, and changes in transcription factor programs in response to loss 
of STAT5a phospho-sites. Additionally, this data was integrated with RNA-seq data from patient 




to determine if phospho-mutants of STAT5a were sufficient to significantly change the intrinsic 
molecular subtype of the MCF7 cells harboring these mutants.197 
5.2. Hypothesis 
We hypothesize that STAT5a phosphorylation of S726 and/or S780 affect STAT5a transcriptional 
activity in response to PRL and that loss of these phospho-sites will result in global transcriptomic 
changes that are independent from the loss of the Y694 residue. 
5.3. Results 
Stable MCF7 single point phospho-mutant cells described in Aim 1 (Chapter 3) were 
stimulated with PRL (250 ng/ml) and subjected to RNA-seq to assess global transcriptomic 















Table 5.1 Significant differentially expressed genes (DEGs) for indicated contrast analyses 
performed in EdgeR filtered for counts per million (CPM)>0.5 to filter lowly expressed genes 

















Multiple analyses were performed prior to filtering differentially expressed genes (DEGs) 
based on fold change of at least 1.5, as seen in Table 5.1. However, a threshold for 1.5-fold change 
allowed us to filter biologically relevant PRL-induced gene expression changes for each STAT5a 
mutant (Table 5.2). Following PRL treatment, MCF7-WT-STAT5a had 510 differentially 
expressed genes (DEGs); specifically, 235 genes were upregulated and 275 genes were 
downregulated (Figure 5.1, Table 8.1). Each STAT5a phospho-deficient mutant had fewer DEGs 
























than the WT-STAT5a. MCF7 cells expressing Y694F-STAT5a had 171 DEGs: 90 genes were 
upregulated and 81 were downregulated. (Table 8.2) MCF7-S726A-STAT5a had the most DEGs 
of the mutant-carrying MCF7s: 285 DEGs total, of which 178 genes were upregulated and 107 
genes were downregulated (Table 8.3). MCF7-S780A-STAT5a cells had 208 DEGs: 182 genes 
were upregulated and 26 were downregulated (Table 8.4). Importantly, when compared to MCF7 
cells expressing WT-STAT5a, most of the DEGs in the MCF7 cells expressing the STAT5a 
mutants were distinct (Figure 5.1).  
 
Table 5.2 Differentially expressed genes determined by RNA-seq analysis of STAT5a-rescued 
MCF7 cells treated with PRL. Included are the PRL vs untreated contrast filtered for fold change 
of at least 1.5. 
PRL treatment vs 
untreated 
Upregulated Genes Downregulated Genes 
WT-STAT5a  235 275 
Y694F-STAT5a  90 81 
S726A-STAT5a 178 107 




Figure 5.1 Significant differentially expressed genes in MCF7 cells expressing STAT5a 
phospho-point mutants are distinct from WT-STAT5a expression. Venn Diagrams of 





Quality control on this dataset was performed in several aspects. First, the STAT5a 
phospho-point mutations were confirmed utilizing RNA-seq BAM files. BAM files are output files 
from the bioinformatics analysis pipeline that contain aligned sequences. Therefore, cropped BAM 
files containing the sequencing for chromosome 17 were aligned to the human reference genome 
(GRCh38/hg38, Dec 2013) in Integrated Genome Browser (IGB 9.1).189 Notably, the expected 
point mutations were intact in the sequenced reads for each STAT5a mutant (Figure 5.2). 
Specifically, for the amino acid mutation Y694F, the adenine (A) nucleotide was replaced with a 
thymine (T; Figure 5.2A). For the amino acid mutations S726A and S780A, the T nucleotide was 
















Figure 5.2 Confirmation of STAT5a point mutations by RNA-sequencing. BAM files 
containing sequencing reads for STAT5a were aligned to chromosome 17 in Integrated Genome 
Browser (IGB) for STAT5a sequence. Sequenced reads were upload to IGB and aligned to the 
human reference genome, with labels for the reads on the left of the snipped screenshots. A) 
Y694F- B), S726A-, and C) S780A-STAT5a mutants reads aligned with chromosome 17 show 





RNA-seq was also performed on the MCF7 cells harboring the empty vector (EV) as a 
control for this experiment. As shown in Figure 5.3, Ingenuity Pathway Analysis (IPA, Qiagen) 
of the EV RNA-seq dataset showed decreased measurement of PRL-induced STAT5a-regulated 
genes, and therefore predicted inhibition of STAT5a activity. Indeed, STAT5a expression in the 
MCF7 EV cells was 6-fold less than MCF7 cells expressing WT-STAT5a (p=1.04x10-17, false 
discovery rate [FDR]=1.60x10-13). To further affirm quality of the dataset, WT-STAT5a PRL-
induced or inhibited genes were compared to previous PRL-regulated transcriptomic data released 
by our laboratory, such that after matching the criteria that the DEG be present in at least two 
datasets, 105 putative PRL-regulated genes were identified (Supplemental Table S2, 
Appendix).70,78 As shown in Chapter 3, a subset of these genes were used to identify functionally-
enriched pathways with PRL treatment that may be changed by expression of the STAT5a mutants 
through IPA (Figure 3.3B, Chapter 3). DEGs from contrasting untreated MCF7 cells harboring 
EV to untreated MCF7 cells expressing WT-STAT5a were overlaid on the IPA pathway and 
showed inhibition of 7 of the 13 queried pathways, including cellular transformation, colony 
formation, proliferation, migration, and cell cycle progression (Figure 5.4A). Inhibition of 10 of 
the 13 pathways was seen when MCF7 cells harboring EV and treated with PRL were compared 
to MCF7 cells expressing WT-STAT5a treated with PRL (Figure 5.4B). Further, this contrast 
showed predicted activation of pathways leading to apoptosis of breast cancer cell lines and cell 





Figure 5.3 STAT5a signaling is predicted to be downregulated in MCF7 cells expressing the 
empty vector (EV) control by Ingenuity Pathway Analysis (IPA). As illustrated here, decreased 











Figure 5.4 IPA functional pathway enrichment analysis of MCF7s expressing EV compared 
to WT-STAT5a largely shows inhibition of chosen pathways. IPA functional pathway analysis 
of the DEGs comparing untreated EV with untreated WT-STAT5a (A) or comparing PRL-treated 
EV with PRL-treated WT-STAT5a (B) overlaying the regulatory network shown in to predict 





As stated previously, multiple contrasts between the MCF7 RNA-seq datasets were 
performed to determine DEGs across the various conditions in this study. One contrast resulted in 
differentially expressed genes by comparing mutant PRL-regulated changes to STAT5a PRL-
regulated changes, ultimately illustrating the change of PRL-regulated gene expression with 
STAT5a phospho-mutants. This contrast for each STAT5a mutant, namely (Mut_PRL-Mut_0)-
(WT_PRL-WT_0) in Table 5.1, was explored in IPA as well. It is important to note that this 
contrast uses the untreated control for each mutant compared to WT-STAT5a, since baseline these 
cells may express genes differentially as well. As shown in Figure 5.5A, expression of the Y694F-
STAT5a mutant in MCF7 cells caused increased expression of BCL6 compared to WT-STAT5a 
in the presence of PRL. With PRL treatment, BCL6 expression is decreased with WT-STAT5a. 
Further, CISH expression was decreased from WT-STAT5a. Together, these changes in expression 
illustrate the role of loss of pY694 on STAT5a canonical function. These findings were confirmed 
by qRT-PCR as illustrated in Chapter 3 (Supplemental Figure S3). Interestingly, each mutant in 
the presence of PRL had an opposite effect on all 13 queried functional predicted pathways 
compared to WT-STAT5a. However, each STAT5a phospho-mutant changed the expression of 
the illustrated PRL-inducible DEGs to different degrees (as based on shades of measurement and 
activation), showing that the STAT5a phospho-sites do not affect PRL-regulated gene expression 
equivalently. Overall, using this subset of putative PRL-regulated DEGs derived from experiments 
with endogenous STAT5a expression may only reflect canonical PRL/STAT5a-regulated gene 




Figure 5.5 Predicted functional effects of the change in magnitude in PRL-induced genes in 
MCF7 cells expressing the STAT5a mutants compared to WT-STAT5a. DEGs of PRL 
stimulated Y694F- (A), S726A- (B), and S780A-STAT5a (C) compared to the DEGs of PRL 
stimulated WT-STAT5a illustrate overall decrease in PRL-responsive functional pathways. 
 
Gene set enrichment analysis (GSEA), is a powerful tool for analyzing molecular profiling 
data to gain insights into biological mechanisms that may be underlying RNA-seq results.195 
Various GSEA were performed on the PRL-stimulated gene expression of each STAT5a mutant 
to determine if and how STAT5a mutations were functionally changing cellular processes. Gene 




were generated from microarray data from NCBI GEO, internal unpublished profiling experiments 
involving perturbation of known cancer genes, or from scientific publications.195,223  
The oncogenic signatures (OS) collection of gene sets represents signatures of cellular 
pathways often dysregulated in cancer. In the presence of PRL, MCF7 cells expressing WT-
STAT5a were enriched in 18 OS gene sets, while MCF7 cells expressing Y694F-STAT5a had 19 
enriched OS gene sets, and MCF7 cells expressing S726A-STAT5a had 30 enriched OS gene sets 
(FDR<0.25). None of the OS gene sets for MCF7 cells expressing S780A-STAT5a met the FDR 















Figure 5.6 MCF7 cells expressing S726A-STAT5a or Y694F-STAT5a share significant 
enriched oncogenic signatures. Venn Diagram comparing enriched oncogenic signature (OS) 
gene sets for MCF7 cells expressing WT-STAT5a or mutants of STAT5a in the presence of PRL. 
These gene sets represent signatures of cellular pathways often dysregulated in cancer. 
Significantly enriched OS for WT-, Y694F-, and S726A-STAT5a FDR <0.25, for S780A-STAT5a 
p<0.05.  
 
All ten of the top 10 significantly enriched OS for MCF7 cells expressing WT-STAT5a 
and treated with PRL were unique, that is, none of these enriched OS appeared in the top 10 for 




significantly enriched OS for MCF7 cells expressing WT-STAT5a in the presence of PRL, 5 of 
these terms (50%) involved upregulation of the KRAS pathway. Conversely, MCF7 cells 
expressing Y694F-STAT5a treated with PRL shared 9 out of the top 10 enriched OS with either 
S726A-STAT5a or S780A-STAT5a, and the only unique OS for these MCF7-Y694F cells was 
STK33_SKM_UP (normalized enrichment score [NES]=1.76, FDR q value=0.009).  
MCF7 cells expressing S726A-STAT5a shared 8 out of 10 of the enriched OS with either 
Y694F-STAT5a or S780A-STAT5a, and was uniquely enriched for LTE2_UP.V1_DN 
(NES=1.71, FDR q value=0.017) and EGFR_UP.V1_UP (NES=1.73, FDR q value=0.019). 
Interestingly, these two gene sets were generated in the same study and share only 10 genes in 
common out of about 195 genes each.224However, 4 of these shared genes make up the leading 
edge of both sets, that is, a subset of genes in a gene list that account for the gene set’s enrichment 
signal.195 Therefore, the significant enrichment of both gene sets in the MCF7-S726A-STAT5a 
cells treated with PRL must depend on the other core genes (numbering ~70) in the leading edge 
subset for these gene sets. 
MCF7 cells expressing S780A-STAT5a only shared 4 out of 10 of the enriched OS with 
Y694F-STAT5a or S726A-STAT5a, however these 4 shared OS were the most significant in the 
top 10 for S780A-STAT5a (FDR<0.89, p<0.023). One OS, PIGF_UP.V1_UP, was shared amongst 
all three STAT5a phospho-mutants in the presence of PRL (NES≥1.58, S780A-STAT5a p=0.001, 
S726A-/Y694F-STAT5a FDR q value≤0.008)  for as well as the untreated MCF7 cells expressing 
WT-STAT5a (Tables 7.5 and 7.6). For the STAT5a phospho-mutants treated with PRL, the 
majority of the leading edge genes in the PIGF_UP.V1_UP  gene set were shared amongst all three 




Utilizing the open-source Enrichr web-based platform, we were able to examine how the 
STAT5a phospho-mutants affect PRL-responsive transcriptional machinery.194 Enrichr includes 
gene set lists that are putative targets for transcription factors (TF) which have been profiled by 
ChIP-seq. Specifically, Enrichr uses data from the Encyclopedia of DNA Elements (ENCODE) 
project where peaks were first identified in the aligned files of 646 experiments profiling TF in 
mammalian cells, and then sorted by distance to the transcription factor start site (TSS). The top 
2000 target genes for each ChIP-seq experiment were retained as gene sets in the library.194,225 
Hierarchical clustering of the odds ratios (OR) of the 812 ENCODE transcriptional gene sets for 
the DEGs from MCF7 cells expressing WT-STAT5a or the phospho-mutants in the presence of 
PRL showed distinct transcriptional patterns (Figure 5.7). Normalized ORs determined that 
S726A-STAT5a and Y694F-STAT5a were enriched in similar TF gene sets. Whereas S780A-
STAT5a and WT-STAT5a enriched similar TF gene sets, there was a distinct proportion of TF 
gene sets in which the normalized ORs for the two were opposite on the -1 to +1 scale (Figure 
5.7). For WT-, Y694F-, and S726A-STAT5a, the top 10 enriched TF gene sets all had p≤0.05 and 
OR≥1.39 (Table 8.7). The top 10 enriched TF gene sets for S780A-STAT5a were p≤0.07 and 
OR≥1.29 (Table 8.7). The top 10 enriched TF gene sets were examined in Figure 3.7 of Chapter 
3 (Table 8.8). STAT5a was confirmed as one of the top transcriptional regulators for PRL-treated 
WT-STAT5a MCF7 cells (OR 2.05, p=0.03; Figure 3.7), and was also enriched significantly in 
S726A-STAT5a MCF7 cells (OR 1.21, p=0.007). However, STAT5a was not identified as a top 
significant TF with PRL treatment for Y694F- or S780A-STAT5a MCF7 cells. Further analysis 
of the top 10 enriched TF gene sets showed that S726A- and Y694F-STAT5a MCF7 cells shared 
6 out of 10 TF gene sets as seen in Figure 5.8, similar to what was seen on a larger scale in Figure 




ESSRA (OR 1.59, p=7.74E-09), whereas cells expressing Y694F-STAT5a were uniquely enriched 
in TF THAP1, IRF3, and FOSL1 (OR ≥ 1.59, p≤2.88E-04). MCF7 cells expressing S780A-
STAT5a had the least enriched TF in common with WT-, Y694F-, or S726A-STAT5a, only 
sharing TF SP1 with S726A-STAT5a and TF FOXA1 with WT-STAT5a (Table 8.7). Further, 
these S780A-STAT5a cells were most significantly and uniquely enriched for STAT3 as a TF (OR 
1.37, p=0.02). 
Figure 5.7 Transcription factor (TF) enrichment shows distinct transcriptional patterns in 
MCF7 cells expressing STAT5a mutants. Hierarchical clustering of the odds ratios for 812 
enriched ENCODE ChIP-seq project transcription factor terms from RNA-seq analysis of PRL 




Figure 5.8 MCF7 cells expressing S726A-STAT5a and Y694F-STAT5a share the most 
enriched transcription factor programs in the presence of PRL. Venn Diagram of the top 10 
enriched ENCODE project TF terms shows distinct and shared TF terms in the various STAT5a 
species. 
 
As a breast cancer cell line, MCF7 cells are classified as luminal A/B.4,65 To determine if 
expression of phospho-point mutants of STAT5a in MCF7 cells could cause intrinsic subtype 
switching, the RNA-seq data were merged with mammary gland tumor (MGT) transcripts from 
PDXs as well as 817 TCGA breast cancer samples as described in Alzubi et al.197  Expression of 




MCF7 dataset and the PDX samples (Figure 5.9A). The MCF7 STAT5a samples correlated 
closely with the PDX MGT samples, ranging from 0.91-0.96. However, there was no pattern of 
greater correlation of the MCF7 samples to luminal B PDX samples (that is, HCI03, HCI09, 
HCI11, HCI13) compared to the basal-like PDX samples (HCI01, HCI02, HCI04, HCI10, HCI16, 
UCD18, UCD52, WHIM2, WHIM30; Figure 5.9A).197 Expression of 1,770 genes related to breast 
cancer was used to determine Pearson’s sample-wise correlations for the MCF7 dataset and PDX 
MGT in addition to RNA-seq from 817 TCGA-BRCA samples (Figure 5.9B).197,206,226 The MCF7 
STAT5a samples ranged from about 0.73-0.94 in correlating to the TCGA-BRCA and PDX 
samples in this comparison (Figure 5.9B). The samples that least correlated to the MCF7 samples 
included one luminal B PDX (HCI13), three TCGA-BRCA triple negative breast cancers, and 
three TCGA-BRCA samples of histologically mixed invasive ductal carcinoma that have reported 











Figure 5.9 Pearson’s sample-wise correlation analyses of MCF7 expressing STAT5a 
phospho-mutants RNA-seq and RNA-seq from PDX tumors and metastases and the Cancer 
Genome Atlas (TCGA) datasets. A) The top 5% most variable gene expression levels from the 
MCF7 dataset and the PDX dataset from Alzubi et al were used to determine Pearson’s sample-
wise correlation .197 B) 1,770 genes  related to breast cancer were used to determine correlation 
between the MCF7 dataset and a dataset consisting of 817 TCGA-BRCA samples and PDX 
samples as described in Alzubi et al.197 Black bars to the left of the analyses indicate MCF7 
samples. 
 
This combined dataset was then analyzed further for PAM50 gene expression (Figure 
5.10).197,226 The PAM50 is used to define the four intrinsic subtypes of breast cancer (i.e., luminal 
A/B, HER2-enriched, and basal-like) based on differential expression of 50 genes, has been shown 
to be predictive of treatment benefits and recurrence risk, and has been used to characterize breast 
cancer cell lines.4,206,226,229 Figure 5.10A shows hierarchical clustering of the full dataset. Figure 
5.10B, a magnified view of the heatmap surrounding the MCF7 dataset, illustrates how the MCF7 
STAT5a samples (luminal A) hierarchically cluster together closely with luminal A TCGA-BRCA 




point mutants do not cause a large enough change in gene expression to elicit an intrinsic subtype 
switch for MCF7 cells. 
Figure 5.10 MCF7 cells expressing STAT5a mutants hierarchically cluster together when 
combined with RNA-seq data from PDX mammary gland tumors and data from 817 tumors 
from the Cancer Genome Atlas (TCGA).197 The PAM50 genes were used to hierarchical cluster 
the combined dataset.4,197,206 A) Complete combined dataset. B) Magnified view of the boxed area 
in (A) surrounding the MCF7 dataset. 
5.4. Discussion 
This study was limited by the low number of biological replicates performed. While 
previous genomic studies in our laboratory using microarray successfully identified DEGs with 
three replicates, recommendations for RNA-seq call for at least six replicates per condition.230 This 
may have led to downstream issues with gene expression quantification. 
Technical bias may have been introduced by mRNA library construction using 
polyadenylated (poly(A)) RNA selection. Although poly(A) selection is known for its low-noise 




other library selection method, ribosomal RNA (rRNA) depletion, selectively removes rRNA, 
enriching samples with the poly(A) mRNA, protein-coding mRNAs that are non-poly(A), and non-
coding RNAs.232 These different RNA sample preparation methods may lead to significant 
variations in quantification of gene expression.231,233 In the case of our RNA-seq dataset, the 
ribosomal 5.8S rRNA was found to be a significant confounder in analysis of DEGs. While FastQ 
screening did not show any contamination from this rRNA, review of the BAM file using IGB 
showed about 80,000 reads aligning to the rRNA region. Therefore, it is likely that rRNA 
contamination of our sequencing samples led to lower read counts for protein-coding mRNA 
during sequencing. This led to downstream issues with analysis, specifically low read counts that 
subsequently decreased the power of identifying significant DEGs. To partially overcome this 
limitation, rRNA genes were removed from the gene matrix by Amy Olex, collaborator and 
bioinformatician. However, this issue ultimately led to the use of p values for identifying 
significance rather than the false discovery rate. To confirm significant DEGs, an analysis 
comparing past genomic datasets from our laboratory to this dataset was performed 
(Supplementary Table S3, Appendix). Consistency across these datasets overall allowed for 
confidence in our data. 
In this chapter, we examined RNA-seq of MCF7 cells expressing single-point phospho-
deficient STAT5a mutants treated with PRL in attempts to identify differentially expressed genes 
and functional pathways for cancer outgrowth. While expression of the STAT5a phospho-mutants 
had less PRL-induced DEGs compared to WT-STAT5a, the DEGs were mostly distinct, and led 
to differences in the functional pathways analyzed. 
Quality of the RNA-seq dataset was performed both by analysis of BAM files for intact 




BAM files confirmed STAT5a point mutations, study of EV showed 6-fold decrease in STAT5a 
expression and an overall decrease in tumorigenicity compared to WT-STAT5a when DEGs and 
functional downstream pathways of STAT5a were analyzed. 
Comparison of the WT-STAT5a dataset to previous microarray and RNA-seq studies 
identified 105 putative PRL-regulated DEGs.70,78,87 These DEGs were used to analyze how the 
STAT5a phospho-mutants changed the expression of PRL-regulated genes in IPA and led to 
predicted changes in the activation or inhibition of upstream regulators and downstream functional 
pathways. However, this gene set, derived from experiments with WT-STAT5a expression, may 
reflect only canonical PRL/STAT5a-regulated gene expression, and consequently be a fraction of 
the overall affect the phospho-serine residues have on STAT5a transcriptional function. 
To this point, single-gene analysis may miss effects on pathways, as cellular processes 
often affect sets of genes acting in concert.195 That is, smaller increases or decreases in all the 
genes encoding members of a specific cellular process may dramatically change the biology of the 
pathway and may be more important than a large increase in a single gene. Therefore, GSEA for 
oncogenic signatures was undertaken to examine how the STAT5a phospho-mutants may affect 
cellular pathways dysregulated in cancer. Importantly, the top 10 most significantly enriched OS 
for PRL-treated WT-STAT5a were unique, and 50% of these terms involved the upregulation of 
the KRAS pathway. Further, the unique enriched OS for PRL-treated Y694F-STAT5a was 
STK33_SKM_UP, a gene set which consists of upregulated genes after the knockdown of the 
serine/threonine kinase STK33.234,235 STK33 is required for survival and proliferation of KRAS-
dependent cancer cells.234,235 Therefore, expression of Y694F-STAT5a functionally upregulates 
the same genes that are upregulated upon knockdown of STK33, showing that transcriptional 




literature surrounding the cooperative role for KRAS and PRL in breast cancer pathogenesis. Most 
recently, Grible et al found that PRLr long and intermediate (PRLrL+I) hetero-dimers cooperate 
with KRAS signal transduction to promote cellular transformation.(Grible et al, in press 2021) 
Further, with GSEA, Grible et al uncovered a significant association of expression of oncogenic 
KRAS in an analysis of TCGA PRLrIhi/PRLrLlo breast cancer samples.(Grible et al, in press 2021) 
In another study of a PRL-driven mammary cancer mouse line, genomic analyses found activating 
mutations and copy number amplifications of KRAS in established tumors that were absent in 
preneoplastic tissues.75 These studies illustrate the need to characterize the complex interplay 
between the PRL/STAT5a pathway and KRAS pathway.  
MCF7-S726A-STAT5a cells were uniquely enriched for LTE2_UP.V1_DN and 
EGFR_UP.V1_UP, gene sets which were derived from the same study.224 LTE2_UP.V1_DN is a 
set of genes downregulated in MCF7 cells that have been adapted for long-term estrogen-
independent growth. EGFR_UP.V1_UP consists of a set of genes upregulated in MCF7 cells 
which, through expression of ligand-activatable EGFR, have hyperactivation of the MAPK 
pathway, and have adapted to estrogen-independent growth with loss of ERα expression.224 
Interestingly, while the gene signature of upregulated genes in estrogen-independent MCF7 cells 
derived from overactive growth factor signaling is different from the up- or downregulated genes 
in MCF7 cells which have been cultured to adapt to long-term estrogen-independent growth, 
S726A-STAT5a MCF7 cells treated with PRL have genes upregulated and downregulated that fit 
both.224 Therefore, while enrichment of these two gene sets seems contrary, altogether they point 
to a bigger picture: that PRL-induced phosphorylation of S726-STAT5a may contribute to MCF7 
estrogen-dependent growth. In fact, PRL has been shown to play a role in regulating and enhancing 




Additionally, PRL can induce ER transcriptional activity in breast cancer cells independent of 
estrogen ligand binding ER, as shown by induction of the ER-target gene pS2.69 Thus, loss of 
pS726-STAT5a may in fact mimic loss of ER on a transcriptomic scale.  
The enriched OS that were shared amongst at least two of the STAT5a phospho-mutants 
show how these phospho-residues cooperatively regulate STAT5a activity. To that point, the OS 
PIGF_UP.V1_UP was enriched in all three STAT5a phospho-mutants when treated with PRL, as 
well as in untreated WT-STAT5a. The PIGF_UP.V1_UP gene set consists of genes upregulated 
in human umbilical cord vein endothelial cells (HUVECs) when treated with the angiogenic factor 
placental growth factor (PIGF).236 Convergence on this pathway may indicate cooperative 
regulation of STAT5a activity by all three phospho-sites. Increased circulating levels of PIGF have 
been found to be associated with nodal and distant metastasis in breast cancer, and increased tissue 
expression of PIGF is found in TNBC cases compared to other intrinsic subtypes.237 Therefore, 
when the phospho-sites of STAT5a are intact, their cooperative role regulating gene expression in 
this case may be antagonistic to PIGF-associated tumorigenicity.   
In order to understand how globally the transcriptional machinery may have been affected 
by loss of each of the STAT5a phospho-sites, in silico TF gene set enrichment analysis was 
performed. Our data from this analysis indicates that an array of TF families may act specifically 
as compensation to loss of pY- or pS-STAT5a function. For example, loss of phosphorylation of 
S726 resulted in one unique enriched TF, ESSRA.  ESSRA is the gene encoding estrogen-related 
receptor α (ERRα, NR3B1). Intriguingly, through competitive genomic crosstalk, ERRα interferes 
with ERα repression of ERBB2, the gene encoding HER2.238 ERRα regulates HER2 expression, 
and transcriptional activity of ERRα is positively modulated by EGFR/ERBB2 signaling in a feed-




and therefore associated decrease in ERα activity, along with the finding that S726A-STAT5a cells 
were enriched for estrogen-independence (by GSEA) bolsters the concept that loss of 
phosphorylation of S726-STAT5a mimics the loss of ERα.  
Similarly, this study also indicated that the SREBP TF family was involved in both Y694F- 
and S726A-STAT5a PRL-regulated gene expression changes. As a TF, SREBP plays a critical 
role in breast cancer migration and invasion, and its involvement in conjunction with the loss of 
pY694 or pS726 may indicate a role in oncogenic signal switches to overcome the loss of 
STAT5a.220 Activation of SREBPs are required for growth factor-independent growth and 
proliferation, which could explain our phenotypic findings with our functional studies. Lastly, 
SREBP acts downstream of oncogenic PI3K or KRAS.239 Along with the findings of enriched OS, 
this finding illustrates the complexity of transcription factor activity in breast cancer, and the 
homeostatic mechanisms that may be at play for oncogenic growth. 
Finally, loss of pS780-STAT5a resulted in enrichment for STAT3. It has been shown 
previously that STAT5 and STAT3 mediate opposing effects on target gene expression and cellular 
phenotypes in breast cancer.240–242 This finding reported here indicates that phosphorylation of the 
S780 residue modulates the balance between STAT5 and STAT3 transcriptional activity.  
Overall, when taken together these findings indicate that PRL-stimulated STAT5a 
transcriptional activity is affected differentially by loss of each phospho-site. Further, signaling 
pathways that have been implicated acting in cooperation with PRL rely on the phospho-sites of 
STAT5a to various degrees. For instance, GSEA of oncogenic signatures indicates that 
transcriptional activity of pY694-STAT5a could affect the KRAS pathway. That is to say, loss of 
pY694-STAT5a enriches a gene set in a manner similar to loss of STK33, a protein that is required 




expressing upY694-STAT5a that is still phosphorylated on pS726 and pS780, there is decreased 
KRAS pathway activity. Conversely, loss of pS726-STAT5a enriched gene sets which indicate 
that intact phosphorylation of S726-STAT5a may contribute to MCF7 estrogen-dependent growth. 
Concurrently, loss of pS726-STAT5a leads to enrichment for an ERRα signature, a TF that is 
known to compete with ERα, indicating that phosphorylation of S726-STAT5a may reinforce ERα 
transcriptional activity. Finally, as discussed above, phosphorylation of S780-STAT5a may 
modulate the balance between STAT5 and STAT3. Thus, while each phospho-site has distinct 
roles in regulating transcriptional machinery, they also act together to regulate STAT5a activity as 
seen in the GSEA where all three phospho-mutants were enriched in the PIGF gene set. 
Inclusion of this dataset with RNA-seq from PDX MGT and TCGA-BRCA samples was 
done to determine if the changes seen on the transcriptional level translated to stratification of the 
samples in the intrinsic subtypes of breast cancer.197 Subtype switching and gene expression 
changes are seen in metastatic tumors compared to primary breast tumors, and have been reported 
after treatment.243–246 A distribution of tumor samples reflecting the different intrinsic subtypes is 
necessary to reveal the predicted intrinsic subtype using the PAM50 gene profile panel.4,206 Thus, 
hierarchical clustering of the integrated STAT5a phospho-mutant, PDX, and TCGA-BRCA 
datasets showed that the regardless of the phospho-point mutation, the STAT5a dataset clustered 
together and did not elicit an intrinsic phenotype switch.  
In total, the RNA-seq results presented indicate that the phospho-sites of STAT5a affect 
STAT5a-mediated gene expression differentially, with specific roles in regulating STAT5a 
activity in various oncogenic pathways. Further, loss of these phospho-sites elicits disparate TF 
programs. Therefore, it can be concluded that rather than the phospho-serine residues having only 




these residues likely regulates STAT5a activity at different genomic regulatory elements. While 
these changes in gene expression were not large enough to elicit intrinsic subtype switching of the 
MCF7 cells, it is possible that phosphorylation of the serine residues could be used as biomarkers 
for stratifying patients and determining outcomes. Future studies of immunohistochemical analysis 
for pS726- and pS780-STAT5a of primary tumors compared to metastases correlated to patient 




6. Chapter 6: Regulation of STAT5a serine phosphorylation by Prolactin 
6.1. Introduction 
PRL/PRLr signaling initiates the mitogen activated protein kinase/extracellular signal 
regulated kinase (MAPK/ERK) cascade concurrent to JAK2/STAT5a signaling, and the kinases 
in the MAPK pathway are known serine/threonine kinases.125 ERK kinases regulate the activity of 
transcriptional factors involved in the control of the cell cycle.34,247 ERK1/2 is known to target 
PMSP consensus motifs. STAT5a residue S726 lies within a PSP motif, missing the methionine 
residue, and so may be a potential weak ERK1/2 target.127,169,174 Further, residue S780 is contained 
within a LSP motif, which may also act as a weak ERK1/2 target.170  
Commonly, to establish if proteins interact, co-immunoprecipitation for protein complexes 
is performed. ERK1/2 and STAT5a have been shown to complex in several reports in the context 
of growth hormone (GH), a member of the same cytokine super family as PRL. In a study by 
Pircher et al, CHO cells (PRLr/GHr-null) stably expressing GHr (the cognate GH receptor) were 
shown to have preformed complexes of ERK1/2-STAT5a which dissociated with GH 
stimulation.32 However ERK1/2:STAT complex formation or dissociation upon stimulation, as 
well as any interdependence of these two proteins, is controversial.248 In fact, Dinerstein-Cali and 
co-authors showed that upon GH stimulation, the association of ERK1/2 and pY- and pS-STAT5a 
was increased in CHO cells.34  
Further work for understanding the relationship between ERK1/2 and STAT5a has utilized 
in vitro kinase assays as well as pharmacological inhibition of the MAPK pathway. Pircher et al 
established that ERK1/2, activated in response to GH, was capable of phosphorylating S780-




inhibitor PD98059 has been used in various studies to determine if STAT5a serine phosphorylation 
was downstream of the MAPK pathway in various cell types upon cytokine stimulation.126–128 
Inhibition of MEK inhibits ERK1/2 phosphorylation and activation, and therefore possible 
downstream targets.249 Interestingly, findings for inhibition of STAT5a serine phosphorylation 
may be cell-type and cytokine-specific. In Nb2 lymphocytes, PD98059 had no effect on IL-2 
induced STAT5a serine phosphorylation nor its ability to bind DNA.126 In another study using Nb2 
lymphocytes and PRL, pretreatment of the cells with PD98059 had no effect on inducible 
phosphorylation of S726, but decreased PRL-independent, constitutive serine phosphorylation of 
STAT5a.127 This study, it must be mentioned, did not examine phosphorylation of S780, which we 
have found to be independent of PRL stimulation, and therefore may in fact be the constitutively 
phosphorylated serine residue in that study. However, in an oncogene RhoA-driven model of 
Madin-Darby Canine Kidney (MDCK) cells also treated with PD98059, phosphorylation of S726 
was decreased with no decrease in phosphorylation of S780.128  
These studies are evidence of the controversial data that exists around STAT5a serine 
phosphorylation. Therefore, we set out to determine if ERK1/2 associated with STAT5a in 
preformed complexes or associated upon PRL stimulation, and if ERK1/2 phosphorylated STAT5a 
serine residues in breast cancer specifically.  
6.2 Hypothesis 
We hypothesize that ERK1/2 is responsible for phosphorylation of at least one serine residue of 





We first sought to determine if ERK1/2 and STAT5a associate in a PRL-dependent 
manner, and if this association depended on the presence of the STAT5a phospho-serine residues 
S726 or S780. As seen in Figure 6.1, with immunoprecipitation targeting V5-STAT5a, STAT5a-
ERK1/2 complexes were present before PRL stimulation. After 30 minutes PRL treatment, there 
was an observable, albeit slight, difference in complex formation (WT-STAT5a). Interestingly, in 
the same co-immunoprecipitation experiment, there is a loss of ERK1/2 complexing with STAT5a 
when pS726 is lost (Figure 6.1A). Further, with loss of pS780, there is an increase in ERK1/2 
complexing with STAT5a (Figure 6.1B).  
Figure 6.1 ERK1/2 interact with STAT5a is dependent on presence of S726 but not S780. 
MCF7 cells rescued with A) S726- or B) S780-STAT5a or WT-STAT5a were immunoprecipitated 
with a V5-specific antibody and protein lysates were analyzed for V5-STAT5a, and total ERK1/2. 





Our laboratory has previously shown that with PRL stimulation, ERK1/2 mediates 
phosphorylation of another serine/threonine kinase, NEK3.41 In those studies, the ERK1/2 
inhibitor, U0126, was shown to specifically inhibit ERK1/2 and NEK3 phosphorylation in 
response to PRL. Therefore, we sought to determine if this inhibitor would inhibit phosphorylation 
of either STAT5a serine residue. U0126 treatment completely inhibited phosphorylation of 
ERK1/2, as expected (Figure 6.2). However, neither the PRL-inducible phosphorylation of S726, 
nor the constitutive phosphorylation of S780 was inhibited. (Figure 6.2A and B, respectively).   
Figure 6.2 Phosphorylation of S726 and S780 are independent of the MEK pathway. MCF7 
cells were treated with the MEK inhibitor for 2 hours and then stimulated with PRL for 30 minutes. 
Analysis by WB for pS726 (A) or pS780 (B) was performed along with pERK1/2. 
 
6.4 Discussion 
Our findings in this Aim show that ERK1/2-STAT5a complexing is dependent on the 
presence of S726 but inhibited by S780. Further, we show that pharmacologic inhibition of the 
MAPK pathway does not inhibit phosphorylation of either of these STAT5a serine residues.  
Like Pircher and coauthors, we found that ERK1/2 and STAT5a are complexed prior to 
PRL stimulation.32 However, there was only a slight dissociation of the complex after 30 minutes 
of PRL stimulation. ERK1/2 is known to have other targets which bind more strongly to inactive 




kinase (RSK).250,251 Therefore it is likely that STAT5a is also bound to inactive ERK1/2, with 
dissociation upon mitogen activation.   
Intriguingly, the pattern of STAT5a-ERK1/2 association in the serine phospho-point 
mutants illustrates how this interaction relies differentially on both residues. The loss of pS726 
decreased ERK1/2-STAT5a association, indicating that the presence of S726 may increase the 
affinity of this interaction. Conversely, the loss of S780 increased the association of ERK1/2-
STAT5a, consistent with previous literature, and suggesting that the phosphorylation of S780 may, 
in fact, decrease the affinity for STAT5a and ERK1/2 interaction.32  
Using the MEK1/2 inhibitor U0126, we found no change in either PRL-stimulated pS726 
nor constitutive pS780. Our results are most consistent with previous studies which found no 
change in either IL-2- or PRL-induced STAT5a serine phosphorylation when cells were treated 
with PD98059, another MEK inhibitor, in different cell types.126,127 While Pircher et al found that 
ERK1/2 directly phosphorylated S780-STAT5a in an in vitro kinase assay, this may not be the 
case in the cellular environment.32 Our results, as well as the studies done by Kirken and 
Yamashita, illustrate that the relationship that exists between ERK1/2 and STAT5a may be cell- 
and cytokine-specific.126,127  
This study was biased and thus leaves the question of which kinase, in response to PRL, 
phosphorylates the STAT5a serine residue S726, unanswered. PRL-PRLr binding concomitantly 
activates the c-Src, JAK2/STAT5, PI3K/AKT, VAV2/RAC1, and MAPK signaling cascades.39,125 
Several lines of work may point to the serine/threonine p21-activated kinase (PAK), downstream 
of RAC1. First, in 2005, Miller et al found that expression of the GEF VAV2 increased STAT5-
mediated gene transcription that was independent of the serine/threonine kinase NEK3.39 This 




pathway has been previously reported as upstream of phosphorylation of STAT3 on S727 in 
response to IL-6.252 Further, in a hematopoietic model of leukemogenic transformation, STAT5 
transactivation was shown to be downstream of the focal adhesion kinase (FAK)/RAC1-
Tiam1/PAK1 axis, although this study examined only STAT5 nuclear translocation and did not 
examine the role serine phosphorylation has on nuclear translocation.253 In yet another model of 
BCR-ABL-driven leukemogenesis, PAK was found to associate with STAT5 and phosphorylate 
S779 (that is, S780).178 Finally, in a study of normal mammary gland development, PAK was 
found to be necessary for phosphorylation of S779 (S780) in mouse HC11 mammary cells and 
normal mammary development.254 However, this study did not examine the PRL-inducible serine 
phosphorylation for either S726 or S780. Therefore, it is apparent that there is a case for studying 
PAK-STAT5a association and phosphorylation in response to PRL in breast cancer cells.  
The results in this study also raise a new question: what is the significance of ERK1/2-
STAT5a association, if not for serine phosphorylation? As stated previously, the ERK1/2-STAT5a 
complex was preformed prior to PRL stimulation, with slight dissociation following PRL 
treatment. It has been previously reported that inactive ERK1/2 is in a complex with other kinases, 
including the serine/threonine kinase RSK, which is activated downstream of ERK1/2.251,255 RSK, 
and any other serine/threonine kinases downstream of ERK1/2 activity are effectively precluded 
from being the possible kinase responsible for STAT5a serine phosphorylation given our findings. 
However, it is possible that ERK1/2 and STAT5a exist in a complex with other, as of yet 
unidentified, kinases that could phosphorylate STAT5a. 
Our work was limited by using pharmacologic agents to determine if ERK1/2 
phosphorylates STAT5a serine residues. Use of ERK1/2 genetic knockdown or knockout would 




kinase responsible for phosphorylating the STAT5a serine residues. Future directions for this aim 
would be to take a non-biased approach and examine other PRL-induced serine/threonine kinases 
and their association with STAT5a. A kinase inhibitor assay with phospho-serine STAT5a as a 
readout would help to narrow the field of serine/threonine kinases that are active downstream of 




7. Chapter 7: Discussion  
7.1. Discussion  
While evidence for STAT5a having a functional role as a survival factor and promoter of 
breast cancer progression has been shown in cell lines and mouse models, in histologic 
examination of patient tumor samples, nuclear localized pY-STAT5a has been found to correlate 
with lower histologic grade, as well as ER and PR expression, whereas loss of nuclear and total 
STAT5a is observed in invasive breast cancer and lymph node metastases, and is associated with 
elevated risk of failure of antiestrogen treatment.143–146,148–150 The dual functionality of STAT5a, 
as a proliferation and survival factor as well as a differentiation factor, is not unheard of, as more 
cancer “gene-chameleons” have been described in which function depends on overall genome 
context and pathway disturbances.256,257  
Phosphorylation of STAT5a residue Y694 in response to cytokine stimulation has long 
been thought to be the only post-translational modification regulating STAT5a activity, however 
a role for STAT5a in the absence of tyrosine phosphorylation is beginning to be appreciated. To 
this point, we know that in the absence of tyrosine phosphorylation STAT5a shuttles in and out of 
the nucleus, which our findings show as well.151–153 (Woock et al, manuscript in review). Further, 
using genomic studies, Park et al supports the idea that upY-STAT5 may act as a partial antagonist 
of the biological activity of pY-STAT5.157,161,162 In fact, their study showed that that upY-STAT5 
suppressed transcriptional programming required for megakaryocytic differentiation, while 
TPO/pY-STAT5 redistribution to promoters with GAS sequences allowed for transcription of 




a growing literature showing that regulation of this transcription factor is more nuanced. Thus, 
determining the regulation of STAT5a activity in the absence of tyrosine phosphorylation, may 
allow us to understand how STAT5a may act as a cancer “gene-chameleon”. 
The phosphorylation of STAT5a on serine residues S726 and S780 had previously been 
shown in human immune cells and mouse tissues169,173,174 Further, in the mouse mammary gland, 
phosphorylation of S780 and S726 increase throughout pregnancy and lactation, but this 
phosphorylation is lost at involution.170,175 While functions have been ascribed for these serine 
residues in hematopoietic models of transformation, their functions are less clear in normal or 
malignant breast tissue.127,130,169,170,175,178,179In hematopoietic studies, mouse transplant studies 
determined that loss of STAT5a serine phosphorylation in leukemic cells delayed disease onset in 
mice.169,178 No such phenotypic study has been performed to understand STAT5a serine 
phosphorylation in breast development or cancer. Instead, the focus has been on STAT5a-target 
gene induction studies, with mixed results dependent on cell type and reporter gene 
construct.127,130,170,175,179 The consensus from these studies had been that the phosphorylation of 
the serine residues mainly negatively regulate canonical phosphorylation of residue Y694 when 
analyzing STAT5a activity on the β-casein gene.127,169,170,175 However, the reliance of these studies 
on the use of the β-casein reporter assay, while useful, are limited in scope when discussing 
STAT5a as a transcription factor with multiple gene targets.  
In this thesis, we show that the phosphorylation of STAT5a on serine residues S726 and 
S780 in both human breast carcinoma cell lines and patient tissue samples in a TMA, and that 
while pS726 increased from tumor grade I-III, pS726 and pS780 co-occurred in 77% of the tissues. 
Phosphorylation of S726 is dependent on PRL, whereas pS780 is PRL-independent and 




Using MCF7 cells expressing single-point and double-point phospho-deficient STAT5a, 
we determined that the loss of STAT5a serine phosphorylation differentially affects breast cancer 
phenotypic characteristics that fall within the hallmarks of cancer.217,218 In MCF7 cells, single-
point mutations of the phospho-sites led to modest, yet significant decreases in soft agar growth 
(Y694F-, S780A-STAT5a), or PRL-induced proliferation (S726A-STAT5a). Expression of 
S726A-STAT5a also led to an increase in the apoptosis protein cleaved caspase 3 in T47D cells. 
These findings indicate that intact expression of each phospho-site contributes to tumorigenicity 
of luminal breast cancer cells in a non-redundant manner. Further, expression of the double-point 
mutant S726A+S780A-STAT5a significantly decreased MCF7 cell proliferation, which was not 
rescued by PRL treatment, decreased the ability of the cells to grow in an anchorage-independent 
manner, and increased the rate of migration. These studies show that intact expression of pS726 
and pS780 is necessary for MCF7 cellular proliferation and the ability to grow without an 
extracellular substrate, and that intact expression pY694 is not sufficient to overcome the loss of 
these phospho-serine residues. Conversely, intact expression of these phospho-serine residues may 
restrict migratory ability of MCF7 cells, ultimately affecting the possibility of metastatic disease. 
Together, the data from both the single-point and double-point phospho-deficient STAT5a studies 
indicate that while each phospho-site has a role in regulating STAT5a, there is cooperative action 
as well. These findings are similar to the those from the hematopoietic studies which showed loss 
of the serine residues decreased leukemic potential both in vitro and in vivo.169,178    
For the first time, the loss of single phospho-sites on STAT5a have been studied for their 
effects on the transcriptome in breast cancer. Previously, the assumption that pY694-STAT5a was 
necessary for most PRL-induced gene expression changes had only been indirectly assessed with 




STAT5a and the subsequent transcriptional activity of select reporter genes. 85,86,136,213–216 The 
overwhelming use of reporter genes in the study of the phospho-serine residues of STAT5a 
supported this assumption. 127,130,170,175,179 
Thus, RNA-sequencing of MCF7 cells expressing single-point phospho-deficient STAT5a 
mutants treated with PRL was performed in attempts to identify differentially expressed genes and 
functional pathways for cancer outgrowth. Expression of the STAT5a phospho-mutants led to 
distinct PRL-induced DEGs compared to WT-STAT5a, which ultimately led to differences in the 
functional pathways analyzed. To this end, GSEA for oncogenic signatures was undertaken to 
examine how the STAT5a phospho-mutants may affect cellular pathways dysregulated in cancer. 
GSEA goes beyond analysis of comparing single gene changes from a list of DEGs, so that smaller 
increases or decreases in all genes encoding members of a cellular process may be considered. 
These small changes may represent dramatic changes in biology of a cellular process or pathway 
that may be more important than the change in a single gene.195 The GSEA analysis revealed that 
signaling pathways, such as KRAS and ERα, which have been implicated in cooperating with PRL 
signaling rely on the phospho-sites differentially.67,69,75 (Grible et al, in press 2021) Additional 
examination of the RNA-seq data using GSEA determined that loss of each STAT5a phospho-site 
led to enrichment for various transcription factors in MCF7 cells. Interestingly, some of the same 
enriched pathways implicated by oncogenic signature analysis were also implicated in examination 
of transcription factor enrichment.  
Overall, the phospho-sites of STAT5a have been shown to mediate gene expression 
differentially, and rather than the phospho-serine residues only modulating canonical pY694-
STAT5a transcriptional activity, most likely these phospho-serine residues regulate STAT5a at 




Comparison of the MCF7 STAT5a phospho-point mutant RNA-seq data with PDX MGT 
and TCGA-BRCA samples led to the findings that the gene expression changes observed in the 
RNA-seq were not large enough to elicit intrinsic subtype switching. However, given the data 
we’ve presented in this thesis, in which pS726 and pS780 are present in tumors spanning grades 
I-III, and the fact that pY694 is lost with breast cancer progression, it is possible that the phospho-
serine residues of STAT5a could be biomarkers to stratify patients and determine outcomes.143,148–
150  
In Aim 3 of this thesis, the targeted focus was to determine if ERK1/2 was the 
serine/threonine kinase responsible for phosphorylation of either S726 or S780 on STAT5a. Given 
the various previous reports showing ERK1/2 associating with STAT5a, and the apparent in vitro 
kinase activity which had been described in response to GH, we hypothesized that ERK1/2 would 
also serine-phosphorylate STAT5a in response to PRL.32,34,127,128 Pharmacologic inhibition of the 
MAPK pathway did not support this hypothesis in luminal breast cancer cells. However, we found 
that ERK1/2 and STAT5a are complexed prior to PRL stimulation, and ERK1/2-STAT5a complex 
association was found to depend on the phospho-serine residues in a contrasting manner; the intact 
expression of S726 may increase the affinity of the interaction, while the presence of S780 may 
decrease the affinity of the interaction. Thus, the kinase responsible for phosphorylating either 
serine residue, and the role of the association of ERK1/2 and STAT5a, remains to be determined. 
7.2. Limitations 
This thesis was limited to the in vitro characterization of STAT5a phospho-serine residues. 
While in vitro approaches are powerful by providing a relatively quick and efficient means to study 
cellular phenotypes and function, they are limited in the ability to recapitulate disease progression 




phospho-deficient mutants was restricted to the luminal cell line, MCF7. Expression of the S726A-
STAT5a mutant in the luminal T47D cell line led to uncontrolled apoptosis, precluding studies of 
the phospho-deficient mutants in T47D cells. Ideally, a range of breast cancer subtypes would have 
been examined for the effects of expression of STAT5a phospho-deficient mutants, to better 
understand how these phospho-sites affect tumorigenicity throughout breast cancer progression. 
 Limitations and technical bias were also introduced in performing the RNA-seq, which has 
been detailed in section 5.4 in Chapter 5. Briefly, a limited number of biological replicates were 
performed, following guidelines for microarray high-throughput sequencing rather than the 
suggested six replicates per condition for RNA-seq.230 This limitation, along with using the 
poly(A)-selection method for preparing the mRNA library for sequencing, ultimately led to the 
use of p values rather than the FDR to identify significant DEGs. To overcome this limitation, 
comparison of the WT-STAT5a dataset to past genomic datasets from our laboratory was 
performed to confirm significant DEGs. 
 The targeted approach to Aim 3 was limited by primarily examining the relationship of 
STAT5a with one serine/threonine kinase, ERK1/2. Further, this study employed pharmacologic 
inhibition of ERK1/2 but did not validate these findings using genetic knockdown of ERK1/2 to 
study the effects of ERK1/2 on STAT5a serine phosphorylation. Often, genetic knockdown or 
knockout by shRNA or siRNA, respectively, is utilized for such validation to mitigate any 
speculation of off-target effects.258  
7.3. Future Directions 
Our data show that upY694-STAT5a has intact phosphorylation of the serine residues S726 
and S780. Further, examining phospho-site mutants by RNA-seq in conjunction with functional 




regulating the phosphorylation of Y694. Phospho-S726 and pS780 have been shown to be more 
influential on proliferation and soft agar growth, respectively, than pY694 in luminal breast cancer 
cells. Thus, it is likely these residues function in breast cancer when pY694-STAT5a is lost and 
contribute to the proliferative, more aggressive functions of STAT5a in breast cancer progression. 
However, the influence of these STAT5a phospho-sites on more aggressive intrinsic 
subtypes of breast cancer, i.e. basal-like or claudin-low, remains to be determined. Therefore a 
future direction of this research would be to express the STAT5a phospho-mutants in a basal-like 
breast cancer cell line such as MDA-MB-231 or MDA-MB-436, which have low levels of 
endogenous STAT5a expression.259,260 Functional studies and RNA-seq of these basal-like breast 
cancer cells expressing the phospho-site mutants could give insight into how the phospho-serine 
residues regulate STAT5a activity in more aggressive breast cancers. Given our findings in luminal 
breast cancer cells, we hypothesize that loss of the phospho-serine residues will lead to decreased 
tumorigenicity in the basal-like subtype, whereas loss of pY694 will be less effective in eliciting 
a change in phenotype or predicted oncogenic pathways. Transplantation of these cells, along with 
the MCF7 expressing STAT5a phospho-site mutants into the mammary glands of NSG mice will 
allow for examination of the functions of these phospho-serine residues in vivo. Examining the 
ability of these phospho-serine residues to affect tumor growth and possible metastatic growth will 
increase our understanding of the function of STAT5a in the progression of more aggressive breast 
cancer. Loss of these phospho-serine residues should lead to decreased tumorigenicity in vivo as 
evidenced by decreased tumor burden and increased overall survival, as seen in the hematopoietic 
mouse models expressing phospho-deficient STAT5a leukemic cells.169,178 
 Another future direction will be to examine primary breast cancer tissues and matched 




examining a TMA for these STAT5a phospho-sites will show differential expression of the 
phospho-sites. Specifically, we hypothesize that loss of pY694 will occur in the metastases, 
whereas there will be similar or increased expression of pS726 and pS780 in the metastatic tissue 
compared to the primary tumor. This future finding would support the idea that phosphorylation 
of these serine residues could be used as a biomarker in primary tumors for potential metastatic 
progression. 
Finally, the kinase responsible for phosphorylating either of the STAT5a serine residues is 
still unknown. Therefore, we propose as a future direction an inhibition assay for potential 
serine/threonine kinases to determine which kinase phosphorylates S726 and S780. Specifically, a 
recent technique was developed, termed kinase inhibitor profiling to identify kinases (KiPIK), to 
identify kinases for specific phosphorylation sites using in vitro kinase assays on cellular extracts 
in the presence of kinase inhibitors, which would be applicable to determining potential kinases 
responsible for STAT5a serine phosphorylation.261 If potential kinases are identified, then we will 
utilize both pharmacologic inhibition (if targeted drugs exist) and genetic knockdown/knockout 
approaches to validate the inhibition assay. We hypothesize that any kinase downstream of 
ERK1/2 will not be responsible for phosphorylation of S726 or S780. This includes the NEK3 
kinase, which is activated by ERK1/2 phosphorylation in response to PRL.39–41 Conversely, PAK 
is potentially responsible for phosphorylating either serine residue, and should therefore be 
included in this study.178,253,254  
While ERK1/2 and downstream kinases are most likely not responsible for STAT5a serine 
phosphorylation, it is evident from our work that ERK1/2 and STAT5a are complexed. A future 
direction of this work is to therefore uncover the function of this association. ERK1/2 and STAT5a 




since ERK1/2 is known to have complex formation with various other proteins.250,251 Further, 
ERK1/2 is largely located in the cytoplasm in quiescent cells, but there is evidence for ERK1/2 in 
the nucleus prior to cytokine stimulation.262 Upon growth-factor or cytokine stimulation, ERK1/2 
translocates to the nucleus, and is known to interact with other proteins, phosphorylate substrates, 
or direct protein-DNA interactions.263 Therefore, it could be hypothesized that ERK1/2 and 
STAT5a interact in the nucleus. Our data indicated that there is ERK1/2-STAT5a complexed both 
prior to and following stimulation, with slight dissociation upon stimulation, however it is still 
possible that there could be nuclear interaction between the two, given upY-STAT5a is shuttled 
into and out of the nucleus.111,152,155,157–159,162,201 Evidence to support this hypothesis would come 
from a nuclear-cytoplasmic cellular fractionation assay followed by co-immunoprecipitation. 
Thus, it could be possible that ERK1/2 acts to direct STAT5a nuclear translocation, or even 





8.1. Supplementary Figures for Chapter 3 
Supplementary Figure S1. TMA for pY694-STAT5a shows weak nuclear staining. 




/Her2 amplified primary tumors included in the TMA (scale bars, 100 μm). Graphs show 
quantification of modified Nuclear Allred scores according to the tumor grade, Ki67 status, and 
molecular subtypes. 
Supplementary Figure S2. Confirmation of STAT5a knockdown and rescue at the mRNA 
level in MCF7 cells. MCF7 cells with stable knockdown (KD) and rescue of STAT5a by indicated 












Supplementary Figure S3. Gene induction is affected differentially by loss of STAT5a 




RNA-sequencing visualized in IPA. B) Expression log ratios of the same panel of PRL-induced 
DEGs of each mutant STAT5a compared to WT-STAT5a + PRL DEGs visualized in IPA, 
illustrating how each mutant specifically increases or decreases expression of these genes 
compared to WT-STAT5a + PRL. C)-F) Confirmatory qRT-PCR analysis of the same panel of 
PRL-inducible or PRL-repressed genes, normalized to total STAT5a expression and GAPDH for 
each sample. **p=0.005, ***p<0.0001 vs. WT-STAT5a + PRL. #p<0.00005 rescue PRL vs. 
untreated. 
Supplemental Figure S4. Effect of single-point phospho-deficient STAT5a mutants on 




type assayed untreated (serum-free media, SFM) or treated with PRL. A) All rescues in SFM or 
SFM + PRL (n=3, p<0.02 compared to WT-STAT5a; see Figure 3.4, Chapter 3) B) Each rescue 
graphed individually comparing SFM to SFM + PRL. n=3, Nonsignificant. 
 
Supplementary Figure S5. Effect of single-point phospho-deficient STAT5a mutants on 
characteristics of MCF7 cells.  A) Representative micrographs of anchorage-independent growth 
assayed by soft agar for WT-STAT5a, EV, or S726A-STAT5a at endpoint. B) Scratch wound 







Supplementary Figure S6. Validation of specificity of STAT5a staining using empty vector 
(EV) control cell line. MCF7 cells transduced with EV pTracer were stained with anti-STAT5a 
antibody and imaged as in Figure 6. Representative merged Hoechst and α-STAT5a images from 
time course illustrate lack of STAT5a staining. 
8.2. Supplementary Tables 
Supplementary Table S1 for Woock et al. Patient characteristics of TMA. 








Black 27 (57.4) 
Hispanic 1 (2.1) 
White 17 (36.2) 
Other 2 (4.3) 
Histologic Grade-n (%) 
I 6 (12.8) 
II 10 (21.3) 
III 27 (57.4) 
Not reported 4 (8.5) 
Ki67 status-n (%) 
Low 18 (38.3) 
Intermediate 4 (8.5) 
High 8 (17.0) 
Not reported 16 (34.0) 
ER Status-n (%) 
Negative 16 (34.0) 
Positive 31 (65.9) 
PR Status-n (%) 
Negative 26 (55.3) 
Positive 21 (44.7) 
HER2 amplified Status-n (%) 
Negative 38 (80.9) 
Positive 9 (19.1) 
Hormone Receptor Status-n (%) 
ER+/ PR- /Her2- 8 (17.0) 
ER+ /PR+/ Her2- 19 (40.4) 
+/+/+ 2 (4.3) 
ER- /PR- /Her2+ 5 (10.6) 
-/-/- 11 (23.4) 
ER+ /PR- /Her2+ 2 (4.3) 
Supplementary Table S2 for Woock et al. is included in Chapter 5 (Table 5.2)  
Supplementary Table S3 for Woock et al. Quality check on WT-STAT5a (PRL vs untreated) 
dataset presented compared to microarray/RNA seq published previously. 
 




Gene FC p value FC p value logFC p value logFC p value 
BCL6 -3.088 0.00828 -3.085 1.29E-19 -2.267 7.58E-10 -2.511 7.23E-
86 
HBP1 -1.72 0.00261 -0.61 1.15E-14 -0.567 0.000266 -0.327 0.00056
8 
FBXO32 -1.577 0.0192 
  
-0.293 0.000216 -0.467 0.00017
1 
YPEL2 -1.544 0.0324 
    
-0.323 0.00322 
TSC22D3 -1.543 0.0281 -0.743 7.63E-16 -0.54 5.96E-07 
  
TXNIP -1.489 0.047 -0.615 1.39E-13 -0.528 3.51E-06 
  
ZNF627 -1.422 0.0275 
    
-0.39 0.00221 
FAM217B -1.417 0.0171 
    
-0.25 0.0159 
EFNA1 -1.398 0.0336 -0.524 9.55E-11 -0.218 0.00086 
  
PAQR6 -1.359 0.00055 -0.203 0.00624 0.339 0.000841 
  
TTLL3 -1.287 0.0388 -0.22 0.00731 0.43 0.000623 
  
NPHP3 -1.264 0.0259 
    
-0.447 0.006 
FRAT1 -1.203 0.00489 -0.691 2.03E-12 -0.412 0.000263 
  
PYCR3 1.222 0.019 0.165 0.00408 
  
0.207 0.0242 
JMJD6 1.238 0.0137 0.737 1.23E-11 0.446 5.07E-05 0.327 0.00774 
STX1A 1.242 0.00406 
    
0.295 0.0308 
SPHK1 1.243 0.0389 0.426 5.52E-09 0.366 0.00106 0.217 0.0151 
CHKA 1.25 0.0143 0.327 0.000156 0.27 0.000416 
  
OSGIN1 1.252 0.0349 0.458 4.16E-08 0.485 0.00106 0.339 0.00084
2 
ANKRD27 1.265 0.0341 0.236 3.55E-06 
  
-0.255 0.00613 
SENP5 1.273 0.0269 0.39 6.66E-08 
  
-0.226 0.0395 












0.662 4.5E-07 0.589 2.31E-
06 
TRMT61A 1.291 0.0143 0.177 0.00433 
  
0.212 0.0325 
ETS2 1.309 0.00607 0.696 1.64E-10 
  
0.239 0.0247 
CD3EAP 1.313 0.00169 0.428 3.31E-08 0.346 0.000262 0.403 0.00014
2 
RPP25 1.314 0.0465 0.301 4.81E-06 
  
0.307 0.00261 
ASB7 1.333 0.0016 0.202 0.000531 
  
-0.28 0.0359 
USP36 1.333 0.00442 0.849 8.59E-08 0.441 6.78E-06 0.229 0.01 
PLA2G15 1.337 0.0162 0.362 1.24E-06 0.34 0.00115 0.225 0.0477 
RRP1 1.337 0.0299 0.458 1.58E-08 
  
0.265 0.00356 
PPAN 1.346 0.00442 0.447 9.98E-10 0.44 0.000804 0.388 5.23E-
05 
PDGFB 1.348 0.0148 0.217 0.00404 
  
0.223 0.0178 
LRRC8E 1.361 0.00953 0.479 4.07E-08 
  
0.245 0.031 
ZNF324 1.368 0.0344 0.203 0.000122 
  
0.33 0.0012 
ABCF2 1.369 0.045 0.338 1.91E-07 
  
0.204 0.0226 
G6PD 1.371 0.0355 
    
0.177 0.0446 
TXNRD1 1.383 0.0388 0.119 0.000864 
  
-0.196 0.0232 
MINPP1 1.385 0.0498 0.234 0.000107 
  
-0.297 0.0407 
PA2G4 1.387 0.0295 0.109 0.00489 
  
0.197 0.021 
DDX28 1.405 0.0111 0.16 0.0036 
  
0.309 0.00676 
RCL1 1.411 0.0167 0.411 2E-09 0.407 1.11E-05 0.392 0.00064
3 
KLF4 1.415 0.00312 0.392 0.000122 
  
-0.262 0.005 
TMEM158 1.415 0.000137 0.497 0.000588 
  
0.904 0.00435 






DDX56 1.432 0.0457 0.147 0.00476 
  
0.212 0.0155 
TSPAN14 1.437 0.0264 0.158 0.00176 
  
0.237 0.0058 
MAT2A 1.437 0.0271 0.625 4.87E-14 0.331 4.06E-05 0.276 0.00133 
CISH 1.44 0.00202 0.707 2.04E-11 1.318 2.96E-11 0.645 7.74E-
10 
RRP7A 1.45 0.0445 0.224 0.00011 0.331 0.000269 0.218 0.0201 
CSRP1 1.466 0.0151 0.322 7.19E-08 
  
0.226 0.00835 




JMJD4 1.476 0.000247 0.338 1.2E-06 
  
0.234 0.0304 
DHCR7 1.487 0.0144 0.172 0.000741 
  
0.201 0.0187 
PUS1 1.495 0.0423 0.395 2.88E-09 0.372 0.000418 0.238 0.0141 
GRPEL1 1.515 0.0248 0.565 3.44E-14 
  
0.25 0.0109 
MIR22HG 1.516 0.000606 0.892 6.15E-14 
  
0.357 0.0464 
NOP56 1.526 0.00315 0.306 0.000061 
  
0.229 0.0101 
SLC20A1 1.531 0.0126 0.46 3.49E-09 
  
0.264 0.00748 
DOLK 1.533 0.004 0.155 0.00355 
  
0.286 0.00328 
BYSL 1.556 0.0126 0.515 7.16E-13 0.451 5.61E-05 0.332 0.00291 
RCAN1 1.572 0.00661 0.57 1.38E-07 0.771 3.2E-07 0.667 1.17E-
09 
CCDC86 1.584 0.0107 0.42 4.51E-11 0.428 5.74E-05 0.34 0.00111 
POLR1C 1.584 0.0011 0.438 1.65E-11 0.467 2.82E-05 0.31 0.00628 
GRWD1 1.589 0.0423 0.252 4.79E-05 
  
0.221 0.0152 
RNF126 1.589 0.017 0.39 2.58E-06 
  
0.231 0.0208 
TWNK 1.602 0.00806 0.449 8.96E-07 0.305 0.00012 0.232 0.0232 






MSRB1 1.638 0.016 0.374 3.51E-10 0.395 0.000237 0.431 2.33E-
06 
NOP2 1.644 0.0166 0.349 1.07E-06 0.289 0.000286 0.186 0.04 
AUNIP 1.649 0.0107 0.408 2.46E-07 
  
0.376 0.00931 
GEMIN4 1.671 0.0345 0.37 3.9E-07 0.262 0.000329 0.263 0.00396 
SLC2A1 1.678 0.0272 0.202 0.000548 
  
0.226 0.00818 
BRPF1 1.707 0.00448 0.347 8.76E-09 
  
0.218 0.0163 
CNN2 1.711 0.00473 0.267 9.19E-05 
  
0.171 0.047 
NOL6 1.722 0.0314 0.272 9.44E-05 
  
0.215 0.0174 
NXT1 1.775 0.00217 0.433 3.4E-11 0.359 0.000282 0.25 0.0252 
NOP16 1.817 0.000846 0.641 3.69E-12 0.478 4.15E-05 0.294 0.00239 
AEN 1.829 0.0206 0.516 9.69E-11 0.36 9.44E-06 0.309 0.00185 
FJX1 1.885 0.000274 0.538 9.96E-11 
  
0.309 0.0112 
RIOX1 1.906 0.0022 0.251 2.32E-05 
  
0.236 0.0148 
CEBPB 1.932 0.000818 0.804 5.82E-17 
  
0.264 0.00347 
PPRC1 2.007 0.000593 0.53 1.31E-09 0.462 2.56E-05 0.333 0.00019
3 
RRS1 2.053 0.00289 0.359 8.47E-10 0.23 0.000894 0.263 0.00412 
ZYX 2.076 0.000448 0.854 9.08E-11 0.511 1.67E-05 0.186 0.0308 
RARA 2.166 0.000791 0.838 4.18E-10 0.639 4.77E-08 0.436 4.1E-07 
SPATA2L 2.326 0.00281 0.556 1.48E-09 0.423 0.00105 0.294 0.00309 
TUFT1 2.351 0.000781 1.259 1.85E-17 
  
0.215 0.0278 
PHLDA2 2.384 0.000907 1.187 4.65E-13 0.699 3.23E-06 0.952 4.1E-08 








MYADM 3.398 5.61E-07 
  




-0.729 6.27E-13 -0.467 0.000066 -0.19 0.0282 
NR2F2 
  




-0.543 1.96E-09 -0.556 0.000314 -0.292 0.00877 
ACKR3 
  
-0.538 5.04E-08 -0.606 0.000585 -0.238 0.00694 
TSC22D1 
  
-0.534 1.6E-12 -0.516 0.000148 -0.256 0.005 
CDKN1B 
  
-0.491 2.67E-08 -0.661 4.44E-05 -0.303 0.00103 
CITED2 
  




0.206 0.000994 0.417 4.74E-07 0.289 0.00104 
PNP 
  
0.317 5.32E-10 0.327 6.27E-05 0.228 0.0303 
MRTO4 
  
0.317 8.66E-05 0.327 0.000624 0.253 0.00729 
MYBBP1A 
  





0.472 2.66E-10 0.329 8.06E-05 0.216 0.0441 
JUN 
  
1.466 3.43E-14 0.301 0.00102 0.207 0.0403 
 
 
Table 8.1 Differentially expressed genes for MCF7 cells expressing WT-STAT5a, PRL vs 
untreated, log10(fold change)>0.58, fold change >1.5. 
WT-STAT5a 
Gene Log10(Fold Change) p value padj 
BCL6 -2.511 7.2E-86 0.0000 
CISH 0.645 7.7E-10 0.0000 
DYNC2H1 1.925 1.1E-09 0.0000 
RCAN1 0.667 1.2E-09 0.0000 
FAM83A 1.078 1.3E-08 0.0002 
PHLDA2 0.952 4.1E-08 0.0004 




BTBD8 -2.979 2.3E-07 0.0015 
RPL23AP47 -6.244 9.5E-07 0.0051 
FP565260.3 0.589 2.3E-06 0.0085 
P2RX2 -0.776 2.5E-06 0.0085 
AC011468.2 -2.938 2.9E-06 0.0094 
SOCS2 0.594 5.1E-06 0.0137 
AL603962.1 6.043 5.3E-06 0.0137 
AL121845.2 6.040 6.2E-06 0.0143 
GCOM1 -0.896 6.3E-06 0.0143 
AP001057.1 0.823 7.7E-06 0.0161 
INPP5F -0.718 8.7E-06 0.0175 
CU633906.1 -5.112 1.1E-05 0.0200 
AC243772.4 -5.992 1.3E-05 0.0216 
AL162151.2 -0.832 1.3E-05 0.0216 
SLC7A5P2 -5.976 1.4E-05 0.0222 
AC012531.2 -5.932 2.0E-05 0.0307 
CHURC1-
FNTB 
-0.950 2.1E-05 0.0307 
AGAP11 -1.466 2.5E-05 0.0362 
AL021546.1 3.131 2.9E-05 0.0400 
CFAP206 -0.881 3.1E-05 0.0419 
MSH5-SAPCD1 -1.249 3.8E-05 0.0506 
Z83844.3 0.685 4.6E-05 0.0547 
AC027644.4 -1.456 5.9E-05 0.0647 
AP000873.1 -2.372 7.0E-05 0.0701 
TNS4 1.123 7.1E-05 0.0701 
IFIT1 -1.363 7.3E-05 0.0708 
AL049650.1 5.701 7.5E-05 0.0718 
ZNF625-ZNF20 -0.922 9.5E-05 0.0858 
AL445363.3 1.123 1.0E-04 0.0883 
RPPH1 -0.622 1.5E-04 0.1210 
PTGES3L-
AARSD1 
1.262 1.7E-04 0.1240 
FGF7P5 -5.580 1.7E-04 0.1240 
AL136982.4 1.583 2.2E-04 0.1520 
UGT1A8 2.377 2.5E-04 0.1586 
AL662884.2 -5.556 2.7E-04 0.1698 
PLGLB2 -2.891 3.1E-04 0.1891 
ZNF490 -0.610 3.3E-04 0.1927 
AL355987.3 -2.606 3.4E-04 0.1951 
GCNT1 0.601 3.5E-04 0.1951 




RASL11A 0.743 3.5E-04 0.1951 
H2BFS -3.861 3.9E-04 0.2068 
ZNF511-PRAP1 1.276 4.0E-04 0.2098 
AMT -3.743 4.3E-04 0.2185 
LINC01260 5.358 4.5E-04 0.2222 
AC106886.2 -1.542 4.6E-04 0.2222 
AC012254.2 -0.732 5.0E-04 0.2335 
AC211476.3 -5.955 5.5E-04 0.2563 
NOTCH1 1.381 5.8E-04 0.2651 
ZRSR2P1 -5.380 5.9E-04 0.2658 
GOLGA8O 5.294 6.3E-04 0.2739 
LIMS4 2.533 6.8E-04 0.2837 
Z84488.2 5.286 7.0E-04 0.2837 
AC104532.1 -5.325 7.2E-04 0.2874 
BPTFP1 1.246 9.1E-04 0.3308 
AL049795.2 -5.255 9.4E-04 0.3368 
RHOQP3 -2.218 9.8E-04 0.3425 
EGR4 0.938 9.8E-04 0.3425 
RPL23AP60 -5.251 1.1E-03 0.3535 
AL021920.3 -5.207 1.1E-03 0.3596 
PVRIG2P -5.996 1.2E-03 0.3741 
AC087289.3 -0.874 1.2E-03 0.3741 
AC027796.3 -6.916 1.2E-03 0.3741 
AL691442.1 1.222 1.3E-03 0.3881 
CACNA1I 1.153 1.4E-03 0.4060 
CBSL -1.310 1.5E-03 0.4174 
AL137247.1 5.085 1.5E-03 0.4174 
AL136295.1 -5.151 1.5E-03 0.4174 
ACP5 -5.124 1.6E-03 0.4341 
FAM156B -0.635 1.7E-03 0.4543 
AC159540.2 2.717 1.8E-03 0.4611 
DUSP2 0.813 1.8E-03 0.4706 
AC073111.4 3.103 1.9E-03 0.4706 
TERC 5.029 1.9E-03 0.4715 
GLDN -0.603 1.9E-03 0.4726 
AL512356.1 1.026 2.0E-03 0.4802 
AC068533.4 -1.910 2.0E-03 0.4802 
CORT -1.912 2.1E-03 0.4802 
LUZP6 4.999 2.1E-03 0.4802 
MFSD2A 0.796 2.2E-03 0.5023 




PCDHA8 -1.119 2.4E-03 0.5280 
PLCXD2 -0.809 2.5E-03 0.5287 
AC013271.1 4.933 2.6E-03 0.5427 
AL021368.3 4.919 2.7E-03 0.5588 
AC004224.2 1.374 2.9E-03 0.5797 
HIST1H3D 4.916 2.9E-03 0.5806 
TVP23C -0.717 3.1E-03 0.5966 
AC083899.1 -0.649 3.2E-03 0.5990 
TAF1A -0.721 3.3E-03 0.6004 
RPL23AP24 4.857 3.5E-03 0.6100 
Z84492.2 -4.943 3.5E-03 0.6100 
NUTM2E 4.848 3.5E-03 0.6123 
AL139353.1 0.844 4.0E-03 0.6414 
COX6B2 4.805 4.1E-03 0.6473 
AC025183.2 -2.581 4.2E-03 0.6514 
AC073343.2 4.792 4.2E-03 0.6550 
ZBTB45P1 -4.861 4.3E-03 0.6550 
LINC02138 4.785 4.3E-03 0.6566 
AP005263.1 4.783 4.3E-03 0.6566 
TMEM158 0.904 4.3E-03 0.6566 
PCDHGB3 -0.588 4.5E-03 0.6682 
ZNF816-
ZNF321P 
4.767 4.6E-03 0.6706 
AC020891.2 -1.937 4.6E-03 0.6706 
EDARADD 0.644 4.6E-03 0.6730 
TMEM110-
MUSTN1 
0.930 4.7E-03 0.6755 
FAM157C 1.268 4.7E-03 0.6755 
AL079301.1 1.838 4.8E-03 0.6768 
AL031123.2 -0.633 4.9E-03 0.6768 
BCLAF1P2 -1.094 4.9E-03 0.6768 
AC008758.6 -4.816 5.0E-03 0.6768 
IFIT3 -1.073 5.0E-03 0.6768 
STOX2 -0.698 5.2E-03 0.6892 
CASS4 1.214 5.4E-03 0.7140 
AC134772.1 1.883 5.5E-03 0.7157 
AL137786.1 -4.786 5.7E-03 0.7295 
AL109766.1 -4.783 5.7E-03 0.7301 
AL121790.2 -4.774 5.8E-03 0.7395 
FOXQ1 -2.520 5.9E-03 0.7408 
NUTM2A -0.633 5.9E-03 0.7408 




AL139393.2 0.779 6.1E-03 0.7471 
AC146944.1 -2.782 6.2E-03 0.7481 
HOXC5 0.714 6.3E-03 0.7481 
CPEB1 -2.500 6.6E-03 0.7745 
RWDD4P1 4.655 6.6E-03 0.7793 
MCRIP2P1 -4.720 6.7E-03 0.7803 
AC008763.2 4.641 6.7E-03 0.7803 
CA9 1.660 6.8E-03 0.7819 
AC242376.2 -1.482 6.8E-03 0.7868 
AC007238.1 0.815 6.9E-03 0.7868 
UGT1A10 -4.703 7.0E-03 0.7953 
STARD9 -1.100 7.1E-03 0.7966 
VN1R108P 4.618 7.1E-03 0.7966 
AL357558.2 1.601 7.1E-03 0.7966 
KRT18P13 4.621 7.1E-03 0.7966 
AC012146.3 4.614 7.2E-03 0.7979 
AL159163.1 4.614 7.6E-03 0.8130 
CORO7-
PAM16 
-4.697 7.6E-03 0.8132 
AL357673.1 -4.696 7.6E-03 0.8132 
WDR7-OT1 -4.668 7.8E-03 0.8171 
AL157392.3 -0.613 8.0E-03 0.8321 
WDR63 -2.760 8.1E-03 0.8356 
BRCC3P1 -4.665 8.2E-03 0.8405 
AC015712.4 -4.660 8.5E-03 0.8527 
AC091167.1 -4.656 8.6E-03 0.8552 
AC025279.2 -4.640 8.6E-03 0.8552 
AC023509.3 1.390 8.8E-03 0.8633 
SERPINA11 1.239 9.1E-03 0.8730 
AL139352.1 -1.418 9.1E-03 0.8774 
FAM78B -0.850 9.3E-03 0.8828 
AC131160.1 -0.813 9.5E-03 0.8947 
AL136295.5 0.782 9.8E-03 0.9028 
AC119674.2 -4.591 1.0E-02 0.9097 
OXCT2 0.945 1.0E-02 0.9104 
AC093904.2 -0.688 1.0E-02 0.9342 
SCARNA9 -1.893 1.0E-02 0.9342 
BBS12 -0.628 1.0E-02 0.9347 
GTF2IRD2P1 -1.702 1.1E-02 0.9454 
DUSP19 -0.835 1.1E-02 0.9460 




AL121748.2 4.476 1.1E-02 0.9502 
CSPG4P10 4.454 1.1E-02 0.9555 
SLC22A13 4.465 1.1E-02 0.9555 
AC105046.1 0.811 1.1E-02 0.9555 
AC073263.2 4.461 1.1E-02 0.9555 
SYT15 -1.110 1.1E-02 0.9555 
CD164L2 0.772 1.1E-02 0.9555 
AC092115.3 -1.054 1.1E-02 0.9555 
AC007229.1 4.454 1.1E-02 0.9555 
U47924.1 4.453 1.1E-02 0.9555 
AC012615.6 3.309 1.1E-02 0.9555 
AC124283.5 4.449 1.1E-02 0.9555 
SNORA50C 4.451 1.1E-02 0.9555 
ENO1P4 -4.542 1.2E-02 0.9617 
GAPDHP72 3.299 1.2E-02 0.9617 
CT45A1 -4.538 1.2E-02 0.9617 
AL137129.1 -4.539 1.2E-02 0.9617 
C9orf153 4.430 1.2E-02 0.9640 
CLEC4A 4.430 1.2E-02 0.9640 
AC011498.1 4.426 1.2E-02 0.9665 
AC072061.1 -0.854 1.2E-02 0.9678 
RPL23AP88 4.414 1.2E-02 0.9790 
AL358074.1 -4.514 1.2E-02 0.9873 
SNHG28 -4.512 1.2E-02 0.9905 
UCN -0.778 1.3E-02 0.9905 
AC025871.2 -4.506 1.3E-02 0.9905 
ADPRM -0.588 1.3E-02 0.9940 
INSL4 -3.159 1.3E-02 1.0000 
IQUB 4.403 1.3E-02 1.0000 
MIA-RAB4B 2.983 1.3E-02 1.0000 
AC092143.2 0.934 1.3E-02 1.0000 
CLEC3B -1.800 1.3E-02 1.0000 
AC008608.2 0.633 1.3E-02 1.0000 
AC005041.1 1.147 1.3E-02 1.0000 
CROCCP3 -0.867 1.3E-02 1.0000 
AC246785.2 -1.751 1.3E-02 1.0000 
ZNF790 -1.422 1.4E-02 1.0000 
LINC02166 1.667 1.4E-02 1.0000 
KISS1 0.810 1.4E-02 1.0000 
PRR34 0.787 1.4E-02 1.0000 




Z84723.1 -2.546 1.5E-02 1.0000 
CU638689.1 -3.233 1.5E-02 1.0000 
KCNK4 1.551 1.6E-02 1.0000 
TRIM31 -0.920 1.6E-02 1.0000 
PEBP4 0.937 1.6E-02 1.0000 
AL390195.1 2.272 1.6E-02 1.0000 
AF111169.1 4.290 1.6E-02 1.0000 
SNORD3A -0.782 1.7E-02 1.0000 
AC005154.6 -4.394 1.7E-02 1.0000 
AP000866.1 -1.097 1.7E-02 1.0000 
CHAC1 0.610 1.7E-02 1.0000 
RWDD4P2 -1.920 1.7E-02 1.0000 
AL772155.3 3.196 1.7E-02 1.0000 
STON1-
GTF2A1L 
-1.406 1.7E-02 1.0000 
SPRN 1.425 1.7E-02 1.0000 
POTEE 0.907 1.7E-02 1.0000 
AC092902.2 -0.681 1.7E-02 1.0000 
AL162430.1 4.278 1.7E-02 1.0000 
AC109587.1 1.682 1.8E-02 1.0000 
OR2L2 3.169 1.8E-02 1.0000 
AC005829.2 -4.362 1.8E-02 1.0000 
DPY19L1P2 4.256 1.8E-02 1.0000 
AP000654.1 -4.362 1.8E-02 1.0000 
HMGN1P4 4.259 1.8E-02 1.0000 
ACTN1-AS1 -4.359 1.8E-02 1.0000 
TMEM249 0.811 1.8E-02 1.0000 
AC010240.3 4.264 1.8E-02 1.0000 
CTAGE3P -4.351 1.8E-02 1.0000 
FSIP2 -4.349 1.8E-02 1.0000 
KHDC1L -4.346 1.9E-02 1.0000 
LINC02204 -4.339 1.9E-02 1.0000 
LINC02327 -4.338 1.9E-02 1.0000 
AC023137.1 4.243 1.9E-02 1.0000 
DNAJC19P5 4.243 1.9E-02 1.0000 
AL023806.1 -0.998 1.9E-02 1.0000 
CTAGE15 4.253 1.9E-02 1.0000 
FXYD4 4.235 1.9E-02 1.0000 
GSAP -0.619 1.9E-02 1.0000 
GNA15 4.231 1.9E-02 1.0000 




AC046168.1 4.230 1.9E-02 1.0000 
PNMT -4.322 1.9E-02 1.0000 
MMP13 -0.682 1.9E-02 1.0000 
AL713922.1 4.226 1.9E-02 1.0000 
MRVI1 -4.316 1.9E-02 1.0000 
AC106028.2 4.222 1.9E-02 1.0000 
TBC1D3P1 4.222 1.9E-02 1.0000 
MTND4P14 4.222 1.9E-02 1.0000 
C8orf46 1.601 2.0E-02 1.0000 
IL24 4.218 2.0E-02 1.0000 
RPL36A-
HNRNPH2 
4.240 2.0E-02 1.0000 
AL356309.3 4.214 2.0E-02 1.0000 
FOXD4L6 2.866 2.0E-02 1.0000 
AC133551.1 -4.319 2.0E-02 1.0000 
SP140 2.664 2.0E-02 1.0000 
AC006252.1 1.185 2.0E-02 1.0000 
AC092653.2 -3.010 2.0E-02 1.0000 
MMP23A 4.216 2.0E-02 1.0000 
AC243919.1 -2.580 2.0E-02 1.0000 
GUSBP5 -1.185 2.1E-02 1.0000 
TP53TG3B -1.175 2.1E-02 1.0000 
AC104506.1 0.853 2.1E-02 1.0000 
MYLK3 -1.304 2.1E-02 1.0000 
RBM26-AS1 1.279 2.1E-02 1.0000 
DNAJB4 -0.822 2.1E-02 1.0000 
KRT85 3.078 2.1E-02 1.0000 
LINC01119 1.428 2.1E-02 1.0000 
AC138466.1 2.171 2.1E-02 1.0000 
KLHL13 -0.785 2.2E-02 1.0000 
U73166.1 -0.822 2.2E-02 1.0000 
AC138894.3 -4.262 2.2E-02 1.0000 
ABCA11P -0.593 2.2E-02 1.0000 
ZBED8 -0.636 2.2E-02 1.0000 
AC009961.1 1.147 2.2E-02 1.0000 
HMGN1P3 -2.058 2.3E-02 1.0000 
PTH1R 2.625 2.3E-02 1.0000 
AL445309.1 -1.288 2.3E-02 1.0000 
SYS1-DBNDD2 -0.853 2.3E-02 1.0000 
AC135506.1 -1.377 2.3E-02 1.0000 




Z97633.1 0.619 2.4E-02 1.0000 
AP000553.1 0.984 2.4E-02 1.0000 
VAX1 1.459 2.4E-02 1.0000 
AC069368.1 -4.241 2.4E-02 1.0000 
ANKRD20A21P -2.014 2.4E-02 1.0000 
MEF2B -0.690 2.4E-02 1.0000 
AC105036.3 2.354 2.4E-02 1.0000 
AC024940.6 -4.223 2.4E-02 1.0000 
AC009093.8 -2.955 2.5E-02 1.0000 
BMS1P11 -4.213 2.5E-02 1.0000 
ARMC4 3.054 2.5E-02 1.0000 
AL138966.2 1.090 2.5E-02 1.0000 
AC008026.1 -4.205 2.5E-02 1.0000 
ZNF230 -0.635 2.5E-02 1.0000 
GLUD1P2 -2.188 2.6E-02 1.0000 
AC093673.1 0.592 2.6E-02 1.0000 
AC012309.1 -4.205 2.6E-02 1.0000 
AL109613.1 3.037 2.6E-02 1.0000 
AC023509.4 0.715 2.6E-02 1.0000 
AGAP7P -0.591 2.6E-02 1.0000 
AL031598.1 -1.829 2.7E-02 1.0000 
NOXRED1 -1.616 2.7E-02 1.0000 
H2AFB3 -1.975 2.7E-02 1.0000 
C1orf127 -2.933 2.7E-02 1.0000 
AC083843.3 -0.845 2.7E-02 1.0000 
ARHGAP9 -4.181 2.7E-02 1.0000 
RGS5 1.518 2.7E-02 1.0000 
CAP2P1 -4.177 2.7E-02 1.0000 
GNL3LP1 -0.743 2.7E-02 1.0000 
AC244517.1 3.018 2.7E-02 1.0000 
PRAMEF12 -4.174 2.7E-02 1.0000 
LINC01143 0.588 2.7E-02 1.0000 
GGTLC1 -4.173 2.7E-02 1.0000 
LINC00899 -4.172 2.7E-02 1.0000 
GLIPR1L2 -4.169 2.7E-02 1.0000 
AC004466.2 -4.168 2.8E-02 1.0000 
AC004554.2 -4.168 2.8E-02 1.0000 
AC009955.1 3.013 2.8E-02 1.0000 
AC008870.2 0.959 2.8E-02 1.0000 
DUTP6 -4.167 2.8E-02 1.0000 




TMPRSS7 3.011 2.8E-02 1.0000 
SAPCD1 1.169 2.8E-02 1.0000 
HMGB1P11 -4.159 2.8E-02 1.0000 
AL589666.1 -0.587 2.8E-02 1.0000 
AC093908.1 1.110 2.8E-02 1.0000 
AC015726.1 -1.294 2.8E-02 1.0000 
AC135178.2 -1.257 2.8E-02 1.0000 
CEP83-AS1 -0.674 2.8E-02 1.0000 
PLAC1 0.876 2.8E-02 1.0000 
AL353795.2 -4.152 2.8E-02 1.0000 
AL358075.2 -2.909 2.8E-02 1.0000 
ITIH6 -0.647 2.8E-02 1.0000 
AC010761.1 -2.902 2.9E-02 1.0000 
TMEM239 2.991 2.9E-02 1.0000 
SNCAIP -4.128 2.9E-02 1.0000 
AC092634.4 -1.054 2.9E-02 1.0000 
LIMS3 -1.011 2.9E-02 1.0000 
CATSPERZ 1.195 3.0E-02 1.0000 
SNHG22 -1.029 3.0E-02 1.0000 
AL645728.1 0.754 3.0E-02 1.0000 
AC004854.2 0.928 3.0E-02 1.0000 
AC156455.1 1.505 3.0E-02 1.0000 
AL354993.1 1.323 3.0E-02 1.0000 
SYNC -0.653 3.0E-02 1.0000 
AC002310.2 -0.821 3.0E-02 1.0000 
CPHL1P -0.733 3.0E-02 1.0000 
FAM95C -0.706 3.1E-02 1.0000 
NHP2P1 0.905 3.1E-02 1.0000 
C20orf197 4.028 3.1E-02 1.0000 
C9orf139 -1.138 3.1E-02 1.0000 
AC027702.1 0.978 3.1E-02 1.0000 
AL049836.1 4.014 3.1E-02 1.0000 
MKRN9P 4.014 3.1E-02 1.0000 
CLEC18C 4.010 3.1E-02 1.0000 
AC006030.1 4.001 3.2E-02 1.0000 
MTX1P1 4.000 3.2E-02 1.0000 
AC217774.1 4.001 3.2E-02 1.0000 
BCRP5 4.001 3.2E-02 1.0000 
PELI2 4.001 3.2E-02 1.0000 
AL049597.1 4.001 3.2E-02 1.0000 




BEST4 3.992 3.2E-02 1.0000 
HSFX3 3.992 3.2E-02 1.0000 
SUCLA2-AS1 3.992 3.2E-02 1.0000 
AP000757.1 3.992 3.2E-02 1.0000 
AC022414.1 1.619 3.2E-02 1.0000 
HLA-DRB5 2.527 3.2E-02 1.0000 
PRAMEF5 3.984 3.2E-02 1.0000 
PMS2P9 -4.093 3.2E-02 1.0000 
AL627309.3 -1.582 3.2E-02 1.0000 
LMO7-AS1 2.523 3.2E-02 1.0000 
SYNPO2L -0.642 3.2E-02 1.0000 
CSTA 3.979 3.3E-02 1.0000 
RF00017 -1.113 3.3E-02 1.0000 
AC106028.3 0.946 3.3E-02 1.0000 
AC104596.1 -0.950 3.3E-02 1.0000 
AL031133.1 3.975 3.3E-02 1.0000 
ZNF442 3.975 3.3E-02 1.0000 
AL158211.3 3.974 3.3E-02 1.0000 
RPSAP31 3.974 3.3E-02 1.0000 
TCL6 3.974 3.3E-02 1.0000 
PRR4 -1.067 3.3E-02 1.0000 
SIM1 3.966 3.3E-02 1.0000 
LRRC4 1.177 3.3E-02 1.0000 
SHBG 1.262 3.3E-02 1.0000 
AC099668.1 3.983 3.3E-02 1.0000 
AC018512.1 1.162 3.4E-02 1.0000 
BTN3A2 -0.975 3.4E-02 1.0000 
PRSS29P 1.805 3.4E-02 1.0000 
AL353764.1 -2.111 3.4E-02 1.0000 
KRT18P29 0.936 3.4E-02 1.0000 
AL390195.2 -1.919 3.4E-02 1.0000 
AC139272.1 -4.055 3.5E-02 1.0000 
PDE1A -0.897 3.5E-02 1.0000 
PIWIL4 -1.498 3.5E-02 1.0000 
GLIS1 1.793 3.5E-02 1.0000 
CHCHD4P3 -1.992 3.5E-02 1.0000 
RGS22 -1.644 3.5E-02 1.0000 
CA4 0.713 3.6E-02 1.0000 
HIST1H2AK -1.547 3.6E-02 1.0000 
SLC2A12 -0.597 3.6E-02 1.0000 




LINC01134 1.895 3.6E-02 1.0000 
UGT1A7 -0.882 3.7E-02 1.0000 
SCARNA12 -2.052 3.7E-02 1.0000 
AL022312.1 1.690 3.7E-02 1.0000 
SPI1 -1.540 3.7E-02 1.0000 
RASL10A 0.600 3.7E-02 1.0000 
COG8 3.574 3.7E-02 1.0000 
AC138969.2 -0.905 3.7E-02 1.0000 
AC239800.4 -4.011 3.7E-02 1.0000 
AC069287.2 1.460 3.8E-02 1.0000 
LINC02170 -1.460 3.8E-02 1.0000 
AC004130.1 -2.808 3.8E-02 1.0000 
HSPA8P15 -1.242 3.8E-02 1.0000 
AP000346.2 1.360 3.8E-02 1.0000 
AC092111.1 0.881 3.8E-02 1.0000 
AC006033.2 -2.796 3.9E-02 1.0000 
FGB 1.119 3.9E-02 1.0000 
DRICH1 2.897 3.9E-02 1.0000 
ZSCAN12 -0.605 3.9E-02 1.0000 
AC073896.2 -0.840 3.9E-02 1.0000 
AC106869.1 -1.238 3.9E-02 1.0000 
NDUFB2-AS1 0.646 3.9E-02 1.0000 
AC010422.5 -3.988 4.0E-02 1.0000 
AC008894.3 -0.655 4.0E-02 1.0000 
AMY2B -3.974 4.0E-02 1.0000 
USP32P2 -0.997 4.0E-02 1.0000 
KIAA0319 -0.658 4.1E-02 1.0000 
AC112503.1 -3.973 4.1E-02 1.0000 
HNRNPA1P54 0.809 4.1E-02 1.0000 
Z98884.2 -3.970 4.1E-02 1.0000 
AC011468.1 -3.969 4.1E-02 1.0000 
DAPL1 2.861 4.1E-02 1.0000 
LINC01661 -3.965 4.1E-02 1.0000 
AP004782.1 -3.963 4.1E-02 1.0000 
AC019163.1 -3.962 4.1E-02 1.0000 
LINC00654 -3.962 4.1E-02 1.0000 
FAM225B -3.963 4.1E-02 1.0000 
TKTL2 -3.961 4.1E-02 1.0000 
AC025884.2 2.860 4.1E-02 1.0000 
GAS5-AS1 -1.036 4.1E-02 1.0000 




AC003101.3 2.857 4.2E-02 1.0000 
TMEM179 -3.955 4.2E-02 1.0000 
AC006160.1 -3.953 4.2E-02 1.0000 
SLC26A10 -1.083 4.2E-02 1.0000 
AC093627.5 -0.829 4.2E-02 1.0000 
ISCA2P1 -3.948 4.2E-02 1.0000 
EI24P2 -3.948 4.2E-02 1.0000 
TUBB7P -1.844 4.2E-02 1.0000 
ARHGAP31-
AS1 
-3.945 4.2E-02 1.0000 
FAM96AP2 -3.945 4.2E-02 1.0000 
AC069503.2 2.072 4.2E-02 1.0000 
AC005358.2 -3.938 4.2E-02 1.0000 
FLRT3 -3.938 4.2E-02 1.0000 
AL645941.3 -3.937 4.2E-02 1.0000 
SLC4A9 -3.937 4.2E-02 1.0000 
OSGEPL1-AS1 -2.296 4.3E-02 1.0000 
TREX1 0.986 4.3E-02 1.0000 
DOCK10 -0.627 4.3E-02 1.0000 
C11orf96 1.748 4.3E-02 1.0000 
AC019322.3 -3.930 4.3E-02 1.0000 
AC068544.1 -3.922 4.3E-02 1.0000 
AL645941.1 -3.922 4.3E-02 1.0000 
TPSB2 -3.922 4.3E-02 1.0000 
AC009163.4 2.413 4.3E-02 1.0000 
PPIAP29 -3.922 4.4E-02 1.0000 
AC138035.2 -3.916 4.4E-02 1.0000 
PDE4B -0.863 4.4E-02 1.0000 
LAMC3 -0.873 4.4E-02 1.0000 
GCNT2 2.431 4.4E-02 1.0000 
AC010422.2 2.158 4.4E-02 1.0000 
AC007613.1 0.885 4.5E-02 1.0000 
AL451164.3 -3.911 4.5E-02 1.0000 
AC064807.2 -1.703 4.5E-02 1.0000 
AC021087.3 -1.494 4.5E-02 1.0000 
MEMO1P1 0.806 4.6E-02 1.0000 
FSTL1 -0.650 4.6E-02 1.0000 
AC026202.3 2.142 4.6E-02 1.0000 
FSTL5 1.313 4.6E-02 1.0000 
AC004801.6 2.139 4.6E-02 1.0000 




IDH1-AS1 -0.749 4.7E-02 1.0000 
AL138781.1 0.670 4.7E-02 1.0000 
AL161729.1 -0.795 4.7E-02 1.0000 
CACNA1A 1.712 4.7E-02 1.0000 
AC093591.1 -3.878 4.7E-02 1.0000 
AC011825.3 -3.885 4.8E-02 1.0000 
AC241584.1 1.822 4.8E-02 1.0000 
MUSTN1 -3.877 4.8E-02 1.0000 
AC005154.3 -1.523 4.8E-02 1.0000 
ANKRD10-IT1 2.380 4.8E-02 1.0000 
HPCAL4 1.815 4.9E-02 1.0000 
AC139491.6 3.744 4.9E-02 1.0000 
EREG -0.714 4.9E-02 1.0000 
SEMA5B -0.612 5.0E-02 1.0000 
PNMA5 3.746 5.0E-02 1.0000 
AC007744.1 3.740 5.0E-02 1.0000 
NPIPA5 1.820 5.0E-02 1.0000 
 
Table 8.2 Differentially expressed genes for MCF7 cells expressing Y694F-STAT5a, PRL vs 
untreated log10(fold change)>0.58, fold change >1.5. 
Y694F-STAT5a 
Gene Log10(Fold Change) p value padj 
BCL6 -0.932 2.4E-06 0.0365 
NR5A2 1.048 2.7E-04 0.4708 
RIMBP3B -1.199 3.3E-04 0.4708 
AC093668.1 -3.691 6.2E-04 0.4708 
RCAN1 0.749 7.3E-04 0.4708 
NABP1 0.745 2.0E-03 0.4708 
AP003071.5 1.690 2.1E-03 0.4708 
ACKR2 -1.021 2.2E-03 0.4708 
AC010468.1 0.725 2.3E-03 0.4708 
AL035078.4 1.084 2.4E-03 0.4708 
ALOX12B -1.324 3.0E-03 0.4708 
NR4A3 0.806 3.1E-03 0.4708 
ZNF669 0.628 3.2E-03 0.4708 
YEATS2-AS1 0.993 3.4E-03 0.4708 
AC011005.1 -1.259 3.8E-03 0.4708 
AC012676.5 1.332 3.9E-03 0.4708 




AL731684.2 1.318 4.0E-03 0.4708 
NRTN -0.687 4.3E-03 0.4708 
C16orf86 -0.806 4.4E-03 0.4708 
CYP4F26P -1.333 4.7E-03 0.4708 
MTCP1 0.766 4.8E-03 0.4708 
WDR93 -0.785 4.8E-03 0.4708 
RPL17-C18orf32 3.453 4.9E-03 0.4708 
AC020910.5 0.957 5.4E-03 0.4708 
AL137002.2 -0.682 5.7E-03 0.4708 
PSCA -0.608 5.8E-03 0.4708 
LRP5L 0.877 7.4E-03 0.4708 
IGFLR1 -0.641 7.5E-03 0.4708 
C22orf23 -0.677 7.6E-03 0.4708 
AC036214.2 0.946 7.7E-03 0.4708 
LINC01508 0.750 7.7E-03 0.4708 
TYMP -0.691 8.5E-03 0.4708 
DOCK9-AS2 -0.961 8.7E-03 0.4708 
AC145207.2 -0.913 8.7E-03 0.4708 
MIR503HG 0.982 8.9E-03 0.4708 
DLEU2 0.614 9.1E-03 0.4708 
GUSBP3 -1.722 9.1E-03 0.4708 
RNU4-1 -1.780 9.2E-03 0.4708 
KCNH1 1.255 9.5E-03 0.4708 
POLR3G 0.717 1.0E-02 0.4708 
AC010616.1 -0.654 1.0E-02 0.4708 
AC131160.1 1.863 1.1E-02 0.4708 
LINC01106 0.883 1.1E-02 0.4708 
AC120114.4 0.668 1.1E-02 0.4708 
ODF3B -0.818 1.1E-02 0.4708 
AC245041.1 1.258 1.1E-02 0.4708 
NUDT4B 2.013 1.1E-02 0.4708 
PELI1 0.609 1.2E-02 0.4708 
AC118553.2 -1.094 1.2E-02 0.4708 
TLX1NB 1.312 1.2E-02 0.4708 
AC100860.1 -1.106 1.3E-02 0.4708 
AC068946.2 -0.904 1.3E-02 0.4708 
ZNF550 0.611 1.3E-02 0.4708 
NELFA 0.651 1.3E-02 0.4708 




PPP5D1 0.792 1.4E-02 0.4708 
MIF-AS1 -1.012 1.4E-02 0.4708 
RN7SK -1.197 1.4E-02 0.4708 
AC093827.5 1.368 1.5E-02 0.4708 
C16orf87 0.640 1.5E-02 0.4708 
P2RX5-
TAX1BP3 
-1.011 1.5E-02 0.4708 
XKR9 1.182 1.5E-02 0.4708 
SLC22A18AS -0.766 1.6E-02 0.4708 
AC245389.2 0.856 1.6E-02 0.4708 
AL021546.1 7.236 1.6E-02 0.4708 
BZW1P2 0.651 1.6E-02 0.4708 
PRSS53 1.596 1.6E-02 0.4708 
MAK16 0.604 1.6E-02 0.4708 
C4orf36 -0.736 1.6E-02 0.4708 
CU633906.1 3.692 1.7E-02 0.4708 
UNC13A 0.789 1.7E-02 0.4708 
LINC01132 0.763 1.7E-02 0.4708 
AL121900.2 2.317 1.8E-02 0.4708 
AC090527.2 -8.073 1.8E-02 0.4708 
PCDHA4 -1.151 1.8E-02 0.4708 
LINC01144 -0.825 1.8E-02 0.4708 
UBE2Q2P1 0.876 1.9E-02 0.4708 
AC012531.2 6.647 1.9E-02 0.4708 
AL161421.1 0.722 2.0E-02 0.4708 
FAM76A 0.612 2.0E-02 0.4708 
AC138904.1 -0.703 2.0E-02 0.4708 
LINC00672 0.772 2.0E-02 0.4708 
TCEA1P2 0.675 2.1E-02 0.4708 
RGMA -0.641 2.1E-02 0.4708 
RN7SL1 -1.069 2.1E-02 0.4708 
SLC4A11 -0.690 2.1E-02 0.4708 
RAB11FIP2 0.662 2.1E-02 0.4708 
C1orf229 -0.874 2.1E-02 0.4708 
AC007405.3 -0.757 2.2E-02 0.4708 
FP236383.3 -1.023 2.2E-02 0.4708 
TEN1-CDK3 -0.989 2.2E-02 0.4708 
AL591684.2 0.903 2.3E-02 0.4708 
C1QTNF3 1.002 2.3E-02 0.4708 




AL355075.4 -1.463 2.4E-02 0.4708 
ANKRD29 0.941 2.4E-02 0.4708 
RN7SL2 -1.010 2.4E-02 0.4708 
HSPA6 1.024 2.5E-02 0.4708 
BASP1-AS1 -0.673 2.5E-02 0.4708 
AL139289.2 -0.611 2.5E-02 0.4708 
SNORD3A -1.479 2.6E-02 0.4708 
GK 0.587 2.6E-02 0.4708 
LIG4 0.604 2.7E-02 0.4708 
MATN4 -0.911 2.7E-02 0.4708 
TAF1A-AS1 0.745 2.7E-02 0.4708 
RPPH1 -0.958 2.7E-02 0.4708 
AL358113.1 1.663 2.8E-02 0.4708 
C9orf50 -0.838 2.8E-02 0.4708 
HOTAIRM1 0.690 2.8E-02 0.4708 
XK 0.726 2.8E-02 0.4708 
IGF2 -6.285 2.8E-02 0.4708 
PNCK -0.616 2.9E-02 0.4708 
MAP4K1 -0.637 2.9E-02 0.4708 
HIST4H4 -0.761 2.9E-02 0.4708 
AC010207.1 0.782 3.0E-02 0.4708 
TENM4 0.929 3.0E-02 0.4708 
RNU4-2 -1.527 3.0E-02 0.4708 
NPIPA2 -2.588 3.0E-02 0.4708 
AL139393.2 0.716 3.0E-02 0.4708 
STAMBPL1 0.792 3.0E-02 0.4708 
ZNF793 0.681 3.1E-02 0.4708 
SNHG25 -0.671 3.1E-02 0.4708 
CCT6P3 0.664 3.1E-02 0.4708 
RN7SL3 -0.984 3.1E-02 0.4708 
FP236383.2 -1.062 3.2E-02 0.4708 
AC064799.1 0.956 3.3E-02 0.4708 
GGN -0.681 3.3E-02 0.4708 
AL354714.2 1.122 3.4E-02 0.4708 
GPR156 0.624 3.4E-02 0.4708 
ZNF519 0.616 3.5E-02 0.4708 
AC118344.2 0.720 3.5E-02 0.4708 
HERC2P5 0.951 3.5E-02 0.4708 




IL17C -0.709 3.5E-02 0.4708 
AOC3 0.866 3.6E-02 0.4708 
AC009779.3 0.889 3.6E-02 0.4708 
CXCR5 -0.751 3.6E-02 0.4708 
SLC6A12 -1.775 3.7E-02 0.4708 
FSTL1 0.735 3.8E-02 0.4708 
RETREG1 0.655 3.8E-02 0.4708 
CAT 2.232 3.8E-02 0.4708 
CFL1P5 -0.633 3.9E-02 0.4708 
AC026471.6 -1.127 4.0E-02 0.4708 
VWCE 0.867 4.0E-02 0.4708 
AC023509.3 1.787 4.0E-02 0.4708 
GGT1 -1.827 4.0E-02 0.4708 
FAM227A 0.706 4.0E-02 0.4708 
ZUFSP 0.585 4.0E-02 0.4708 
AC027575.2 -0.833 4.1E-02 0.4708 
AC242376.2 1.013 4.1E-02 0.4708 
AC105046.1 0.715 4.2E-02 0.4708 
C1orf116 -0.716 4.2E-02 0.4708 
TMEM191C -0.911 4.3E-02 0.4708 
DDIT4-AS1 -0.897 4.3E-02 0.4708 
LINC01124 -0.726 4.5E-02 0.4708 
CASC11 0.882 4.5E-02 0.4708 
FAM157C 1.422 4.5E-02 0.4708 
CARD9 -0.697 4.6E-02 0.4708 
ALG1L9P -0.631 4.7E-02 0.4708 
VILL -0.683 4.7E-02 0.4708 
AC009133.2 -0.763 4.7E-02 0.4708 
RMRP -2.168 4.7E-02 0.4708 
AC011603.2 -0.597 4.8E-02 0.4708 
ADRA2B -0.816 4.8E-02 0.4708 
CDKN2B-AS1 0.684 4.8E-02 0.4708 
AL358781.1 -0.601 4.9E-02 0.4708 
SDHAP2 -7.790 4.9E-02 0.4708 
TMEM151A -0.704 4.9E-02 0.4708 
PIK3CD-AS2 -0.895 4.9E-02 0.4708 





Table 8.3 Differentially expressed genes for MCF7 cells expressing S726A-STAT5a, PRL vs 
untreated log10(fold change)>0.58, fold change >1.5. 
S726A-STAT5a 
Gene Log10(Fold Change) p value padj 
BCL6 -2.120 0.000 0.0000 
NR4A3 2.102 0.000 0.0147 
SRSF5 0.828 0.000 0.0501 
RASL11A 1.292 0.000 0.0501 
ADORA2A 8.622 0.000 0.1365 
RCAN1 0.994 0.000 0.1365 
MB21D2 0.919 0.000 0.1481 
CISH 0.625 0.000 0.1841 
MFSD2A 1.480 0.000 0.1841 
NR5A2 1.155 0.000 0.2468 
SH3RF1 0.808 0.000 0.2998 
NT5DC3 0.619 0.001 0.4059 
WNT6 -0.672 0.001 0.4059 
AP001057.1 0.690 0.002 0.4059 
NKX3-2 -1.084 0.002 0.4059 
AC124798.1 1.694 0.002 0.4059 
CD164L2 -1.553 0.002 0.4059 
AC027307.2 -0.645 0.002 0.4059 
FAM156B -0.988 0.002 0.4059 
TP53TG3C -6.523 0.002 0.4059 
AL139393.2 1.285 0.002 0.4059 
TMCC2 -0.847 0.002 0.4059 
TNFAIP8 0.846 0.002 0.4059 
UBE2V1P2 -1.546 0.003 0.4059 
GFOD1 0.625 0.003 0.4059 
NPIPB13 0.935 0.003 0.4059 
AL050341.2 0.904 0.003 0.4059 
RAET1G -0.940 0.003 0.4059 
FOSL1 0.613 0.003 0.4059 
MOGS -1.039 0.004 0.4059 
TERT -1.107 0.004 0.4059 
MELTF-AS1 -0.640 0.004 0.4059 
SCART1 0.928 0.004 0.4059 




GPR156 0.969 0.004 0.4059 
KLF6 0.789 0.004 0.4059 
AL109840.2 -0.714 0.004 0.4059 
ZNF775 -0.597 0.005 0.4059 
NKX2-8 -0.855 0.005 0.4059 
AL442663.3 1.020 0.005 0.4059 
MAP1LC3B2 1.133 0.005 0.4059 
AMD1 0.599 0.005 0.4059 
SIX2 -0.746 0.005 0.4059 
AC009118.2 1.432 0.005 0.4059 
AL117332.1 -0.790 0.005 0.4059 
SMIM27 -0.615 0.005 0.4059 
NABP1 0.707 0.005 0.4059 
ARRDC4 0.713 0.005 0.4059 
C3orf80 1.356 0.005 0.4059 
EPGN 1.453 0.005 0.4059 
AC113935.1 0.596 0.006 0.4059 
VTCN1 0.622 0.006 0.4059 
COL28A1 0.952 0.006 0.4059 
AP000438.1 1.096 0.006 0.4059 
FRMD6 0.699 0.006 0.4059 
ATXN7 1.497 0.006 0.4059 
C5orf30 0.686 0.006 0.4059 
AL138976.2 1.133 0.006 0.4059 
SGPP1 0.665 0.006 0.4059 
ELOVL4 0.794 0.007 0.4059 
AC138932.2 0.722 0.007 0.4059 
AC105339.2 1.795 0.007 0.4059 
IL12A 1.336 0.007 0.4059 
NXT2 0.694 0.007 0.4059 
RPP40 0.631 0.007 0.4059 
FRMD4B 0.616 0.008 0.4059 
SMIM13 0.604 0.008 0.4059 
AC110285.2 0.975 0.008 0.4059 
RIMBP3 -0.668 0.008 0.4059 
LINC01836 -0.594 0.008 0.4059 
ZBTB8A 0.744 0.008 0.4059 
MT-ND6 0.697 0.008 0.4059 




GABRD -0.803 0.008 0.4059 
AC024592.3 -0.741 0.009 0.4059 
AC113189.4 -0.765 0.009 0.4059 
AC105052.4 0.766 0.009 0.4059 
AC010531.6 -0.901 0.009 0.4059 
ZNF815P -0.691 0.010 0.4059 
Z83844.3 -0.960 0.010 0.4059 
PDE1A -1.166 0.010 0.4059 
ZNF559 0.664 0.010 0.4059 
TUBB8P12 -1.582 0.010 0.4059 
AC002350.1 1.086 0.010 0.4059 
FAM157C -1.865 0.010 0.4059 
GPR68 -0.621 0.010 0.4059 
TAF1A-AS1 0.842 0.010 0.4059 
PCDHAC2 0.802 0.011 0.4059 
LINC00982 -0.980 0.011 0.4059 
CALHM3 -1.119 0.011 0.4059 
PSCA -0.600 0.011 0.4059 
MIR22HG 0.690 0.011 0.4059 
AC099336.2 -0.927 0.011 0.4059 
THSD8 -0.661 0.012 0.4059 
SPECC1L-
ADORA2A 
-9.189 0.012 0.4059 
GGT1 -1.491 0.012 0.4059 
ZNF57 0.608 0.012 0.4059 
CCT6B 0.644 0.012 0.4059 
GDF1 -0.646 0.012 0.4059 
MST1P2 1.281 0.012 0.4059 
CSPG4 -1.241 0.012 0.4059 
NR4A1 0.759 0.012 0.4059 
MZT1 0.661 0.012 0.4059 
PPAT 0.654 0.012 0.4059 
EGR4 0.868 0.012 0.4059 
KLF9 0.684 0.013 0.4059 
AL139353.1 -1.217 0.013 0.4059 
IGF2 4.557 0.013 0.4059 
PRSS36 -0.971 0.013 0.4059 
AC084018.2 0.815 0.013 0.4059 
AC145207.3 -1.125 0.013 0.4059 




CASS4 0.884 0.014 0.4059 
PFKFB4 -0.582 0.014 0.4059 
ARG2 0.798 0.014 0.4059 
DYNC1I1 0.957 0.014 0.4059 
AC004264.1 0.746 0.015 0.4059 
ETV2 -0.625 0.015 0.4059 
BSCL2 -0.583 0.015 0.4059 
HOXA13 1.795 0.015 0.4059 
GNL3LP1 0.938 0.015 0.4059 
AC015871.3 0.769 0.016 0.4059 
LINC01132 0.884 0.016 0.4059 
CDRT4 -2.642 0.016 0.4059 
IKBKGP1 -0.691 0.016 0.4059 
AC233280.1 1.141 0.016 0.4059 
AC091057.1 0.937 0.016 0.4059 
SMG1P2 0.603 0.017 0.4059 
ZNF23 0.671 0.017 0.4059 
PSD2 0.881 0.017 0.4059 
ZNF81 0.666 0.017 0.4059 
AC087632.1 -0.661 0.017 0.4059 
ITPKA -0.601 0.018 0.4059 
ZDHHC11B 0.880 0.018 0.4059 
PSPN -0.723 0.018 0.4059 
C4orf48 -0.587 0.018 0.4059 
AC048341.1 0.962 0.018 0.4059 
REM2 0.672 0.018 0.4059 
AC106038.1 0.585 0.018 0.4059 
AL117339.5 1.321 0.018 0.4059 
AC124944.3 0.655 0.018 0.4059 
ARHGAP26 -1.024 0.018 0.4059 
ANKRD6 0.584 0.018 0.4059 
WDR43 0.602 0.019 0.4059 
AC120114.4 0.904 0.019 0.4059 
EGR2 0.871 0.019 0.4059 
TREX2 -0.828 0.019 0.4059 
LINC00672 1.007 0.019 0.4059 
KCTD12 0.796 0.019 0.4059 
WDFY4 -0.787 0.019 0.4059 




AP000812.5 -2.567 0.020 0.4059 
HOTAIRM1 0.785 0.020 0.4059 
AL035563.1 1.091 0.020 0.4059 
AC009779.3 1.039 0.020 0.4059 
AC009053.2 -0.837 0.020 0.4059 
RNFT1-DT 0.634 0.021 0.4059 
ZNF587B 0.597 0.021 0.4059 
AC022210.1 -1.116 0.021 0.4059 
CHRM1 -0.599 0.021 0.4059 
TGFBR3L -0.649 0.021 0.4059 
AC016027.1 0.635 0.022 0.4059 
MSH5-SAPCD1 2.042 0.022 0.4059 
RGPD2 2.086 0.022 0.4059 
AC131009.3 0.889 0.022 0.4059 
AC108488.1 1.434 0.023 0.4059 
AC005829.1 -1.194 0.024 0.4059 
SLC26A2 0.659 0.024 0.4059 
GCNT1 0.759 0.024 0.4059 
THUMPD2 0.597 0.024 0.4059 
ZNF433 0.586 0.025 0.4059 
RPPH1 -0.749 0.025 0.4059 
DRAXIN -0.794 0.025 0.4059 
PAQR5 0.640 0.025 0.4059 
LYPLA1 0.645 0.025 0.4059 
FNDC4 -0.612 0.025 0.4059 
SLC25A16 0.598 0.025 0.4059 
MAMSTR -0.783 0.025 0.4059 
PCDHGA7 1.140 0.025 0.4059 
B3GNT6 0.885 0.025 0.4059 
AP001486.2 0.910 0.025 0.4059 
BACH1 0.699 0.026 0.4059 
AL356019.2 0.935 0.026 0.4059 
LPAR5 -0.675 0.026 0.4059 
SLC25A21 0.586 0.027 0.4059 
CYP24A1 1.170 0.028 0.4059 
GOLGA6L10 0.968 0.028 0.4059 
C21orf91 0.800 0.029 0.4059 
SOWAHA 0.743 0.029 0.4059 




NIPAL1 0.757 0.029 0.4059 
MAGED4 -2.548 0.029 0.4059 
CABCOCO1 0.786 0.030 0.4059 
SLX1A -1.023 0.031 0.4059 
ERC2 0.736 0.031 0.4059 
DLEU2 0.738 0.031 0.4059 
AC092279.2 0.872 0.032 0.4059 
AC020917.4 0.991 0.032 0.4059 
NALT1 0.685 0.032 0.4059 
CDH15 -0.736 0.032 0.4059 
PEG13 -0.602 0.032 0.4059 
GOLGA2P5 0.599 0.033 0.4059 
AP003071.5 1.035 0.033 0.4059 
AL731569.1 0.733 0.033 0.4059 
FAM81A 0.745 0.033 0.4059 
AL359258.3 0.693 0.033 0.4059 
ZC3H12C 0.821 0.033 0.4059 
MINOS1-NBL1 2.106 0.034 0.4059 
AC004997.1 -1.554 0.034 0.4059 
NOXO1 -0.646 0.035 0.4059 
AC004877.1 0.766 0.035 0.4059 
AC025594.2 -0.614 0.035 0.4059 
PSMC6 0.789 0.035 0.4059 
RND3 0.603 0.035 0.4059 
BCDIN3D-AS1 -0.926 0.035 0.4059 
AC022968.1 0.901 0.036 0.4059 
AL354714.2 0.951 0.036 0.4059 
STK38L 0.635 0.036 0.4059 
AL353763.2 0.763 0.036 0.4059 
PRKAA2 0.823 0.036 0.4059 
ROBO1 1.435 0.037 0.4059 
AKR7A3 0.915 0.037 0.4059 
CRYBG2 -0.623 0.037 0.4059 
AL451062.3 -0.881 0.037 0.4059 
TENM4 -1.062 0.037 0.4059 
LINC00641 0.742 0.037 0.4059 
AL133523.1 0.605 0.037 0.4059 
AL137025.1 -0.771 0.037 0.4059 




AC106820.4 1.005 0.038 0.4059 
AC079848.1 0.962 0.038 0.4059 
FSTL1 -0.581 0.039 0.4059 
AC093525.8 0.759 0.039 0.4059 
AC005034.3 0.620 0.039 0.4059 
TLR5 -1.103 0.039 0.4059 
LINC00852 0.783 0.039 0.4059 
MYLK4 0.855 0.039 0.4059 
GIN1 0.620 0.039 0.4059 
TCTE3 0.848 0.040 0.4059 
SLC12A9-AS1 -0.627 0.040 0.4059 
LINC02288 0.774 0.040 0.4059 
NELFA -0.592 0.040 0.4059 
FP236383.2 -0.638 0.041 0.4059 
AC126177.4 -0.623 0.041 0.4059 
COG8 2.652 0.041 0.4059 
AC099778.1 0.691 0.041 0.4059 
GPCPD1 0.590 0.042 0.4059 
CYP4F22 -0.859 0.042 0.4059 
SYT5 -0.886 0.042 0.4059 
ULK4P1 2.728 0.043 0.4059 
C3orf52 0.677 0.043 0.4059 
AC006330.1 0.841 0.043 0.4059 
ZNF596 0.833 0.043 0.4059 
GOLGA8A 0.868 0.043 0.4059 
ARC 0.618 0.043 0.4059 
LRRC4B -0.786 0.043 0.4059 
AC131160.1 0.955 0.044 0.4059 
TMEM270 -0.966 0.044 0.4059 
FOXA2 -0.615 0.045 0.4059 
FKBP1C -0.657 0.045 0.4059 
BOLA3-AS1 -0.750 0.045 0.4059 
AL355075.4 -1.139 0.045 0.4059 
RDM1 -0.601 0.046 0.4059 
LETM2 -0.612 0.046 0.4059 
ADRA2B -0.642 0.046 0.4059 
SYNC 1.170 0.047 0.4059 
C20orf144 -0.776 0.047 0.4059 




TEX48 -0.869 0.047 0.4059 
ALDH1L2 0.838 0.048 0.4059 
AP003469.2 -1.066 0.048 0.4059 
FAM95C 0.636 0.048 0.4059 
AC105046.1 0.830 0.048 0.4059 
NOTCH1 1.446 0.048 0.4059 
SMIM22 -0.638 0.049 0.4059 
LRP12 0.690 0.049 0.4059 
MMP9 -0.612 0.049 0.4059 
PPTC7 0.609 0.049 0.4059 
KATNBL1 0.599 0.049 0.4059 
ULK4P2 -2.382 0.049 0.4059 
NFKBIZ 0.599 0.049 0.4059 
AC012321.1 -0.980 0.049 0.4059 
AC005225.4 0.626 0.049 0.4059 
CCDC103 -1.006 0.050 0.4059 
FHAD1 0.745 0.050 0.4059 
 
Table 8.4 Differentially expressed genes for MCF7 cells expressing S780A-STAT5a, PRL vs 
untreated log10(fold change)>0.58, fold change >1.5. 
S780A-STAT5a 
Gene Log10(Fold Change) p value padj 
BCL6 -2.423 0.0000 0.0002 
AC105046.1 1.589 0.0002 1.0000 
FAM157C 2.935 0.0003 1.0000 
SOCS2 0.803 0.0003 1.0000 
RASL11A 1.047 0.0005 1.0000 
NPIPB13 1.167 0.0006 1.0000 
MIR503HG 1.575 0.0006 1.0000 
RCAN1 0.935 0.0007 1.0000 
C8orf59 0.703 0.0008 1.0000 
COX7B 0.675 0.0009 1.0000 
CISH 0.747 0.0011 1.0000 
RSL24D1 0.893 0.0011 1.0000 
AC093668.1 -4.056 0.0012 1.0000 
AL355075.4 1.917 0.0017 1.0000 
EEF1E1 0.816 0.0018 1.0000 




MRPL1 0.860 0.0028 1.0000 
LINC01132 1.060 0.0029 1.0000 
MND1 0.676 0.0031 1.0000 
CABCOCO1 0.773 0.0033 1.0000 
RN7SL1 1.194 0.0034 1.0000 
SH3RF1 0.742 0.0035 1.0000 
C15orf41 2.350 0.0036 1.0000 
RPPH1 1.542 0.0037 1.0000 
ITGB3BP 0.946 0.0038 1.0000 
SLC22A20P 1.253 0.0038 1.0000 
LINC00345 1.045 0.0039 1.0000 
JKAMP 0.586 0.0041 1.0000 
TXNDC9 0.916 0.0044 1.0000 
PSMA2 0.674 0.0045 1.0000 
DNAJC25-GNG10 0.974 0.0045 1.0000 
C18orf65 -1.276 0.0046 1.0000 
CCNC 0.702 0.0047 1.0000 
SNORA73B 1.827 0.0048 1.0000 
ETFRF1 0.874 0.0051 1.0000 
RPL7P1 0.678 0.0053 1.0000 
CAPZA2 0.900 0.0058 1.0000 
MRPL13 0.721 0.0059 1.0000 
AC092687.3 1.015 0.0059 1.0000 
COMMD8 0.868 0.0060 1.0000 
RPL21P119 -8.213 0.0064 1.0000 
AC107068.1 1.190 0.0068 1.0000 
EIF3E 0.725 0.0071 1.0000 
AP000525.1 0.895 0.0072 1.0000 
RPL5P34 0.763 0.0073 1.0000 
SYT15 2.309 0.0075 1.0000 
NR4A3 1.072 0.0075 1.0000 
AL662899.2 0.866 0.0076 1.0000 
AL590652.1 1.051 0.0081 1.0000 
RPL22L1 0.582 0.0088 1.0000 
ACKR2 -1.011 0.0091 1.0000 
EPHX4 0.807 0.0092 1.0000 
ICOSLG 0.585 0.0095 1.0000 
ANAPC10 0.688 0.0096 1.0000 




KBTBD8 1.460 0.0100 1.0000 
NABP1 1.089 0.0103 1.0000 
XRCC4 0.983 0.0105 1.0000 
TPRKB 0.581 0.0112 1.0000 
AC073842.2 1.023 0.0112 1.0000 
RN7SK 1.342 0.0114 1.0000 
AC244197.3 0.612 0.0115 1.0000 
PYGM 0.791 0.0115 1.0000 
RPL26P19 0.621 0.0118 1.0000 
AC092139.1 1.425 0.0120 1.0000 
SYNJ2BP-COX16 1.379 0.0121 1.0000 
COPS2 0.834 0.0123 1.0000 
AL139393.2 1.053 0.0124 1.0000 
SERPINF1 0.607 0.0127 1.0000 
AL009174.1 0.716 0.0128 1.0000 
ZNF138 0.946 0.0129 1.0000 
AL162151.2 0.875 0.0130 1.0000 
CENPQ 0.986 0.0130 1.0000 
AL121845.3 0.688 0.0131 1.0000 
GCNT1 0.846 0.0134 1.0000 
COG8 8.991 0.0134 1.0000 
RN7SL2 1.129 0.0138 1.0000 
RUSC1-AS1 0.711 0.0143 1.0000 
ZNF98 0.998 0.0143 1.0000 
TSHZ3 0.693 0.0144 1.0000 
TDH 1.188 0.0144 1.0000 
AC099568.2 0.637 0.0145 1.0000 
AC011497.2 0.797 0.0148 1.0000 
Z95331.1 -1.238 0.0149 1.0000 
KIAA1586 0.893 0.0152 1.0000 
AL031009.1 1.496 0.0156 1.0000 
EIF4BP7 -0.739 0.0164 1.0000 
AL121845.2 -6.910 0.0164 1.0000 
LRRC37A11P -0.844 0.0165 1.0000 
VN1R1 1.007 0.0166 1.0000 
AC159540.2 -3.949 0.0171 1.0000 
PDZD7 -1.087 0.0174 1.0000 
AC126474.2 0.908 0.0174 1.0000 




AC073585.1 1.196 0.0176 1.0000 
GPC2 0.671 0.0181 1.0000 
LINC02163 -1.054 0.0182 1.0000 
AC008560.1 1.009 0.0196 1.0000 
SPECC1L-ADORA2A -8.442 0.0201 1.0000 
LINC01376 0.836 0.0206 1.0000 
STYK1 1.193 0.0213 1.0000 
HIST2H3C 8.892 0.0213 1.0000 
FAM171B 0.854 0.0217 1.0000 
AC018638.2 1.018 0.0219 1.0000 
MSMB 0.641 0.0219 1.0000 
AC113189.2 6.765 0.0220 1.0000 
MZT1 0.818 0.0221 1.0000 
ACAP1 0.784 0.0226 1.0000 
TNFAIP8L3 -1.080 0.0230 1.0000 
CU633904.1 7.192 0.0231 1.0000 
SHISA2 -0.608 0.0231 1.0000 
AL021368.2 1.813 0.0241 1.0000 
EDN1 -0.710 0.0243 1.0000 
WASH4P 0.690 0.0244 1.0000 
AL137002.2 -0.661 0.0244 1.0000 
SNORD3A 1.021 0.0246 1.0000 
STX17-AS1 0.864 0.0250 1.0000 
AC040162.1 0.590 0.0257 1.0000 
MBLAC2 0.839 0.0259 1.0000 
RPL23AP53 1.000 0.0262 1.0000 
CCDC112 0.642 0.0267 1.0000 
HAT1 0.652 0.0267 1.0000 
MFSD2A 0.875 0.0268 1.0000 
HIST1H4E 1.476 0.0275 1.0000 
ID2-AS1 0.939 0.0278 1.0000 
SCOC 0.597 0.0279 1.0000 
FBLN2 -0.658 0.0281 1.0000 
NPHP3-ACAD11 7.734 0.0282 1.0000 
GGT5 1.088 0.0286 1.0000 
C20orf204 0.867 0.0287 1.0000 
AC141586.3 -0.868 0.0287 1.0000 
AL603750.1 0.730 0.0290 1.0000 




GNG10 0.621 0.0297 1.0000 
ALOX12B 1.494 0.0298 1.0000 
GNL3LP1 1.131 0.0300 1.0000 
JAGN1 1.069 0.0307 1.0000 
CT62 -0.819 0.0308 1.0000 
RAD51AP1 0.875 0.0308 1.0000 
C12orf29 0.660 0.0314 1.0000 
TGDS 0.644 0.0315 1.0000 
AL359878.1 0.949 0.0319 1.0000 
AC083843.3 1.666 0.0322 1.0000 
TTC34 0.800 0.0328 1.0000 
CU634019.1 -7.172 0.0328 1.0000 
DVL3 0.803 0.0331 1.0000 
MAB21L3 1.105 0.0334 1.0000 
AL080276.2 0.672 0.0337 1.0000 
SPTB 1.708 0.0339 1.0000 
FHAD1 0.931 0.0340 1.0000 
LINC00346 -0.743 0.0345 1.0000 
DLL4 0.594 0.0346 1.0000 
GIN1 0.839 0.0360 1.0000 
TNFAIP8 0.808 0.0361 1.0000 
ZNF195 0.676 0.0363 1.0000 
TYW3 0.595 0.0371 1.0000 
AC079781.5 -0.905 0.0371 1.0000 
AL122058.1 0.968 0.0373 1.0000 
AC027644.4 1.298 0.0379 1.0000 
RPL31P63 0.829 0.0379 1.0000 
PRDM12 0.770 0.0380 1.0000 
PDIA2 0.836 0.0380 1.0000 
TRAPPC13 0.747 0.0380 1.0000 
DBF4 0.756 0.0381 1.0000 
RN7SL3 1.253 0.0383 1.0000 
ITGB2-AS1 1.035 0.0387 1.0000 
Z93930.2 0.783 0.0390 1.0000 
AC005520.1 0.883 0.0391 1.0000 
AC004951.4 0.768 0.0394 1.0000 
AC138811.2 6.239 0.0398 1.0000 
AL139011.2 0.904 0.0406 1.0000 




BBIP1 0.637 0.0413 1.0000 
GOLGA8H 0.790 0.0417 1.0000 
MT-ND6 0.648 0.0419 1.0000 
AC215522.2 0.669 0.0425 1.0000 
AC004477.1 0.763 0.0425 1.0000 
RGPD1 3.280 0.0428 1.0000 
AC138932.2 0.668 0.0439 1.0000 
AC008543.1 1.141 0.0441 1.0000 
DUSP10 -0.630 0.0443 1.0000 
AC093525.8 0.729 0.0444 1.0000 
AC006330.1 1.030 0.0444 1.0000 
FAM226B 1.211 0.0445 1.0000 
AC105052.1 2.729 0.0446 1.0000 
IFIH1 2.067 0.0447 1.0000 
LCA5L 0.671 0.0449 1.0000 
AC122688.3 0.594 0.0453 1.0000 
SSX2IP 0.902 0.0456 1.0000 
AP001486.2 1.423 0.0458 1.0000 
EMILIN1 -0.582 0.0462 1.0000 
SNHG22 0.810 0.0463 1.0000 
SPEF2 0.691 0.0467 1.0000 
AC128689.1 -0.923 0.0469 1.0000 
AC146944.4 1.703 0.0475 1.0000 
VIM-AS1 0.942 0.0476 1.0000 
OTUD6B 0.763 0.0477 1.0000 
IL1R1 0.619 0.0478 1.0000 
POTEKP 1.623 0.0479 1.0000 
TMED5 0.613 0.0481 1.0000 
TMEM161B 0.693 0.0484 1.0000 
AL645728.1 0.600 0.0485 1.0000 
PHOSPHO1 1.706 0.0489 1.0000 
AC011379.2 0.774 0.0494 1.0000 
AL353763.2 0.861 0.0494 1.0000 
AC073610.3 1.970 0.0496 1.0000 
AC083799.1 0.591 0.0496 1.0000 






Table 8.5 Details for top 10 enriched oncogenic signatures for each STAT5a mutant in the 
presence of PRL. Terms were ranked by normalized enrichment score (NES).  
Enriched Oncogenic Signatures 
WT-STAT5a + 
PRL treatment 

















54 0.568 1.662 0.000 0.075 1226 tags=33%, 
list=9%, 
signal=36% 





115 0.462 1.551 0.000 0.102 1288 tags=25%, 
list=9%, 
signal=28% 










95 0.479 1.593 0.007 0.115 2287 tags=34%, 
list=16%, 
signal=40% 

































187 0.501 1.848 0.000 0.007 4312 tags=62%, 
list=30%, 
signal=88% 
STK33_UP 199 0.480 1.756 0.000 0.009 3911 tags=47%, 
list=28%, 
signal=64% 

























118 0.465 1.633 0.000 0.028 5067 tags=55%, 
list=36%, 
signal=85% 





















110 0.532 1.871 0.000 0.006 2588 tags=38%, 
list=18%, 
signal=46% 
STK33_UP 201 0.487 1.852 0.000 0.006 3792 tags=50%, 
list=27%, 
signal=68% 























164 0.450 1.686 0.000 0.018 5316 tags=63%, 
list=38%, 
signal=100% 





















188 0.522 1.547 0.000 0.230 3174 tags=48%, 
list=22%, 
signal=61% 










119 0.491 1.387 0.023 0.886 2113 tags=20%, 
list=15%, 
signal=23% 
WNT_UP.V1_UP 100 0.496 1.378 0.030 0.784 3130 tags=25%, 
list=22%, 
signal=32% 
P53_DN.V1_DN 108 0.472 1.332 0.046 0.879 618 tags=12%, 
list=4%, 
signal=12% 






















Table 8.6 Details for top 10 enriched oncogenic signatures for each untreated STAT5a 
mutant. Terms were ranked by normalized enrichment score (NES).  
Enriched Oncogenic Signatures 
WT-STAT5a 
Untreated 











42 -0.623 -1.614 0.013 0.233 3544 tags=55%, 
list=25%, 
signal=73% 
PIGF_UP.V1_UP 152 -0.505 -1.553 0.003 0.266 4628 tags=51%, 
list=33%, 
signal=74% 





73 -0.506 -1.419 0.042 0.432 1672 tags=18%, 
list=12%, 
signal=20% 
TGFB_UP.V1_DN 147 -0.476 -1.456 0.006 0.432 2729 tags=27%, 
list=19%, 
signal=33% 
CRX_DN.V1_UP 87 -0.462 -1.312 0.068 0.478 3009 tags=34%, 
list=21%, 
signal=44% 
JAK2_DN.V1_DN 108 -0.446 -1.312 0.059 0.511 3562 tags=41%, 
list=25%, 
signal=54% 
SRC_UP.V1_DN 117 -0.437 -1.295 0.061 0.520 1644 tags=20%, 
list=12%, 
signal=22% 












































68 -0.492 -1.803 0.000 0.010 2210 tags=43%, 
list=16%, 
signal=50% 
















21 -0.585 -1.646 0.021 0.027 2099 tags=52%, 
list=15%, 
signal=61% 































































































50 -0.431 -1.244 0.134 0.498 1019 tags=22%, 
list=7%, 
signal=24% 





49 -0.437 -1.293 0.075 0.512 965 tags=22%, 
list=7%, 
signal=24% 










137 -0.350 -1.195 0.082 0.532 1293 tags=15%, 
list=9%, 
signal=16% 









102 -0.369 -1.212 0.100 0.537 1155 tags=19%, 
list=8%, 
signal=20% 




Table 8.7 Details for top 10 ENCODE TF enriched terms for each STAT5a mutant. Terms 
were ranked by odds ratio. 
Top 10 ENCODE TF terms 
WT-STAT5a 
Overlap p-value padj 
Odds 
Ratio 
MAX 56/2000 0.00752 1 1.39 
HDAC2 29/913 0.01114 1 1.57 
FOSL2 16/469 0.02967 1 1.69 
TEAD4 17/493 0.02334 1 1.71 
NFIC 24/663 0.00447 1 1.79 
FOXA1 16/435 0.01605 1 1.82 
JUND 9/241 0.05678 1 1.85 
NFE2 11/287 0.03222 1 1.90 
STAT5A 9/217 0.03274 1 2.05 
TCF12 5/104 0.05979 1 2.38 
Top 10 ENCODE TF terms  
Y694F-STAT5a 
Overlap p-value padj 
Odds 
Ratio 
THAP1 191/1775 6.49E-11 1.77E-08 1.58 
IRF3 82/755 1.80E-05 1.94E-04 1.59 
SIX5 138/1258 1.21E-08 7.62E-07 1.61 
SREBF2 45/405 8.42E-04 0.004187834 1.63 
SREBF1 138/1234 3.57E-09 3.24E-07 1.64 
PBX3 238/2098 4.03E-16 3.29E-13 1.66 
JUND 14/123 0.0405 0.077219684 1.67 
NR3C1 26/211 0.00246 0.009216281 1.81 
FOSL1 28/203 2.88E-04 0.001867847 2.02 
SUPT20H 26/172 1.06E-04 8.09E-04 2.22 
Top 10 ENCODE TF terms  
S726A-STAT5a 
Overlap p-value padj 
Odds 
Ratio 
NR3C1 28/211 0.02307 0.06255534 1.48 
SUPT20H 23/172 0.03404 0.083160569 1.49 
SREBF1 167/1234 2.83E-08 1.93E-06 1.51 




TEAD4 61/447 6.13E-04 0.004068339 1.52 
SIX5 172/1258 8.24E-09 1.12E-06 1.53 
SP1 171/1249 8.29E-09 9.66E-07 1.53 
PBX3 291/2098 2.98E-15 2.43E-12 1.55 
ESRRA 146/1023 7.74E-09 1.26E-06 1.59 
TCF12 15/104 0.04407 0.101577738 1.61 
Top 10 ENCODE TF terms  
S780A-STAT5a 
Overlap p-value padj 
Odds 
Ratio 
SP1 35/1727 0.07116 1 1.29 
TRIM28 42/2000 0.03152 1 1.34 
USF2 42/2000 0.03152 1 1.34 
STAT3 43/2000 0.02102 1 1.37 
MYBL2 35/1595 0.02772 1 1.40 
FOXA1 20/889 0.06862 1 1.43 
TAF1 13/512 0.06164 1 1.62 
FOXP2 11/423 0.07127 1 1.66 
RXRA 5/139 0.06839 1 2.29 
ZZZ3 11/293 0.00685 1 2.39 
 
Table 8.8 Odds ratio of top 10 enriched ENCODE Transcription Factors for each STAT5a 
mutant in gene set enrichment analysis using Enrichr. Data used for Figure 7 in Woock et al 
(submitted). 










MAX 1.39 1.42 1.33 0.86 
HDAC2 1.57 1.46 1.00 1.33 
FOSL2 1.69 0.91 1.05 0.41 
TEAD4 1.71 1.13 1.11 1.42 
NFIC 1.79 1.08 0.99 1.15 
FOXA1 1.82 1.25 1.36 0.59 
JUND 1.85 1.34 1.39 0.53 
NFE2 1.90 1.43 1.32 1.11 
STAT5A 2.05 1.15 1.29 0.29 
TCF12 2.38 0.56 1.61 0.61 










THAP1 0.50 1.58 1.29 0.65 




SIX5 0.75 1.61 1.53 0.91 
SREBF2 0.73 1.63 1.30 0.79 
SREBF1 1.12 1.64 1.51 0.57 
PBX3 0.90 1.66 1.55 0.88 
JUND 2.01 1.67 1.27 0.08 
NR3C1 0.47 1.81 1.48 0.30 
FOSL1 1.46 2.02 1.32 1.57 
SUPT20H 0.58 2.22 1.49 0.74 










NR3C1 0.47 1.81 1.48 0.30 
SUPT20H 0.58 2.22 1.49 0.74 
SREBF1 1.12 1.64 1.51 0.57 
JUND 1.10 1.47 1.52 0.63 
TEAD4 1.11 1.41 1.52 0.85 
SIX5 0.75 1.61 1.53 0.91 
SP1 0.95 1.56 1.53 0.87 
PBX3 0.90 1.66 1.55 0.88 
ESRRA 0.63 1.53 1.59 0.56 
TCF12 2.38 0.56 1.61 0.61 










SP1 1.03 1.16 1.28 1.29 
TRIM28 0.64 1.17 1.09 1.34 
USF2 1.06 1.42 1.27 1.34 
STAT3 0.99 1.10 1.13 1.37 
MYBL2 0.87 1.21 1.08 1.40 
FOXA1 1.17 1.16 1.09 1.43 
TAF1 0.97 0.80 1.00 1.62 
FOXP2 1.40 1.46 1.27 1.66 
RXRA 1.78 1.16 1.04 2.29 





8.2. Uncropped Western blots for Woock et al (Chapter 3), submitted February 2021 
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